Prescription attached:-
đŠē LIPU MED â COMPLETE CLINICAL CASE REVIEW
āϏāĻŽā§āĻĒā§āϰā§āĻŖ āĻĻā§āĻŦāĻŋāĻāĻžāώāĻŋāĻ āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻā§āϏ āĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āĻŦāĻŋāĻļā§āϞā§āώāĻŖ
đ§ TC(1486).(02). Dermatology Department Case No. 107
Suspected Superficial Dermatophytosis with Possible Coexisting Allergic Rhinitis: Clinical Diagnosis, Prescription Analysis and Evidence-Based Management

āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϤā§āĻŦāĻā§āϰ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ āĻŦāĻž āĻĻāĻžāĻĻ āĻāĻŦāĻ āϏāĻšāĻžāĻŦāϏā§āĻĨāĻžāύāĻāĻžāϰ⧠āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ: āϰā§āĻāύāĻŋāϰā§āĻŖā§, āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āĻŦāĻŋāĻļā§āϞā§āώāĻŖ āĻ āĻĒā§āϰāĻŽāĻžāĻŖāĻāĻŋāϤā§āϤāĻŋāĻ āĻāĻŋāĻāĻŋā§āϏāĻž
Case Category â āĻā§āϏā§āϰ āĻŦāĻŋāĻāĻžāĻ: Dermatology â āĻāϰā§āĻŽāϰā§āĻāĨ¤
Case Type â āĻā§āϏā§āϰ āϧāϰāύ: Retrospective Prescription-Based Clinical Assessment â āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻāĻĒāϰ āĻāĻŋāϤā§āϤāĻŋ āĻāϰ⧠āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻŽā§āϞā§āϝāĻžā§āύāĨ¤
Case Materials â āĻā§āϏā§āϰ āĻāĻĒāĻāϰāĻŖ: One Prescription, Zero Investigation Reports, Zero Clinical Photographs â āĻāĻāĻāĻŋ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ, āĻā§āύ⧠āĻĒāϰā§āĻā§āώāĻžāϰ āϰāĻŋāĻĒā§āϰā§āĻ āύā§āĻ, āϰā§āĻā§āϰ āĻĒā§āĻĨāĻ āĻāĻŦāĻŋ āύā§āĻāĨ¤
Diagnostic Status â āϰā§āĻāύāĻŋāϰā§āĻŖā§ā§āϰ āĻ āĻŦāϏā§āĻĨāĻž: Provisional, Not Confirmed â āϏāĻŽā§āĻāĻžāĻŦā§āϝ, āύāĻŋāĻļā§āĻāĻŋāϤ āύā§āĨ¤
Overall Diagnostic Confidence â āϏāĻžāĻŽāĻā§āϰāĻŋāĻ āϰā§āĻāύāĻŋāϰā§āĻŖā§ā§āϰ āĻŦāĻŋāĻļā§āĻŦāĻžāϏāϝā§āĻā§āϝāϤāĻž: 0.65/1.00āĨ¤
Clinical Evidence Statement â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻĒā§āϰāĻŽāĻžāĻŖ āϏāĻŽā§āĻĒāϰā§āĻā§ āĻā§āώāĻŖāĻž
The independent diagnosis is inferred from the medicines and general instructions written on the prescription.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āϞā§āĻāĻž āĻāώā§āϧ āĻāĻŦāĻ āϏāĻžāϧāĻžāϰāĻŖ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āĻŦāĻŋāĻļā§āϞā§āώāĻŖ āĻāϰ⧠āϏā§āĻŦāĻžāϧā§āύāĻāĻžāĻŦā§ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϰā§āĻāύāĻŋāϰā§āĻŖā§ āĻāϰāĻž āĻšā§ā§āĻā§āĨ¤
No specific chief complaint, physical examination findings or diagnostic test result is documented.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻĒā§āϰāϧāĻžāύ āĻ āĻāĻŋāϝā§āĻ, āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ āĻŦāĻž āϰā§āĻāύāĻŋāϰā§āĻŖā§ā§āϰ āĻā§āύ⧠āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ āϞā§āĻāĻž āύā§āĻāĨ¤
Clinical Confidence â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻŦāĻŋāĻļā§āĻŦāĻžāϏāϝā§āĻā§āϝāϤāĻž: 0.98 â āϤāĻĨā§āϝā§āϰ āϏā§āĻŽāĻžāĻŦāĻĻā§āϧāϤāĻž āĻļāύāĻžāĻā§āϤ āĻāϰāĻžāϰ āĻā§āώā§āϤā§āϰā§āĨ¤
đ§ 01. ORIGINAL PRESCRIPTION INFORMATION
āĻŽā§āϞ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āϤāĻĨā§āϝ
| Parameter â āĻŦāĻŋāώ⧠| Original Information â āĻŽā§āϞ āϤāĻĨā§āϝ |
|---|---|
| Patient Name â āϰā§āĻā§āϰ āύāĻžāĻŽ | Nasima Begum â āύāĻžāϏāĻŋāĻŽāĻž āĻŦā§āĻāĻŽ |
| Age â āĻŦā§āϏ | 35 years â ā§Šā§Ģ āĻŦāĻāϰ |
| Sex â āϞāĻŋāĻā§āĻ | Female, inferred from patient identification â āϰā§āĻā§āϰ āĻĒāϰāĻŋāĻā§ āĻĨā§āĻā§ āύāĻžāϰ⧠āĻŦāϞ⧠āϧāĻžāϰāĻŖāĻž |
| Prescription Date â āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āϤāĻžāϰāĻŋāĻ | 20 October 2026 â ⧍ā§Ļ āĻ āĻā§āĻā§āĻŦāϰ ⧍ā§Ļ⧍ā§Ŧ |
| Physician â āĻāĻŋāĻāĻŋā§āϏāĻ | Dr. Hassan Ahmed â āĻĄāĻž. āĻšāĻžāϏāĻžāύ āĻāĻšāĻŽā§āĻĻ |
| Qualifications â āĻļāĻŋāĻā§āώāĻžāĻāϤ āϝā§āĻā§āϝāϤāĻž | MBBS, BCS (Health), CCD (BIRDEM), DDV (BMU) â āĻŽā§āĻĻā§āϰāĻŋāϤ āϤāĻĨā§āϝ āĻ āύā§āϝāĻžā§ā§ |
| Training â āĻĒā§āϰāĻļāĻŋāĻā§āώāĻŖ | Fellowship Training in Dermatosurgery â āĻĄāĻžāϰā§āĻŽāĻžāĻā§āϏāĻžāϰā§āĻāĻžāϰāĻŋāϤ⧠āĻĢā§āϞā§āĻļāĻŋāĻĒ āĻĒā§āϰāĻļāĻŋāĻā§āώāĻŖ |
| Additional Training â āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻĒā§āϰāĻļāĻŋāĻā§āώāĻŖ | Advanced Training in Sexual Medicine â āϝā§āύ āĻāĻŋāĻāĻŋā§āϏāĻžāĻŦāĻŋāĻā§āĻāĻžāύ⧠āĻāύā§āύāϤ āĻĒā§āϰāĻļāĻŋāĻā§āώāĻŖ |
| Speciality â āĻŦāĻŋāĻļā§āώāĻā§āĻ āĻā§āώā§āϤā§āϰ | Skin, Allergy & Sexual Diseases â āĻāϰā§āĻŽāϰā§āĻ, āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻ āϝā§āύāϰā§āĻ |
| Department â āĻŦāĻŋāĻāĻžāĻ | Skin & VD / Dermatology â āĻāϰā§āĻŽ āĻ āϝā§āύāϰā§āĻ āĻŦāĻŋāĻāĻžāĻ |
| Physician Diagnosis â āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϰā§āĻāύāĻŋāϰā§āĻŖā§ | Not documented â āϞā§āĻāĻž āύā§āĻ |
| Investigation â āĻĒāϰā§āĻā§āώāĻž | Not documented â āϞā§āĻāĻž āύā§āĻ |
| Follow-up â āĻĒā§āύāϰāĻžā§ āĻĻā§āĻāĻžāύā§āϰ āϏāĻŽā§ | Approximately two months appears handwritten â āϏāĻŽā§āĻāĻŦāϤ āĻĻā§āĻ āĻŽāĻžāϏ āĻĒāϰā§; āĻšāĻžāϤā§āϰ āϞā§āĻāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āύ⧠|
Information Extraction Confidence â āϤāĻĨā§āϝ āĻļāύāĻžāĻā§āϤāĻāϰāĻŖā§āϰ āĻŦāĻŋāĻļā§āĻŦāĻžāϏāϝā§āĻā§āϝāϤāĻž: 0.95āĨ¤
āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āύāĻŋāĻŦāύā§āϧāύ āύāĻŽā§āĻŦāϰ āĻ āĻ āϏā§āĻĒāώā§āĻ āĻšāĻžāϤā§āϰ āϞā§āĻāĻž āϝāĻžāĻāĻžāĻ āĻāĻžā§āĻž āύāϤā§āύ āĻāϰ⧠āĻāϞā§āϞā§āĻ āĻāϰāĻž āĻšā§āύāĻŋāĨ¤
đŠ 02. CHIEF COMPLAINTS (C/C)
āϰā§āĻā§āϰ āĻĒā§āϰāϧāĻžāύ āĻ āĻāĻŋāϝā§āĻ
Definition â āϏāĻāĻā§āĻāĻž
Chief Complaints are the main symptoms or problems for which a patient seeks medical consultation.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§ āϝ⧠āĻĒā§āϰāϧāĻžāύ āϏāĻŽāϏā§āϝāĻž āĻŦāĻž āĻāĻĒāϏāϰā§āĻā§āϰ āĻāĻžāϰāĻŖā§ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻāĻžāĻā§ āĻāϏā§āύ, āϤāĻžāĻā§ Chief Complaints āĻŦāĻž āĻĒā§āϰāϧāĻžāύ āĻ āĻāĻŋāϝā§āĻ āĻŦāϞāĻž āĻšā§āĨ¤
A. Doctor-Documented Chief Complaints â āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϞā§āĻāĻž āĻ āĻāĻŋāϝā§āĻ
Not documented â āĻāϞā§āϞā§āĻ āύā§āĻāĨ¤
The physician did not explicitly document the patient’s symptoms.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻāĻŋā§āϏāĻ āϰā§āĻā§āϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāĻĒāϏāϰā§āĻāĻā§āϞ⧠āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āϞā§āĻā§āύāύāĻŋāĨ¤
Confidence: 0.99āĨ¤
B. Possible Chief Complaints â āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĒā§āϰāϧāĻžāύ āĻ āĻāĻŋāϝā§āĻ
1. Possible Itching of Skin â āϤā§āĻŦāĻā§ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻā§āϞāĻāĻžāύāĻŋāĨ¤
Itraconazole and luliconazole treatment suggests a possible fungal skin disorder that may cause itching.
āĻŦāĻžāĻāϞāĻž: Itraconazole āĻ Luliconazole āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻžāϰāĻŖā§ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āĻāϰā§āĻŽāϰā§āĻā§āϰ āϏāύā§āĻĻā§āĻš āĻšāĻā§āĻā§āĨ¤ āĻ āϧāϰāύā§āϰ āϰā§āĻā§ āĻā§āϞāĻāĻžāύāĻŋ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.70āĨ¤
2. Possible Skin Rash â āϤā§āĻŦāĻā§ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĢā§āϏāĻā§ā§āĻŋ āĻŦāĻž āĻĻāĻžāĻāĨ¤
Superficial dermatophytosis commonly produces erythematous or scaly skin lesions.
āĻŦāĻžāĻāϞāĻž: āϤā§āĻŦāĻā§āϰ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖā§ āϏāĻžāϧāĻžāϰāĻŖāϤ āϞāĻžāϞāĻā§ āĻĻāĻžāĻ āĻ āĻĨāĻŦāĻž āĻā§āϏāĻžāϝā§āĻā§āϤ āĻā§āώāϤ āĻĻā§āĻāĻž āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.65āĨ¤
3. Possible Nasal Allergy â āύāĻžāĻā§āϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĨ¤
Fexofenadine and fluticasone nasal spray suggest treatment of possible allergic rhinitis.
āĻŦāĻžāĻāϞāĻž: Fexofenadine āĻ Fluticasone Nasal Spray āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻžāϰāĻŖā§ āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻāύāĻŋāϤ āϰā§āĻā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āϰā§ā§āĻā§āĨ¤
Confidence: 0.75āĨ¤
4. Possible Recurrent Fungal Infection â āĻŦāĻžāϰāĻŦāĻžāϰ āĻšāĻā§āĻž āĻāϤā§āϰāĻžāĻ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻžāĨ¤
Combined oral and topical antifungal treatment may indicate extensive or difficult-to-treat infection, but recurrence is not documented.
āĻŦāĻžāĻāϞāĻž: āĻŽā§āĻā§ āĻāĻžāĻā§āĻžāϰ āĻāĻŦāĻ āϤā§āĻŦāĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ āĻāĻāϏāĻā§āĻā§ āĻĻā§āĻā§āĻžā§ āĻŦā§āϝāĻžāĻĒāĻ āĻŦāĻž āĻāĻāĻŋāϞ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āϝāĻžā§āĨ¤ āϤāĻŦā§ āĻŦāĻžāϰāĻŦāĻžāϰ āϰā§āĻ āĻšāĻā§āĻžāϰ āĻāϤāĻŋāĻšāĻžāϏ āϞā§āĻāĻž āύā§āĻāĨ¤
Confidence: 0.40āĨ¤
Clinical Interpretation â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻŦā§āϝāĻžāĻā§āϝāĻž
These findings are medication-based possibilities, not patient-reported complaints.
āĻŦāĻžāĻāϞāĻž: āĻāĻā§āϞ⧠āĻāώā§āϧ āĻĻā§āĻā§ āĻāϰāĻž āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϧāĻžāϰāĻŖāĻžāĨ¤ āϰā§āĻā§ āύāĻŋāĻā§ āĻāĻ āĻ āĻāĻŋāϝā§āĻāĻā§āϞ⧠āĻāĻžāύāĻŋā§ā§āĻā§āύâāĻāĻŽāύ āϞāĻŋāĻāĻŋāϤ āϤāĻĨā§āϝ āύā§āĻāĨ¤
Confidence: 0.98āĨ¤
đ§ 03. CLINICAL HISTORY ASSESSMENT
āϰā§āĻā§āϰ āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻ āĻŦāϰā§āϤāĻŽāĻžāύ āĻāϤāĻŋāĻšāĻžāϏ
History Parameters â āĻāϤāĻŋāĻšāĻžāϏā§āϰ āĻŦāĻŋāώā§āϏāĻŽā§āĻš
| Abbreviation â āϏāĻāĻā§āώāĻŋāĻĒā§āϤ āϰā§āĻĒ | English Meaning â āĻāĻāϰā§āĻāĻŋ āĻ āϰā§āĻĨ | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ | Doctor’s Documentation â āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϞā§āĻāĻž āϤāĻĨā§āϝ |
|---|---|---|---|
| C/C | Chief Complaints | āĻĒā§āϰāϧāĻžāύ āĻ āĻāĻŋāϝā§āĻ | Not documented â āύā§āĻ |
| I/H | Illness History | āĻŦāϰā§āϤāĻŽāĻžāύ āĻ āϏā§āϏā§āĻĨāϤāĻžāϰ āĻāϤāĻŋāĻšāĻžāϏ | Not documented â āύā§āĻ |
| HPI | History of Present Illness | āĻŦāϰā§āϤāĻŽāĻžāύ āϰā§āĻā§āϰ āĻŦāĻŋāϏā§āϤāĻžāϰāĻŋāϤ āĻāϤāĻŋāĻšāĻžāϏ | Not documented â āύā§āĻ |
| O/H | Obstetric History or Other History, depending on context | āĻĒā§āϰāϏā§āϤāĻŋ āĻāϤāĻŋāĻšāĻžāϏ āĻŦāĻž āĻĒā§āϰāĻžāϏāĻā§āĻāĻŋāĻ āĻ āύā§āϝāĻžāύā§āϝ āĻāϤāĻŋāĻšāĻžāϏ | Not documented â āύā§āĻ |
| D/H | Drug History | āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻāώā§āϧ āϏā§āĻŦāύā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | Not documented â āύā§āĻ |
| M/H | Medical History | āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | Not documented â āύā§āĻ |
| P/H | Past History | āĻ āϤā§āϤ āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | Not documented â āύā§āĻ |
| F/H | Family History | āĻĒāĻžāϰāĻŋāĻŦāĻžāϰāĻŋāĻ āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | Not documented â āύā§āĻ |
| S/H | Social History | āϏāĻžāĻŽāĻžāĻāĻŋāĻ āĻ āĻā§āĻŦāύāϝāĻžāĻĒāύā§āϰ āĻāϤāĻŋāĻšāĻžāϏ | Not documented â āύā§āĻ |
| Allergy H/O | History of Allergy | āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻāϤāĻŋāĻšāĻžāϏ | Not documented â āύā§āĻ |
Important History Required â āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻāϤāĻŋāĻšāĻžāϏ āϝāĻž āύā§āĻā§āĻž āĻĒā§āϰā§ā§āĻāύ
1. Duration of Illness â āϰā§āĻā§āϰ āϏā§āĻĨāĻžā§āĻŋāϤā§āĻŦāĨ¤
How long have the skin lesions been present?
āĻŦāĻžāĻāϞāĻž: āϤā§āĻŦāĻā§āϰ āϏāĻŽāϏā§āϝāĻžāĻāĻŋ āĻāϤāĻĻāĻŋāύ āϧāϰ⧠āϰā§ā§āĻā§?
2. Site of Infection â āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϏā§āĻĨāĻžāύāĨ¤
Which part of the body is affected?
āĻŦāĻžāĻāϞāĻž: āĻļāϰā§āϰā§āϰ āĻā§āύ āϏā§āĻĨāĻžāύ⧠āĻĻāĻžāĻ āĻŦāĻž āĻā§āώāϤ āϰā§ā§āĻā§?
3. Previous Antifungal Therapy â āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ āĻāĻŋāĻāĻŋā§āϏāĻžāĨ¤
Has the patient previously used oral or topical antifungals?
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§ āĻāĻā§ āĻā§āύ⧠āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ āĻā§āϝāĻžāĻŦāϞā§āĻ āĻŦāĻž āĻā§āϰāĻŋāĻŽ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰā§āĻā§āύ āĻāĻŋ?
4. Steroid Cream History â āϏā§āĻā§āϰā§ā§āĻĄāϝā§āĻā§āϤ āĻā§āϰāĻŋāĻŽ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāϤāĻŋāĻšāĻžāϏāĨ¤
Has the patient used steroid-containing combination creams?
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§ āĻāĻā§ āϏā§āĻā§āϰā§ā§āĻĄāϝā§āĻā§āϤ āĻŽāĻŋāĻļā§āϰ āĻā§āϰāĻŋāĻŽ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰā§āĻā§āύ āĻāĻŋ?
5. Diabetes History â āĻĄāĻžā§āĻžāĻŦā§āĻāĻŋāϏā§āϰ āĻāϤāĻŋāĻšāĻžāϏāĨ¤
Does the patient have diabetes or symptoms suggesting uncontrolled blood glucose?
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āĻĄāĻžā§āĻžāĻŦā§āĻāĻŋāϏ āĻāĻā§ āĻāĻŋ āĻ āĻĨāĻŦāĻž āϰāĻā§āϤ⧠āĻļāϰā§āĻāϰāĻž āĻŦā§āĻļāĻŋ āĻĨāĻžāĻāĻžāϰ āĻāĻĒāϏāϰā§āĻ āϰā§ā§āĻā§ āĻāĻŋ?
6. Pregnancy History â āĻāϰā§āĻāϧāĻžāϰāĻŖāϏāĻāĻā§āϰāĻžāύā§āϤ āĻāϤāĻŋāĻšāĻžāϏāĨ¤
Is the patient pregnant, breastfeeding or planning pregnancy?
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§ āĻŦāϰā§āϤāĻŽāĻžāύ⧠āĻāϰā§āĻāĻŦāϤā§, āϏāύā§āϤāĻžāύāĻā§ āĻŦā§āĻā§āϰ āĻĻā§āϧ āĻāĻžāĻā§āĻžāĻā§āĻā§āύ āĻ āĻĨāĻŦāĻž āĻāϰā§āĻāϧāĻžāϰāĻŖā§āϰ āĻĒāϰāĻŋāĻāϞā§āĻĒāύāĻž āĻāϰāĻā§āύ āĻāĻŋ?
7. Hepatic and Cardiac History â āϞāĻŋāĻāĻžāϰ āĻ āĻšā§āĻĻā§âāϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏāĨ¤
Is there any history of liver disease or heart failure?
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āϞāĻŋāĻāĻžāϰā§āϰ āϰā§āĻ āĻ āĻĨāĻŦāĻž āĻšā§āĻĻā§âāϝāύā§āϤā§āϰā§āϰ āĻāĻžāϰā§āϝāĻā§āώāĻŽāϤāĻž āĻāĻŽā§ āϝāĻžāĻā§āĻžāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻāĻā§ āĻāĻŋ?
8. Household Exposure â āĻĒāϰāĻŋāĻŦāĻžāϰā§āϰ āϏāĻāϏā§āĻĒāϰā§āĻļāĻāύāĻŋāϤ āĻāϤāĻŋāĻšāĻžāϏāĨ¤
Do other household members have similar skin lesions?
āĻŦāĻžāĻāϞāĻž: āĻĒāϰāĻŋāĻŦāĻžāϰā§āϰ āĻ āύā§āϝ āĻāĻžāϰāĻ āĻāĻāĻ āϧāϰāύā§āϰ āϤā§āĻŦāĻā§āϰ āϏāĻŽāϏā§āϝāĻž āϰā§ā§āĻā§ āĻāĻŋ?
Assessment â āĻŽā§āϞā§āϝāĻžā§āύ
No relevant history was explicitly recorded.
āĻŦāĻžāĻāϞāĻž: āĻāĻĒāϰā§āĻā§āϤ āĻā§āύ⧠āĻāϤāĻŋāĻšāĻžāϏāĻ āĻāĻŋāĻāĻŋā§āϏāĻ āĻŽā§āϞ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āϏā§āĻĒāώā§āĻāĻāĻžāĻŦā§ āϞā§āĻā§āύāύāĻŋāĨ¤
Confidence: 0.98āĨ¤
đŠ 04. PHYSICAL EXAMINATION (O/E)
āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ
Definition â āϏāĻāĻā§āĻāĻž
On Examination refers to clinical findings obtained during physical examination.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻāĻŋā§āϏāĻ āϰā§āĻā§āĻā§ āϏāϰāĻžāϏāϰāĻŋ āĻĒāϰā§āĻā§āώāĻž āĻāϰ⧠āϝ⧠āϞāĻā§āώāĻŖ āĻŦāĻž āĻĒāϰāĻŋāĻŦāϰā§āϤāύ āĻļāύāĻžāĻā§āϤ āĻāϰā§āύ, āϏā§āĻā§āϞā§āĻā§ On Examination āĻŦāĻž O/E āĻŦāϞāĻž āĻšā§āĨ¤
Doctor’s Original O/E â āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻŽā§āϞ āĻĒāϰā§āϝāĻŦā§āĻā§āώāĻŖ
Not documented â āϞā§āĻāĻž āύā§āĻāĨ¤
Expected Findings in Dermatophytosis â āĻĻāĻžāĻĻ āĻĨāĻžāĻāϞ⧠āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϞāĻā§āώāĻŖ
1. Annular Plaque â āĻŦā§āϤā§āϤāĻžāĻāĻžāϰ āĻā§āώāϤāĨ¤
A ring-shaped skin lesion may occur in tinea corporis.
āĻŦāĻžāĻāϞāĻž: āĻļāϰā§āϰā§āϰ āĻĻāĻžāĻĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āϤā§āĻŦāĻā§ āĻā§āϞāĻžāĻāĻžāϰ āĻā§āώāϤ āĻĻā§āĻāĻž āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
2. Peripheral Scaling â āĻā§āώāϤā§āϰ āĻĒā§āϰāĻžāύā§āϤ⧠āĻā§āϏāĻž āĻāĻ āĻžāĨ¤
Scaling may be prominent at the active border of a dermatophyte lesion.
āĻŦāĻžāĻāϞāĻž: āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āĻā§āώāϤā§āϰ āϏāĻā§āϰāĻŋā§ āĻĒā§āϰāĻžāύā§āϤ⧠āĻā§āϏāĻž āĻāĻ āĻž āĻĻā§āĻāĻž āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
3. Central Clearing â āĻā§āώāϤā§āϰ āĻŽāĻžāĻāĻāĻžāύ āϤā§āϞāύāĻžāĻŽā§āϞāĻ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻĨāĻžāĻāĻžāĨ¤
Some lesions demonstrate relative clearing in the centre.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻā§ āĻĻāĻžāĻĻā§āϰ āĻā§āώāϤā§āϰ āĻŽāĻžāĻā§āϰ āĻ āĻāĻļ āϤā§āϞāύāĻžāĻŽā§āϞāĻ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻĻā§āĻāĻž āϝāĻžā§āĨ¤
4. Excoriation â āĻā§āϞāĻāĻžāύā§āϰ āĻāĻāĻā§āĨ¤
Scratching may produce secondary skin injury.
āĻŦāĻžāĻāϞāĻž: āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻā§āϞāĻāĻžāύā§āϰ āĻāĻžāϰāĻŖā§ āϤā§āĻŦāĻā§ āĻāĻāĻā§ āĻŦāĻž āĻā§āώāϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Expected Nasal Findings â āύāĻžāĻ āĻĒāϰā§āĻā§āώāĻž āĻāϰāϞ⧠āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϞāĻā§āώāĻŖ
1. Pale or Swollen Turbinates â āύāĻžāĻā§āϰ āĻā§āϤāϰā§āϰ āĻāĻžāϰāĻŦāĻŋāύā§āĻ āĻĢā§āϝāĻžāĻāĻžāĻļā§ āĻŦāĻž āĻĢā§āϞāĻžāĨ¤
These findings may occur in allergic rhinitis.
āĻŦāĻžāĻāϞāĻž: āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϤ⧠āύāĻžāĻā§āϰ āĻā§āϤāϰā§āϰ āĻāĻžāϰāĻŦāĻŋāύā§āĻ āĻĢā§āϝāĻžāĻāĻžāĻļā§ āĻŦāĻž āĻĢā§āϞ⧠āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
2. Watery Nasal Discharge â āύāĻžāĻ āĻĻāĻŋā§ā§ āĻĒāĻžāύāĻŋāϰ āĻŽāϤ⧠āϏā§āϰāĻžāĻŦāĨ¤
Watery rhinorrhoea is a common allergic symptom.
āĻŦāĻžāĻāϞāĻž: āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻ āϰāĻžāĻāύāĻžāĻāĻāĻŋāϏ⧠āύāĻžāĻ āĻĻāĻŋā§ā§ āĻĒāĻžāϤāϞāĻž āĻĒāĻžāύāĻŋāϰ āĻŽāϤ⧠āϏā§āϰāĻžāĻŦ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Clinical Limitation â āϏā§āĻŽāĻžāĻŦāĻĻā§āϧāϤāĻž
These are textbook descriptions, not actual findings observed in Nasima Begum.
āĻŦāĻžāĻāϞāĻž: āĻāĻā§āϞ⧠āĻĒāĻžāĻ ā§āϝāĻĒā§āϏā§āϤāĻā§ āĻŦāϰā§āĻŖāĻŋāϤ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϞāĻā§āώāĻŖāĨ¤ āύāĻžāϏāĻŋāĻŽāĻž āĻŦā§āĻāĻŽā§āϰ āĻļāϰā§āϰ⧠āĻāĻ āϞāĻā§āώāĻŖāĻā§āϞ⧠āĻĒāĻžāĻā§āĻž āĻā§āĻā§âāĻāĻŽāύ āĻĒā§āϰāĻŽāĻžāĻŖ āύā§āĻāĨ¤
Confidence: 0.98 for general clinical descriptions; patient-specific findings remain unknownāĨ¤
đ§ 05. OTHER CLINICAL EXAMINATION PARAMETERS
āĻ āύā§āϝāĻžāύā§āϝ āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻĒāϰā§āĻā§āώāĻžāϰ āĻŦāĻŋāώā§
| Parameter â āĻŦāĻŋāώ⧠| English Meaning â āĻāĻāϰā§āĻāĻŋ āĻ āϰā§āĻĨ | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ | Status â āĻ āĻŦāϏā§āĻĨāĻž |
|---|---|---|---|
| O/S/E | Other/Systemic Examination | āĻ āύā§āϝāĻžāύā§āϝ āĻ āĻā§āĻ-āĻĒā§āϰāϤā§āϝāĻā§āĻā§āϰ āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻž | Not documented â āύā§āĻ |
| O/G/E | Obstetric and Gynaecological Examination | āĻĒā§āϰāϏā§āϤāĻŋ āĻ āϏā§āϤā§āϰā§āϰā§āĻāϏāĻāĻā§āϰāĻžāύā§āϤ āĻĒāϰā§āĻā§āώāĻž | Not documented â āύā§āĻ |
| G/E | General Examination | āϏāĻžāϧāĻžāϰāĻŖ āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻž | Not documented â āύā§āĻ |
| Vitals | Vital Signs | āϰāĻā§āϤāĻāĻžāĻĒ, āύāĻžā§āĻŋāϰ āĻāϤāĻŋ, āϤāĻžāĻĒāĻŽāĻžāϤā§āϰāĻž āĻāϤā§āϝāĻžāĻĻāĻŋ | Not documented â āύā§āĻ |
| Skin Examination | Dermatological Examination | āϤā§āĻŦāĻā§āϰ āĻā§āώāϤ āĻĒāϰā§āĻā§āώāĻž | Not documented â āύā§āĻ |
| ENT Examination | Ear, Nose and Throat Examination | āĻāĻžāύ, āύāĻžāĻ āĻ āĻāϞāĻžāϰ āĻĒāϰā§āĻā§āώāĻž | Not documented â āύā§āĻ |
| Systemic Examination | Examination of Organ Systems | āĻŦāĻŋāĻāĻŋāύā§āύ āĻ āĻā§āĻā§āϰ āĻāĻžāϰā§āϝāĻā§āϰāĻŽ āĻĒāϰā§āĻā§āώāĻž | Not documented â āύā§āĻ |
Confidence: 0.98āĨ¤
Important Observation â āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻĒāϰā§āϝāĻŦā§āĻā§āώāĻŖ
No systemic examination findings or vital signs are written.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻā§āύ⧠āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ āĻŦāĻž Vital Signs āϞā§āĻāĻž āύā§āĻāĨ¤
đŠ 06. DEFINITION OF THE SUSPECTED DISEASES
āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϰā§āĻāĻā§āϞā§āϰ āϏāĻāĻā§āĻāĻž
Disease 1: Superficial Dermatophytosis â āϤā§āĻŦāĻā§āϰ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ
Definition â āϏāĻāĻā§āĻāĻž
Dermatophytosis is a fungal infection affecting keratinized tissues, including the skin, hair and nails.
āĻŦāĻžāĻāϞāĻž: Dermatophytosis āĻšāϞ⧠āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ, āϝāĻž āϤā§āĻŦāĻ, āĻā§āϞ āĻāĻŦāĻ āύāĻā§āϰ āĻā§āϰāĻžāĻāĻŋāύāϝā§āĻā§āϤ āĻ āĻāĻļā§ āĻāĻā§āϰāĻŽāĻŖ āĻāϰā§āĨ¤
Common Types â āϏāĻžāϧāĻžāϰāĻŖ āϧāϰāύ
Tinea Corporis â āĻļāϰā§āϰā§āϰ āĻĻāĻžāĻĻāĨ¤
Fungal infection involving the glabrous skin of the body.
āĻŦāĻžāĻāϞāĻž: āĻļāϰā§āϰā§āϰ āϞā§āĻŽāĻŦāĻŋāĻšā§āύ āĻŦāĻž āϤā§āϞāύāĻžāĻŽā§āϞāĻ āĻŽāϏā§āĻŖ āϤā§āĻŦāĻā§āϰ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
Tinea Cruris â āĻā§āĻāĻāĻāĻŋāϰ āĻĻāĻžāĻĻāĨ¤
Dermatophyte infection involving the groin region.
āĻŦāĻžāĻāϞāĻž: āĻā§āĻāĻāĻāĻŋ āĻ āĻāĻļāĻĒāĻžāĻļā§āϰ āϤā§āĻŦāĻā§āϰ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
Tinea Pedis â āĻĒāĻžā§ā§āϰ āĻĻāĻžāĻĻāĨ¤
Dermatophyte infection involving the feet.
āĻŦāĻžāĻāϞāĻž: āĻĒāĻžā§ā§āϰ āϤā§āĻŦāĻā§ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
Tinea Manuum â āĻšāĻžāϤā§āϰ āĻĻāĻžāĻĻāĨ¤
Dermatophyte infection involving the hands.
āĻŦāĻžāĻāϞāĻž: āĻšāĻžāϤā§āϰ āϤā§āĻŦāĻā§āϰ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
Tinea Unguium â āύāĻā§āϰ āĻāϤā§āϰāĻžāĻ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
Dermatophyte infection involving the nails.
āĻŦāĻžāĻāϞāĻž: āύāĻā§ dermatophyte āĻāϤā§āϰāĻžāĻā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
Patient-Specific Interpretation â āϰā§āĻā§āĻāĻŋāϤā§āϤāĻŋāĻ āĻŦā§āϝāĻžāĻā§āϝāĻž
The affected anatomical site is not documented; therefore, the specific type of tinea cannot be determined.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āĻļāϰā§āϰā§āϰ āĻā§āύ āĻāĻžā§āĻāĻžā§ āϏāĻāĻā§āϰāĻŽāĻŖ āĻšā§ā§āĻā§ āϤāĻž āϞā§āĻāĻž āύā§āĻāĨ¤ āϤāĻžāĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻāĻāĻžāĻŦā§ Tinea Corporis, Tinea Cruris āĻŦāĻž āĻ āύā§āϝ āĻā§āύ⧠āϧāϰāύ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϏāĻŽā§āĻāĻŦ āύā§āĨ¤
Confidence: 0.95 for definition; 0.70 for suspected diseaseāĨ¤
Disease 2: Allergic Rhinitis â āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ
Definition â āϏāĻāĻā§āĻāĻž
Allergic rhinitis is an IgE-mediated inflammatory disorder of the nasal mucosa caused by exposure to allergens.
āĻŦāĻžāĻāϞāĻž: āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻ āϰāĻžāĻāύāĻžāĻāĻāĻŋāϏ āĻšāϞ⧠āĻ ā§āϝāĻžāϞāĻžāϰā§āĻā§āύā§āϰ āϏāĻāϏā§āĻĒāϰā§āĻļā§ IgE-mediated āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻžāϰ āĻŽāĻžāϧā§āϝāĻŽā§ āύāĻžāĻā§āϰ āĻā§āϤāϰā§āϰ āĻļā§āϞā§āώā§āĻŽāĻŋāĻ āĻāĻŦāϰāĻŖā§ āĻĒā§āϰāĻĻāĻžāĻš āϏā§āώā§āĻāĻŋ āĻšāĻā§āĻžāĨ¤
Common Symptoms â āϏāĻžāϧāĻžāϰāĻŖ āĻāĻĒāϏāϰā§āĻ
Sneezing â āĻšāĻžāĻāĻāĻŋāĨ¤
Rhinorrhoea â āύāĻžāĻ āĻĻāĻŋā§ā§ āĻĒāĻžāύāĻŋ āĻĒā§āĻžāĨ¤
Nasal Itching â āύāĻžāĻ āĻā§āϞāĻāĻžāύā§āĨ¤
Nasal Congestion â āύāĻžāĻ āĻŦāύā§āϧ āĻĨāĻžāĻāĻžāĨ¤
Watery Eyes â āĻā§āĻ āĻĻāĻŋā§ā§ āĻĒāĻžāύāĻŋ āĻĒā§āĻžāĨ¤
Patient-Specific Interpretation â āϰā§āĻā§āĻāĻŋāϤā§āϤāĻŋāĻ āĻŦā§āϝāĻžāĻā§āϝāĻž
The prescription includes fexofenadine and intranasal fluticasone, but the patient’s nasal symptoms are undocumented.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠Fexofenadine āĻāĻŦāĻ āύāĻžāĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ Fluticasone āϰā§ā§āĻā§āĨ¤ āϤāĻŦā§ āϰā§āĻā§āϰ āύāĻžāĻā§āϰ āĻĒā§āϰāĻā§āϤ āĻāĻĒāϏāϰā§āĻāĻā§āϞ⧠āϞā§āĻāĻž āύā§āĻāĨ¤
Confidence: 0.75āĨ¤
đ§ 07. ETIOLOGY AND PATHOPHYSIOLOGY
āϰā§āĻā§āϰ āĻāĻžāϰāĻŖ āĻ āϰā§āĻ āϏā§āώā§āĻāĻŋāϰ āĻĒā§āϰāĻā§āϰāĻŋā§āĻž
A. Etiology of Dermatophytosis â āĻĻāĻžāĻĻā§āϰ āĻāĻžāϰāĻŖ
Common dermatophyte organisms include:
āĻŦāĻžāĻāϞāĻž: āĻĻāĻžāĻĻ āϏā§āώā§āĻāĻŋāĻāĻžāϰ⧠āϏāĻžāϧāĻžāϰāĻŖ āĻāϤā§āϰāĻžāĻāĻā§āϞ⧠āĻšāϞā§â
- Trichophyton rubrum â āĻĻāĻžāĻĻ āϏā§āώā§āĻāĻŋāĻāĻžāϰ⧠āĻāĻāĻāĻŋ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻāϤā§āϰāĻžāĻāĨ¤
- Trichophyton mentagrophytes complex â āĻĻāĻžāĻĻ āϏā§āώā§āĻāĻŋāĻāĻžāϰ⧠āĻāϤā§āϰāĻžāĻā§āϰ āĻāĻāĻāĻŋ āĻā§āώā§āĻ ā§āĨ¤
- Trichophyton indotineae â āĻĻāĻā§āώāĻŋāĻŖ āĻāĻļāĻŋā§āĻžā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ, āĻāĻāύ⧠āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ-āĻĒā§āϰāϤāĻŋāϰā§āϧ⧠āĻāϤā§āϰāĻžāĻāĨ¤
- Epidermophyton floccosum â āϤā§āĻŦāĻā§ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻāĻāĻāĻŋ āĻāĻžāϰāĻŖāĨ¤
- Microsporum species â āϤā§āĻŦāĻ āĻ āĻā§āϞā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖ āĻāĻāĻžāϤ⧠āĻĒāĻžāϰā§āĨ¤
Pathophysiology â āϰā§āĻ āϏā§āώā§āĻāĻŋāϰ āĻĒā§āϰāĻā§āϰāĻŋā§āĻž
Dermatophytes colonize keratin-containing tissues and use keratin as a nutrient source.
āĻŦāĻžāĻāϞāĻž: Dermatophyte āĻāϤā§āϰāĻžāĻ āϤā§āĻŦāĻā§āϰ āĻā§āϰāĻžāĻāĻŋāύāϝā§āĻā§āϤ āĻ āĻāĻļā§ āĻŦā§āĻĻā§āϧāĻŋ āĻĒāĻžā§ āĻāĻŦāĻ āĻā§āϰāĻžāĻāĻŋāύāĻā§ āĻĒā§āώā§āĻāĻŋāϰ āĻā§āϏ āĻšāĻŋāϏā§āĻŦā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰā§āĨ¤
Fungal invasion and the host inflammatory response may produce redness, scaling and itching.
āĻŦāĻžāĻāϞāĻž: āĻāϤā§āϰāĻžāĻā§āϰ āĻāĻā§āϰāĻŽāĻŖ āĻāĻŦāĻ āĻļāϰā§āϰā§āϰ āĻĒā§āϰāϤāĻŋāϰā§āϧāĻŦā§āϝāĻŦāϏā§āĻĨāĻžāϰ āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻžā§ āϞāĻžāϞāĻā§ āĻĻāĻžāĻ, āĻā§āϏāĻž āĻāĻ āĻž āĻ āĻā§āϞāĻāĻžāύāĻŋ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
B. Etiology of Allergic Rhinitis â āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻāĻžāϰāĻŖ
Common allergens include house dust mites, pollen, animal dander and mould spores.
āĻŦāĻžāĻāϞāĻž: āϧā§āϞāĻžāϰ āĻŽāĻžāĻāĻ, āĻĢā§āϞā§āϰ āϰā§āĻŖā§, āĻĒā§āϰāĻžāĻŖā§āϰ āĻļāϰā§āϰ āĻĨā§āĻā§ āĻāϰ⧠āĻĒā§āĻž āĻ ā§āϝāĻžāϞāĻžāϰā§āĻā§āύ āĻāĻŦāĻ āĻāϤā§āϰāĻžāĻā§āϰ āϏā§āĻĒā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āϏā§āώā§āĻāĻŋ āĻāϰāϤ⧠āĻĒāĻžāϰā§āĨ¤
Pathophysiology â āϰā§āĻ āϏā§āώā§āĻāĻŋāϰ āĻĒā§āϰāĻā§āϰāĻŋā§āĻž
Allergen exposure activates IgE-sensitized mast cells and stimulates the release of histamine and other inflammatory mediators.
āĻŦāĻžāĻāϞāĻž: āĻ ā§āϝāĻžāϞāĻžāϰā§āĻā§āύā§āϰ āϏāĻāϏā§āĻĒāϰā§āĻļā§ IgE-āϏāĻāĻŦā§āĻĻāύāĻļā§āϞ Mast Cell āϏāĻā§āϰāĻŋā§ āĻšā§ā§ Histamine āĻ āĻ āύā§āϝāĻžāύā§āϝ āĻĒā§āϰāĻĻāĻžāĻšāϏā§āώā§āĻāĻŋāĻāĻžāϰ⧠āĻĒāĻĻāĻžāϰā§āĻĨ āύāĻŋāĻāϏāϰāĻŖ āĻāϰā§āĨ¤
These mediators cause sneezing, itching, watery discharge and nasal congestion.
āĻŦāĻžāĻāϞāĻž: āĻāϏāĻŦ āϰāĻžāϏāĻžā§āύāĻŋāĻ āĻĒāĻĻāĻžāϰā§āĻĨā§āϰ āĻĒā§āϰāĻāĻžāĻŦā§ āĻšāĻžāĻāĻāĻŋ, āĻā§āϞāĻāĻžāύāĻŋ, āύāĻžāĻ āĻĻāĻŋā§ā§ āĻĒāĻžāύāĻŋ āĻĒā§āĻž āĻāĻŦāĻ āύāĻžāĻ āĻŦāύā§āϧ āĻĨāĻžāĻāĻžāϰ āϏāĻŽāϏā§āϝāĻž āĻĻā§āĻāĻž āĻĻā§ā§āĨ¤
Scientific Confidence â āĻŦā§āĻā§āĻāĻžāύāĻŋāĻ āĻŦāĻŋāĻļā§āĻŦāĻžāϏāϝā§āĻā§āϝāϤāĻž: 0.98āĨ¤
đŠ 08. INVESTIGATIONS
āϰā§āĻāύāĻŋāϰā§āĻŖā§ā§āϰ āĻĒāϰā§āĻā§āώāĻž
Physician-Documented Investigations â āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϞā§āĻāĻž āĻĒāϰā§āĻā§āώāĻž
None documented â āĻā§āύ⧠āĻĒāϰā§āĻā§āώāĻž āϞā§āĻāĻž āύā§āĻāĨ¤
Suggested Investigations â āĻĒā§āϰā§ā§āĻāύ āĻ āύā§āϝāĻžā§ā§ āĻĒā§āϰāϏā§āϤāĻžāĻŦāĻŋāϤ āĻĒāϰā§āĻā§āώāĻž
| Investigation â āĻĒāϰā§āĻā§āώāĻž | Purpose â āĻāĻĻā§āĻĻā§āĻļā§āϝ | Interpretation â āĻŦā§āϝāĻžāĻā§āϝāĻž | Confidence |
|---|---|---|---|
| Skin Scraping for KOH â āϤā§āĻŦāĻā§āϰ āĻā§āϏāĻžāϰ KOH āĻĒāϰā§āĻā§āώāĻž | Detect fungal elements â āĻāϤā§āϰāĻžāĻ āĻļāύāĻžāĻā§āϤ āĻāϰāĻž | Hyphae support fungal infection â āĻšāĻžāĻāĻĢāĻž āĻĒāĻžāĻā§āĻž āĻā§āϞ⧠āĻāϤā§āϰāĻžāĻā§āϰ āĻĒāĻā§āώ⧠āĻĒā§āϰāĻŽāĻžāĻŖ | 0.95 |
| Fungal Culture â āĻāϤā§āϰāĻžāĻā§āϰ āĻāĻžāϞāĻāĻžāϰ | Identify fungal growth â āĻāϤā§āϰāĻžāĻā§āϰ āĻŦā§āĻĻā§āϧāĻŋ āĻļāύāĻžāĻā§āϤ āĻāϰāĻž | Useful in persistent infection â āĻĻā§āϰā§āĻāϏā§āĻĨāĻžā§ā§ āϏāĻāĻā§āϰāĻŽāĻŖā§ āĻāĻžāϰā§āϝāĻāϰ | 0.92 |
| Fungal Species Identification â āĻāϤā§āϰāĻžāĻā§āϰ āĻĒā§āϰāĻāĻžāϤāĻŋ āĻļāύāĻžāĻā§āϤāĻāϰāĻŖ | Identify unusual/resistant organisms â āĻ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻŦāĻž āĻĒā§āϰāϤāĻŋāϰā§āϧ⧠āĻāϤā§āϰāĻžāĻ āĻļāύāĻžāĻā§āϤ | Consider in selected resistant cases â āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāĻŋāĻāĻŋā§āϏāĻžāĻĒā§āϰāϤāĻŋāϰā§āϧ⧠āϰā§āĻā§ āĻŦāĻŋāĻŦā§āĻā§āϝ | 0.90 |
| Liver Function Tests â āϞāĻŋāĻāĻžāϰā§āϰ āĻāĻžāϰā§āϝāĻā§āώāĻŽāϤāĻž āĻĒāϰā§āĻā§āώāĻž | Assess systemic antifungal safety â āĻŽā§āĻā§ āĻāĻžāĻā§āĻžāϰ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞā§āϰ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž | Interpret according to clinical risk â āϰā§āĻā§āϰ āĻā§āĻāĻāĻŋ āĻ āύā§āϝāĻžā§ā§ āĻŦā§āϝāĻžāĻā§āϝāĻž | 0.95 |
| Blood Glucose/HbA1c â āϰāĻā§āϤ⧠āĻļāϰā§āĻāϰāĻž āĻĒāϰā§āĻā§āώāĻž | Assess diabetes when indicated â āĻĒā§āϰā§ā§āĻāύ āĻ āύā§āϝāĻžā§ā§ āĻĄāĻžā§āĻžāĻŦā§āĻāĻŋāϏ āĻŽā§āϞā§āϝāĻžā§āύ | Not routinely required for every case â āϏāĻŦāĻžāϰ āĻāύā§āϝ āĻŦāĻžāϧā§āϝāϤāĻžāĻŽā§āϞāĻ āύ⧠| 0.90 |
| Pregnancy Assessment â āĻāϰā§āĻāϧāĻžāϰāĻŖ āĻŽā§āϞā§āϝāĻžā§āύ | Assess medicine-related reproductive risk â āĻāώā§āϧā§āϰ āĻĒā§āϰāĻāύāύāϏāĻāĻā§āϰāĻžāύā§āϤ āĻā§āĻāĻāĻŋ āĻŽā§āϞā§āϝāĻžā§āύ | Relevant before systemic antifungal therapy â āĻŽā§āĻā§ āĻāĻžāĻā§āĻžāϰ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞā§āϰ āĻāĻā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ | 0.95 |
| Bacterial Culture â āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϰ āĻāĻžāϞāĻāĻžāϰ | Assess suspected bacterial infection â āϏāύā§āĻĻā§āĻšāĻāύāĻ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻž āϏāĻāĻā§āϰāĻŽāĻŖ āĻļāύāĻžāĻā§āϤ | Only when clinically indicated â āĻĒā§āϰā§ā§āĻāύ āĻšāϞā§āĻ āĻāϰāĻž āĻāĻāĻŋāϤ | 0.85 |
Clinical Interpretation â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻŦā§āϝāĻžāĻā§āϝāĻž
KOH microscopy is particularly useful when the appearance of a lesion is atypical or the diagnosis is uncertain.
āĻŦāĻžāĻāϞāĻž: āϤā§āĻŦāĻā§āϰ āĻā§āώāϤ āĻ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻĻā§āĻāĻžāϞ⧠āĻ āĻĨāĻŦāĻž āϰā§āĻāύāĻŋāϰā§āĻŖā§ āĻ āύāĻŋāĻļā§āĻāĻŋāϤ āĻšāϞ⧠KOH āĻĒāϰā§āĻā§āώāĻž āĻŦāĻŋāĻļā§āώāĻāĻžāĻŦā§ āĻāĻĒāĻāĻžāϰā§āĨ¤
Routine fungal culture or extensive blood investigations are not required for every uncomplicated localized tinea infection.
āĻŦāĻžāĻāϞāĻž: āϏāĻžāϧāĻžāϰāĻŖ āϏā§āĻŽāĻŋāϤ āĻĻāĻžāĻĻā§āϰ āĻĒā§āϰāϤāĻŋāĻāĻŋ āϰā§āĻā§āϰ āĻāύā§āϝ āĻĢāĻžāĻā§āĻāĻžāϞ āĻāĻžāϞāĻāĻžāϰ āĻ āĻĨāĻŦāĻž āĻ āύā§āĻ āϰāĻā§āϤāĻĒāϰā§āĻā§āώāĻž āĻĒā§āϰā§ā§āĻāύ āĻšā§ āύāĻžāĨ¤
Confidence: 0.95āĨ¤
đ§ 09. DIFFERENTIAL DIAGNOSIS
āĻŦāĻŋāĻāϞā§āĻĒ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϰā§āĻāύāĻŋāϰā§āĻŖā§
| Diagnosis â āϰā§āĻ | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ | Supporting Evidence â āϏāĻŽāϰā§āĻĨāύāĻāĻžāϰ⧠āϤāĻĨā§āϝ | Confidence |
|---|---|---|---|
| Superficial Dermatophytosis | āĻĻāĻžāĻĻ āĻŦāĻž āϤā§āĻŦāĻā§āϰ āĻāϤā§āϰāĻžāĻ āϏāĻāĻā§āϰāĻŽāĻŖ | Oral and topical antifungals â āĻŽā§āĻā§ āĻ āĻŦāĻžāĻšā§āϝāĻŋāĻ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ | 0.70 |
| Allergic Rhinitis | āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ | Fexofenadine and nasal fluticasone â āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻāώā§āϧ | 0.75 |
| Pityriasis Versicolor | āĻā§āϞāĻŋ | Itraconazole may be used â Itraconazole āĻŦā§āϝāĻŦāĻšā§āϤ āĻšāϤ⧠āĻĒāĻžāϰ⧠| 0.35 |
| Cutaneous Candidiasis | āϤā§āĻŦāĻā§āϰ āĻā§āϝāĻžāύāĻĄāĻŋāĻĄāĻž āϏāĻāĻā§āϰāĻŽāĻŖ | Some antifungals have activity â āĻāĻŋāĻā§ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ āĻāĻžāϰā§āϝāĻāϰ | 0.30 |
| Eczematous Dermatitis | āĻāĻāĻāĻŋāĻŽāĻžāĻāύāĻŋāϤ āϤā§āĻŦāĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻš | Can resemble tinea â āĻĻāĻžāĻĻā§āϰ āĻŽāϤ⧠āĻĻā§āĻāϤ⧠āĻšāϤ⧠āĻĒāĻžāϰ⧠| 0.25 |
| Secondary Bacterial Skin Infection | āϤā§āĻŦāĻā§āϰ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻž āϏāĻāĻā§āϰāĻŽāĻŖ | Possible antibiotic entry â āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžā§ā§āĻāĻŋāĻ | 0.25 |
Final Differential Interpretation â āĻā§ā§āĻžāύā§āϤ āĻŦāĻŋāĻāϞā§āĻĒ āϰā§āĻ āĻŽā§āϞā§āϝāĻžā§āύ
Dermatophytosis is the leading medication-supported possibility. Allergic rhinitis is a separate possible coexisting condition.
āĻŦāĻžāĻāϞāĻž: āĻāώā§āϧā§āϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ āύā§āϝāĻžā§ā§ āĻĻāĻžāĻĻ āϏāĻŦāĻā§ā§ā§ āĻŦā§āĻļāĻŋ āϏāύā§āĻĻā§āĻš āĻšāĻā§āĻā§āĨ¤ āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻāĻāĻāĻŋ āĻĒā§āĻĨāĻ āϏāĻšāĻžāĻŦāϏā§āĻĨāĻžāύāĻāĻžāϰ⧠āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϰā§āĻāĨ¤
Confidence: 0.70āĨ¤
đŠ 10. ORIGINAL PRESCRIPTION DRUG IDENTIFICATION
āĻŽā§āϞ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻāώā§āϧ āĻļāύāĻžāĻā§āϤāĻāϰāĻŖ
| No. | Drug â āĻāώā§āϧ | Generic â āĻā§āύā§āϰāĻŋāĻ | Intended Purpose â āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻĻā§āĻĻā§āĻļā§āϝ | Reading Confidence |
|---|---|---|---|---|
| 1 | Itracon SUBA 65 mg | Itraconazole â āĻāĻā§āϰāĻžāĻā§āύāĻžāĻāϞ | Systemic Antifungal â āĻŽā§āĻā§ āĻāĻžāĻā§āĻžāϰ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ | 0.99 |
| 2 | Tinacure Cream 30 g | Luliconazole 1% â āϞā§āϞāĻŋāĻā§āύāĻžāĻāϞ | Topical Antifungal â āϤā§āĻŦāĻā§āϰ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ | 0.98 |
| 3 | Zimax 500 mg | Azithromycin â āĻāĻāĻŋāĻĨā§āϰā§āĻŽāĻžāĻāϏāĻŋāύ | Antibiotic â āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžā§ā§āĻāĻŋāĻ | 0.95 |
| 4 | Fastel 180 mg | Fexofenadine â āĻĢā§āĻā§āϏā§āĻĢā§āύāĻžāĻĄāĻŋāύ | Antihistamine â āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻāώā§āϧ | 0.99 |
| 5 | ABC Bar | Probable antifungal cleansing bar â āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ āϏāĻžāĻŦāĻžāύ | Supportive skin care â āϤā§āĻŦāĻā§āϰ āϏāĻšāĻžā§āĻ āϝāϤā§āύ | 0.90 |
| 6 | Snofas Nasal Spray | Fluticasone Furoate â āĻĢā§āϞā§āĻāĻŋāĻāĻžāϏāύ āĻĢāĻŋāĻāϰā§ā§ā§āĻ | Intranasal Corticosteroid â āύāĻžāĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāϰā§āĻāĻŋāĻā§āϏā§āĻā§āϰā§ā§āĻĄ | 0.98 |
Prescription Legibility Warning â āĻšāĻžāϤā§āϰ āϞā§āĻāĻž āϏāĻŽā§āĻĒāϰā§āĻā§ āϏāϤāϰā§āĻāϤāĻž
Itracon SUBA-āĻāϰ āύāĻŋāĻā§ āĻāĻāĻžāϧāĻŋāĻ āĻĄā§āĻ āĻ āϏāĻŽā§āϏāĻāĻā§āϰāĻžāύā§āϤ āύāĻŋāϰā§āĻĻā§āĻļ āϰā§ā§āĻā§, āϤāĻŦā§ āϏā§āĻā§āϞ⧠āύāĻŋāϰā§āĻāϰāϝā§āĻā§āϝāĻāĻžāĻŦā§ āϏāĻŽā§āĻĒā§āϰā§āĻŖ āĻĒā§āĻž āϝāĻžāĻā§āĻā§ āύāĻžāĨ¤
Zimax-āĻāϰ āĻĒāĻžāĻļā§ āĻŦā§ āĻāĻāĻāĻŋ āĻāĻžāĻāĻž āĻŦāĻž āĻāĻŋāĻšā§āύ āϰā§ā§āĻā§āĨ¤ āĻāϰ āĻ āϰā§āĻĨ āĻāώā§āϧāĻāĻŋ āĻŦāĻžāϤāĻŋāϞ āĻāϰāĻž āĻšā§ā§āĻā§ āĻāĻŋ āύāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āύā§āĨ¤
āĻŦāĻžāĻāϞāĻž āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ: āĻŽā§āϞ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϏāĻā§āĻā§ āϝāĻžāĻāĻžāĻ āĻāĻžā§āĻž āĻāĻ āĻĻā§āĻ āĻāώā§āϧā§āϰ āĻĄā§āĻ āĻŦāĻž āĻŦā§āϝāĻŦāĻšāĻžāϰ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Confidence: 0.98āĨ¤
đ§ 11. COMPLETE MEDEx MEDICINE REVIEW
MedEx āĻ āύā§āϏāĻžāϰ⧠āĻĒā§āϰāϤāĻŋāĻāĻŋ āĻāώā§āϧā§āϰ āĻĒā§āϰā§āĻŖ ā§§ā§-āĻĒā§āϝāĻžāϰāĻžāĻŽāĻŋāĻāĻžāϰ āĻŦāĻŋāĻļā§āϞā§āώāĻŖ
đ MEDICINE 01 â ITRACON SUBA 65 MG
1. Generic Name â āĻā§āύā§āϰāĻŋāĻ āύāĻžāĻŽ
Itraconazole â āĻāĻā§āϰāĻžāĻā§āύāĻžāĻāϞāĨ¤
Confidence: 0.99āĨ¤
2. Brand Name â āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āύāĻžāĻŽ
Itracon SUBA 65 mg â Navana Pharmaceuticals Ltd.
āĻŦāĻžāĻāϞāĻž: āύāĻāĻžāύāĻž āĻĢāĻžāϰā§āĻŽāĻžāϏāĻŋāĻāĻāĻŋāĻā§āϝāĻžāϞāϏā§āϰ āĻāĻā§āϰāĻžāĻāύ āϏā§āĻŦāĻž ā§Ŧā§Ģ āĻŽāĻŋāĻā§āϰāĻž āĻā§āϝāĻžāĻĒāϏā§āϞāĨ¤
Confidence: 0.99āĨ¤
3. MedEx Alternate Brands â āĻŽā§āĻĄāĻāĻā§āϏ āĻ āύā§āϝāĻžā§ā§ āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
SUBA-i 65 mg, Subacon 65 mg, SuperItra 65 mg, Itracare SB 65 mg.
āĻŦāĻžāĻāϞāĻž: āĻāĻāĻ āĻā§āύā§āϰāĻŋāĻā§āϰ SUBA-āĻāĻžāϤā§ā§ āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄāĨ¤
Confidence: 0.98āĨ¤
4. MedEx Therapeutic Class â āĻŽā§āĻĄāĻāĻā§āϏā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžāĻāϤ āĻļā§āϰā§āĻŖāĻŋ
Drugs for subcutaneous and mycoses.
āĻŦāĻžāĻāϞāĻž: āϤā§āĻŦāĻā§āϰ āĻāĻā§āϰāϤāϰ āĻ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻāώā§āϧā§āϰ āĻļā§āϰā§āĻŖāĻŋāĨ¤
Confidence: 0.99āĨ¤
5. Pharmacological Class â āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Triazole Antifungal â āĻā§āϰāĻžā§āĻžāĻā§āϞ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞāĨ¤
āĻŦāĻžāĻāϞāĻž: Azole āĻļā§āϰā§āĻŖāĻŋāϰ āĻāϤā§āϰāĻžāĻāĻŦāĻŋāϰā§āϧ⧠āĻāώā§āϧāĨ¤
Confidence: 0.99āĨ¤
6. Use/Purpose â āĻāώā§āϧā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ
English: Treatment of susceptible superficial and selected systemic fungal infections.
āĻŦāĻžāĻāϞāĻž: āϏāĻāĻŦā§āĻĻāύāĻļā§āϞ āĻāĻĒāϰāĻŋāĻāĻžāĻā§āϰ āĻāϤā§āϰāĻžāĻ āϏāĻāĻā§āϰāĻŽāĻŖ āĻāĻŦāĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāĻā§āϰ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϰā§āĻā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžāĨ¤
Confidence: 0.99āĨ¤
7. Why Prescribed to This Patient â āĻāĻ āϰā§āĻā§āĻā§ āĻā§āύ āĻĻā§āĻā§āĻž āĻšāϤ⧠āĻĒāĻžāϰā§
English: Most likely intended for suspected dermatophytosis.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĻāĻžāĻĻ āĻŦāĻž āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϤā§āĻŦāĻā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻāύā§āϝ āĻĻā§āĻā§āĻž āĻšā§ā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.75āĨ¤
8. Side Effects â āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
English: Nausea, abdominal discomfort, headache, liver enzyme elevation, hepatitis, oedema and occasionally serious drug reactions.
āĻŦāĻžāĻāϞāĻž: āĻŦāĻŽāĻŋāĻāĻžāĻŦ, āĻĒā§āĻā§āϰ āĻ āϏā§āĻŦāϏā§āϤāĻŋ, āĻŽāĻžāĻĨāĻžāĻŦā§āϝāĻĨāĻž, āϞāĻŋāĻāĻžāϰā§āϰ āĻāύāĻāĻžāĻāĻŽ āĻŦā§āĻĻā§āϧāĻŋ, āĻšā§āĻĒāĻžāĻāĻžāĻāĻāĻŋāϏ, āĻļāϰā§āϰ āĻĢā§āϞ⧠āϝāĻžāĻā§āĻž āĻāĻŦāĻ āĻāĻāύ⧠āĻā§āϰā§āϤāϰ āĻāώā§āϧ-āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻžāĨ¤
Confidence: 0.98āĨ¤
9. Direct MedEx Link â āϏāϰāĻžāϏāϰāĻŋ āĻŽā§āĻĄāĻāĻā§āϏ āϞāĻŋāĻāĻ
āĻŦāĻžāĻāϞāĻž: āĻāĻ āϞāĻŋāĻāĻā§ āĻāώā§āϧā§āϰ āĻŽā§āϞ MedEx āϤāĻĨā§āϝ, āĻĄā§āĻ, āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž āĻāĻŦāĻ āĻŽā§āϞā§āϝ āĻĻā§āĻāĻž āϝāĻžāĻŦā§āĨ¤
10. Unit Price, Strip Price and Other Composition â āĻāĻāĻ āĻŽā§āϞā§āϝ, āϏā§āĻā§āϰāĻŋāĻĒ āĻŽā§āϞā§āϝ āĻ āĻ āύā§āϝāĻžāύā§āϝ āĻāĻ āύ
Unit Price â āĻĒā§āϰāϤāĻŋ āĻā§āϝāĻžāĻĒāϏā§āϞ: ā§ŗ20āĨ¤
Strip Price â ā§§ā§Ļ āĻā§āϝāĻžāĻĒāϏā§āϞ: ā§ŗ200āĨ¤
Pack Price â ā§Šā§Ļ āĻā§āϝāĻžāĻĒāϏā§āϞ: ā§ŗ600āĨ¤
Other Forms â āĻ āύā§āϝāĻžāύā§āϝ āĻāĻ āύ: 100 mg capsule, 200 mg tablet, 50 mg/5 mL oral solution â ā§§ā§Ļā§Ļ āĻŽāĻŋāĻā§āϰāĻž āĻā§āϝāĻžāĻĒāϏā§āϞ, ⧍ā§Ļā§Ļ āĻŽāĻŋāĻā§āϰāĻž āĻā§āϝāĻžāĻŦāϞā§āĻ āĻāĻŦāĻ āĻāĻžāĻā§āĻžāϰ āϏāϞāĻŋāĻāĻļāύāĨ¤
Confidence: 0.99āĨ¤
11. Mechanism of Action â āĻāώā§āϧā§āϰ āĻāĻžāϰā§āϝāĻĒā§āϰāĻā§āϰāĻŋā§āĻž
English: Inhibits fungal CYP-dependent lanosterol 14-alpha-demethylase, reducing ergosterol synthesis and impairing fungal cell membrane function.
āĻŦāĻžāĻāϞāĻž: āĻāϤā§āϰāĻžāĻā§āϰ Ergosterol āϤā§āϰāĻŋāϰ āĻĒā§āϰāĻā§āϰāĻŋā§āĻž āĻŦāĻžāϧāĻžāĻā§āϰāϏā§āϤ āĻāϰ⧠āĻā§āώāĻāĻŋāϞā§āϞāĻŋāϰ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻāĻžāϰā§āϝāĻā§āϰāĻŽ āύāώā§āĻ āĻāϰā§āĨ¤
Confidence: 0.99āĨ¤
12. Drug Indications â āϝā§āϏāĻŦ āϰā§āĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻšā§
Tinea corporis â āĻļāϰā§āϰā§āϰ āĻĻāĻžāĻĻāĨ¤
Tinea cruris â āĻā§āĻāĻāĻāĻŋāϰ āĻĻāĻžāĻĻāĨ¤
Tinea pedis â āĻĒāĻžā§ā§āϰ āĻĻāĻžāĻĻāĨ¤
Pityriasis versicolor â āĻā§āϞāĻŋāĨ¤
Onychomycosis â āύāĻā§āϰ āĻāϤā§āϰāĻžāĻ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
Selected systemic mycoses â āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāĻā§āϰ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
Confidence: 0.98āĨ¤
13. Drug Interactions and Contraindications â āĻāώā§āϧā§āϰ āĻĒāĻžāϰāϏā§āĻĒāϰāĻŋāĻ āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž āĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ āύāĻŋāώā§āϧ
English: Itraconazole strongly inhibits CYP3A4 and can interact with simvastatin, selected sedatives, antiarrhythmics and other medicines.
āĻŦāĻžāĻāϞāĻž: Itraconazole CYP3A4 āĻāύāĻāĻžāĻāĻŽā§āϰ āĻāĻžāϰā§āϝāĻā§āϰāĻŽ āĻāĻŽāĻžā§āĨ¤ āĻĢāϞ⧠Simvastatin, āĻāĻŋāĻā§ āĻā§āĻŽā§āϰ āĻāώā§āϧ, āĻšā§āĻĻā§âāϏā§āĻĒāύā§āĻĻāύā§āϰ āĻāώā§āϧ āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ āĻāώā§āϧā§āϰ āϏāĻā§āĻā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
English: Avoid use in relevant contraindicated conditions, including pregnancy and certain cardiac conditions, according to product labeling.
āĻŦāĻžāĻāϞāĻž: āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻāĻŦāĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻšā§āĻĻā§âāϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻāώā§āϧā§āϰ āĻ āύā§āĻŽā§āĻĻāĻŋāϤ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āĻ āύā§āϝāĻžā§ā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻā§āĻžāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.98āĨ¤
14. Precautions and Warnings â āϏāϤāϰā§āĻāϤāĻž
English: Review liver disease, heart failure, pregnancy status and concurrent medication before use.
āĻŦāĻžāĻāϞāĻž: āĻāώā§āϧ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻā§ āϞāĻŋāĻāĻžāϰā§āϰ āϰā§āĻ, āĻšā§āĻĻā§âāϝāύā§āϤā§āϰā§āϰ āϏāĻŽāϏā§āϝāĻž, āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āĻ āύā§āϝāĻžāύā§āϝ āĻāώā§āϧā§āϰ āĻāϤāĻŋāĻšāĻžāϏ āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.98āĨ¤
15. Dosage and Administration â āĻŽāĻžāϤā§āϰāĻž āĻ āϏā§āĻŦāύāĻŦāĻŋāϧāĻŋ
MedEx Reference Dose â āĻŽā§āĻĄāĻāĻā§āϏā§āϰ āĻāĻĻāĻžāĻšāϰāĻŖ āĻĄā§āĻ:
For tinea corporis/cruris, the SUBA formulation monograph lists 65 mg once daily for 15 days or 65 mg twice daily for 7 days.
āĻŦāĻžāĻāϞāĻž: āĻļāϰā§āϰ āĻŦāĻž āĻā§āĻāĻāĻāĻŋāϰ āĻĻāĻžāĻĻā§āϰ āĻā§āώā§āϤā§āϰ⧠MedEx SUBA formulation-āĻāϰ āĻāύā§āϝ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻĒāϰāĻŋāϏā§āĻĨāĻŋāϤāĻŋāϤ⧠āĻĻā§āύāĻŋāĻ ā§Ŧā§Ģ āĻŽāĻŋāĻā§āϰāĻž ā§§ā§Ģ āĻĻāĻŋāύ āĻ āĻĨāĻŦāĻž āĻĻā§āύāĻŋāĻ āĻĻā§āĻāĻŦāĻžāϰ ā§Ŧā§Ģ āĻŽāĻŋāĻā§āϰāĻž ā§ āĻĻāĻŋāύā§āϰ āĻĄā§āĻ āĻāϞā§āϞā§āĻ āĻāϰā§āĻā§āĨ¤
Important â āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ: This is reference information, not a confirmed dose for Nasima Begum.
āĻŦāĻžāĻāϞāĻž: āĻāĻāĻŋ āϏāĻžāϧāĻžāϰāĻŖ āϤāĻĨā§āϝāĨ¤ āύāĻžāϏāĻŋāĻŽāĻž āĻŦā§āĻāĻŽā§āϰ āĻāύā§āϝ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āύāĻŋāϰā§āϧāĻžāϰāĻŋāϤ āĻĄā§āĻ āύāĻŋāĻļā§āĻāĻŋāϤ āύā§āĨ¤
SUBA and conventional itraconazole formulations must not be substituted milligram-for-milligram without clinical verification.
āĻŦāĻžāĻāϞāĻž: SUBA āĻ āϏāĻžāϧāĻžāϰāĻŖ Itraconazole formulation āĻāĻāĻ āĻŽāĻŋāϞāĻŋāĻā§āϰāĻžāĻŽ āϧāϰ⧠āϏāϰāĻžāϏāϰāĻŋ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Confidence: 0.99 for monograph information; prescription-dose certainty: lowāĨ¤
16. Pregnancy and Lactation â āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύ
English: Systemic itraconazole is generally avoided or contraindicated in pregnancy, depending on the indication and product labeling. Breastfeeding requires specialist assessment.
āĻŦāĻžāĻāϞāĻž: āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻžā§ āĻŽā§āĻā§ āĻāĻžāĻā§āĻžāϰ Itraconazole āϏāĻžāϧāĻžāϰāĻŖāϤ āĻā§āĻŋā§ā§ āĻāϞāϤ⧠āĻšā§ āĻ āĻĨāĻŦāĻž āύāĻŋāώāĻŋāĻĻā§āϧ āĻĨāĻžāĻā§āĨ¤ āϏā§āϤāύā§āϝāĻĻāĻžāύāĻāĻžāϞ⧠āĻŦāĻŋāĻļā§āώāĻā§āĻā§āϰ āĻŽā§āϞā§āϝāĻžā§āύ āĻĒā§āϰā§ā§āĻāύāĨ¤
Confidence: 0.98āĨ¤
17. Other Compositions / Combinations â āĻ āύā§āϝāĻžāύā§āϝ āĻāĻ āύ āĻŦāĻž āϏāĻāĻŽāĻŋāĻļā§āϰāĻŖ
English: Conventional capsules, tablets, oral solutions and SUBA formulations are available. No fixed combination is confirmed from this prescription.
āĻŦāĻžāĻāϞāĻž: āϏāĻžāϧāĻžāϰāĻŖ āĻā§āϝāĻžāĻĒāϏā§āϞ, āĻā§āϝāĻžāĻŦāϞā§āĻ, āĻāĻžāĻā§āĻžāϰ āϏāϞāĻŋāĻāĻļāύ āĻāĻŦāĻ SUBA formulation āĻĒāĻžāĻā§āĻž āϝāĻžā§āĨ¤ āĻāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻā§āύ⧠fixed-dose combination āĻļāύāĻžāĻā§āϤ āĻšā§āύāĻŋāĨ¤
Confidence: 0.98āĨ¤
Clinical Verdict â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ
English: Potentially appropriate for selected fungal infections, but exact indication, dose, duration and safety require confirmation.
āĻŦāĻžāĻāϞāĻž: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖā§ āĻāώā§āϧāĻāĻŋ āĻāĻĒāϝā§āĻā§ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ āϤāĻŦā§ āϰā§āĻ, āĻĄā§āĻ, āϏāĻŽā§āĻāĻžāϞ āĻāĻŦāĻ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
Overall Confidence: 0.85āĨ¤
đ MEDICINE 02 â TINACURE 1% CREAM
1. Generic Name â āĻā§āύā§āϰāĻŋāĻ āύāĻžāĻŽ
Luliconazole 1% â āϞā§āϞāĻŋāĻā§āύāĻžāĻāϞ ā§§%āĨ¤
Confidence: 0.99āĨ¤
2. Brand Name â āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āύāĻžāĻŽ
Tinacure Cream â Healthcare Pharmaceuticals Ltd.
āĻŦāĻžāĻāϞāĻž: āĻšā§āϞāĻĨāĻā§ā§āĻžāϰ āĻĢāĻžāϰā§āĻŽāĻžāϏāĻŋāĻāĻāĻŋāĻā§āϝāĻžāϞāϏā§āϰ āĻāĻŋāύāĻžāĻāĻŋāĻāϰ āĻā§āϰāĻŋāĻŽāĨ¤
Confidence: 0.99āĨ¤
3. MedEx Alternate Brands â āĻŽā§āĻĄāĻāĻā§āϏā§āϰ āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Lulicure, Lulider, Lulikill, Lulima, Lulitin, Lulitop.
āĻŦāĻžāĻāϞāĻž: āĻāĻāĻ āĻā§āύā§āϰāĻŋāĻā§āϰ āĻŦāĻŋāĻāϞā§āĻĒ āĻā§āϰāĻŋāĻŽāĨ¤
Confidence: 0.98āĨ¤
4. MedEx Therapeutic Class â āĻāĻŋāĻāĻŋā§āϏāĻžāĻāϤ āĻļā§āϰā§āĻŖāĻŋ
Miscellaneous topical agents â āϤā§āĻŦāĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻ āύā§āϝāĻžāύā§āϝ āĻāĻŋāĻāĻŋā§āϏāĻžāĻāϤ āĻāώā§āϧāĨ¤
Confidence: 0.99āĨ¤
5. Pharmacological Class â āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Topical Azole Antifungal â āϤā§āĻŦāĻā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻ ā§āϝāĻžāĻā§āϞ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞāĨ¤
Confidence: 0.99āĨ¤
6. Use/Purpose â āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ
English: Treatment of selected superficial dermatophyte infections.
āĻŦāĻžāĻāϞāĻž: āϤā§āĻŦāĻā§āϰ āĻāĻĒāϰāĻŋāĻāĻžāĻā§āϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžāĨ¤
Confidence: 0.99āĨ¤
7. Why Prescribed to This Patient â āĻā§āύ āĻĻā§āĻā§āĻž āĻšāϤ⧠āĻĒāĻžāϰā§
English: Probably intended to treat suspected fungal lesions on the skin.
āĻŦāĻžāĻāϞāĻž: āϤā§āĻŦāĻā§āϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĻāĻžāĻĻ āĻŦāĻž āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āĻā§āώāϤā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻāύā§āϝ āĻĻā§āĻā§āĻž āĻšā§ā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.85āĨ¤
8. Side Effects â āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
English: Local burning, irritation, erythema and contact dermatitis.
āĻŦāĻžāĻāϞāĻž: āĻā§āϰāĻŋāĻŽ āϞāĻžāĻāĻžāύā§āϰ āϏā§āĻĨāĻžāύ⧠āĻā§āĻŦāĻžāϞāĻž, āϤā§āĻŦāĻ āϞāĻžāϞ āĻšāĻā§āĻž āĻ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻāύāĻŋāϤ āĻĒā§āϰāĻĻāĻžāĻšāĨ¤
Confidence: 0.98āĨ¤
9. Direct MedEx Link â āĻŽā§āĻĄāĻāĻā§āϏ āϞāĻŋāĻāĻ
10. Unit Price, Strip Price and Composition â āĻŽā§āϞā§āϝ āĻ āĻāĻ āύ
30 g Tube Price â ā§Šā§Ļ āĻā§āϰāĻžāĻŽ āĻāĻŋāĻāĻŦ: ā§ŗ280āĨ¤
Strip Price â āϏā§āĻā§āϰāĻŋāĻĒ āĻŽā§āϞā§āϝ: Not applicable â āĻĒā§āϰāϝā§āĻā§āϝ āύā§āĨ¤
Composition â āĻāĻ āύ: Luliconazole 1% â āϞā§āϞāĻŋāĻā§āύāĻžāĻāϞ ā§§%āĨ¤
Confidence: 0.99āĨ¤
11. Mechanism â āĻāĻžāϰā§āϝāĻĒā§āϰāĻā§āϰāĻŋā§āĻž
English: Inhibits fungal lanosterol demethylase and disrupts ergosterol synthesis.
āĻŦāĻžāĻāϞāĻž: āĻāϤā§āϰāĻžāĻā§āϰ āĻā§āώāĻāĻŋāϞā§āϞāĻŋ āϤā§āϰāĻŋāϰ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻāĻĒāĻžāĻĻāĻžāύ Ergosterol āĻā§āĻĒāĻžāĻĻāύ āĻŦāĻžāϧāĻžāĻā§āϰāϏā§āϤ āĻāϰā§āĨ¤
Confidence: 0.99āĨ¤
12. Indications â āĻŦā§āϝāĻŦāĻšāĻžāϰāϝā§āĻā§āϝ āϰā§āĻ
Tinea corporis â āĻļāϰā§āϰā§āϰ āĻĻāĻžāĻĻāĨ¤
Tinea cruris â āĻā§āĻāĻāĻāĻŋāϰ āĻĻāĻžāĻĻāĨ¤
Interdigital tinea pedis â āĻĒāĻžā§ā§āϰ āĻāĻā§āϞā§āϰ āĻĢāĻžāĻāĻā§āϰ āĻĻāĻžāĻĻāĨ¤
Confidence: 0.99āĨ¤
13. Interactions and Contraindications â āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž āĻ āύāĻŋāώā§āϧāĻžāĻā§āĻāĻž
English: Contraindicated in patients with known hypersensitivity to luliconazole.
āĻŦāĻžāĻāϞāĻž: Luliconazole-āĻ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻĨāĻžāĻāϞ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
English: Clinically significant systemic interactions are less likely because systemic exposure is limited.
āĻŦāĻžāĻāϞāĻž: āϤā§āĻŦāĻā§āϰ āĻŽāĻžāϧā§āϝāĻŽā§ āĻļāϰā§āϰ⧠āĻļā§āώāĻŖ āĻāĻŽ āĻšāĻā§āĻžā§ āĻā§āϰā§āϤāϰ systemic interaction-āĻāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āϤā§āϞāύāĻžāĻŽā§āϞāĻ āĻāĻŽāĨ¤
Confidence: 0.95āĨ¤
14. Precautions â āϏāϤāϰā§āĻāϤāĻž
English: For external use only; avoid eyes, mouth and mucosal surfaces.
āĻŦāĻžāĻāϞāĻž: āĻļā§āϧ⧠āϤā§āĻŦāĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāύā§āϝāĨ¤ āĻā§āĻ, āĻŽā§āĻ āĻ āĻļā§āϞā§āώā§āĻŽāĻŋāĻ āĻāĻŋāϞā§āϞāĻŋāϤ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Confidence: 0.99āĨ¤
15. Dosage and Administration â āĻŽāĻžāϤā§āϰāĻž āĻ āĻŦā§āϝāĻŦāĻšāĻžāϰāĻŦāĻŋāϧāĻŋ
English: MedEx lists once-daily application for one week in tinea corporis/cruris and two weeks in interdigital tinea pedis.
āĻŦāĻžāĻāϞāĻž: MedEx āĻ āύā§āϝāĻžā§ā§ āĻļāϰā§āϰ āĻŦāĻž āĻā§āĻāĻāĻāĻŋāϰ āĻĻāĻžāĻĻā§ āϏāĻžāϧāĻžāϰāĻŖāϤ āĻĻāĻŋāύ⧠āĻāĻāĻŦāĻžāϰ āĻāĻ āϏāĻĒā§āϤāĻžāĻš āĻāĻŦāĻ āĻĒāĻžā§ā§āϰ āĻāĻā§āϞā§āϰ āĻĢāĻžāĻāĻā§āϰ āĻĻāĻžāĻĻā§ āĻĻāĻŋāύ⧠āĻāĻāĻŦāĻžāϰ āĻĻā§āĻ āϏāĻĒā§āϤāĻžāĻš āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āύāĻŋāϰā§āĻĻā§āĻļ āϰā§ā§āĻā§āĨ¤
Important â āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ: Patient-specific instructions must be verified from the treating physician.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āĻāύā§āϝ āύāĻŋāϰā§āϧāĻžāϰāĻŋāϤ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻŦā§āϝāĻŦāĻšāĻžāϰāĻŦāĻŋāϧāĻŋ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻāĻžāĻ āĻĨā§āĻā§ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.99āĨ¤
16. Pregnancy and Lactation â āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύ
English: Use after benefitârisk assessment; avoid application where an infant could ingest the medicine.
āĻŦāĻžāĻāϞāĻž: āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύāĻāĻžāϞ⧠āĻĒā§āϰā§ā§āĻāύā§ā§āϤāĻž āĻ āĻā§āĻāĻāĻŋ āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤ āĻļāĻŋāĻļā§āϰ āĻŽā§āĻā§ āϞāĻžāĻāĻžāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āϰā§ā§āĻā§ āĻāĻŽāύ āϏā§āĻĨāĻžāύ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻā§āĻžāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.95āĨ¤
17. Other Compositions / Combinations â āĻ āύā§āϝāĻžāύā§āϝ āĻāĻ āύ
English: Other luliconazole 1% brands and lotion formulations exist; no specific fixed-dose combination is identified here.
āĻŦāĻžāĻāϞāĻž: Luliconazole 1%-āĻāϰ āĻ āύā§āϝāĻžāύā§āϝ āĻā§āϰāĻŋāĻŽ āĻ āϞā§āĻļāύ āĻĒāĻžāĻā§āĻž āϝāĻžā§āĨ¤ āĻāĻāĻžāύ⧠āĻā§āύ⧠āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻŽāĻŋāĻļā§āϰ-āĻāώā§āϧ āĻļāύāĻžāĻā§āϤ āĻāϰāĻž āĻšā§āύāĻŋāĨ¤
Confidence: 0.98āĨ¤
Clinical Verdict â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ
English: A reasonable topical antifungal option if a compatible dermatophyte infection is confirmed.
āĻŦāĻžāĻāϞāĻž: āĻāĻĒāϝā§āĻā§āϤ āϧāϰāύā§āϰ āĻĻāĻžāĻĻ āύāĻŋāĻļā§āĻāĻŋāϤ āĻšāϞ⧠āĻāĻāĻŋ āĻāĻžāϰā§āϝāĻāϰ āĻŦāĻžāĻšā§āϝāĻŋāĻ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ āĻāĻŋāĻāĻŋā§āϏāĻž āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Overall Confidence: 0.90āĨ¤
đ MEDICINE 03 â ZIMAX 500 MG
1. Generic Name â āĻā§āύā§āϰāĻŋāĻ āύāĻžāĻŽ
Azithromycin Dihydrate â āĻāĻāĻŋāĻĨā§āϰā§āĻŽāĻžāĻāϏāĻŋāύ āĻĄāĻžāĻāĻšāĻžāĻāĻĄā§āϰā§āĻāĨ¤
Confidence: 0.99āĨ¤
2. Brand Name â āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āύāĻžāĻŽ
Zimax 500 mg â Square Pharmaceuticals PLC.
āĻŦāĻžāĻāϞāĻž: āϏā§āĻā§āĻžāϰ āĻĢāĻžāϰā§āĻŽāĻžāϏāĻŋāĻāĻāĻŋāĻā§āϝāĻžāϞāϏā§āϰ āĻāĻŋāĻŽā§āϝāĻžāĻā§āϏ ā§Ģā§Ļā§Ļ āĻŽāĻŋāĻā§āϰāĻž āĻā§āϝāĻžāĻŦāϞā§āĻāĨ¤
Confidence: 0.99āĨ¤
3. MedEx Alternate Brands â āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Other azithromycin brands include Zithrin and various locally marketed azithromycin products.
āĻŦāĻžāĻāϞāĻž: Zithrin āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ āĻā§āĻŽā§āĻĒāĻžāύāĻŋāϰ Azithromycin āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āĻĒāĻžāĻā§āĻž āϝāĻžā§āĨ¤
Confidence: 0.95āĨ¤
4. MedEx Therapeutic Class â āĻāĻŋāĻāĻŋā§āϏāĻžāĻāϤ āĻļā§āϰā§āĻŖāĻŋ
Macrolides â āĻŽā§āϝāĻžāĻā§āϰā§āϞāĻžāĻāĻĄ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžā§ā§āĻāĻŋāĻāĨ¤
Confidence: 0.99āĨ¤
5. Pharmacological Class â āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Azalide Antibiotic â āĻāĻāĻžāϞāĻžāĻāĻĄ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžā§ā§āĻāĻŋāĻāĨ¤
Confidence: 0.99āĨ¤
6. Use/Purpose â āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ
English: Treatment of susceptible bacterial infections.
āĻŦāĻžāĻāϞāĻž: āϏāĻāĻŦā§āĻĻāύāĻļā§āϞ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžāĨ¤
Confidence: 0.99āĨ¤
7. Why Prescribed to This Patient â āĻā§āύ āĻĻā§āĻā§āĻž āĻšāϤ⧠āĻĒāĻžāϰā§
English: A bacterial infection may have been considered, but the indication is undocumented and the entry may have been crossed out.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻāĻŋā§āϏāĻ āĻšā§āϤ⧠āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰā§āĻāĻŋāϞā§āύāĨ¤ āϤāĻŦā§ āĻāĻžāϰāĻŖ āϞā§āĻāĻž āύā§āĻ āĻāĻŦāĻ āĻāώā§āϧāĻāĻŋ āĻā§āĻā§ āĻĻā§āĻā§āĻž āĻšā§ā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.25āĨ¤
8. Side Effects â āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
English: Nausea, diarrhoea, abdominal pain, liver injury and possible QT-interval prolongation.
āĻŦāĻžāĻāϞāĻž: āĻŦāĻŽāĻŋāĻāĻžāĻŦ, āĻĄāĻžā§āϰāĻŋā§āĻž, āĻĒā§āĻāĻŦā§āϝāĻĨāĻž, āϞāĻŋāĻāĻžāϰā§āϰ āϏāĻŽāϏā§āϝāĻž āĻāĻŦāĻ āĻāĻŋāĻā§ āϰā§āĻā§āϰ āĻšā§āĻĻā§âāϏā§āĻĒāύā§āĻĻāύā§āϰ āĻŦā§āĻĻā§āϝā§āϤāĻŋāĻ āĻāύā§āĻĻā§ āĻĒāϰāĻŋāĻŦāϰā§āϤāύāĨ¤
Confidence: 0.98āĨ¤
9. Direct MedEx Link â āĻŽā§āĻĄāĻāĻā§āϏ āϞāĻŋāĻāĻ
10. Unit Price, Strip Price and Composition â āĻŽā§āϞā§āϝ āĻ āĻāĻ āύ
Unit Price â āĻĒā§āϰāϤāĻŋ āĻā§āϝāĻžāĻŦāϞā§āĻ: ā§ŗ40āĨ¤
Strip Price â āĻā§āĻāĻŋ āĻā§āϝāĻžāĻŦāϞā§āĻ: ā§ŗ240āĨ¤
Other Forms â āĻ āύā§āϝāĻžāύā§āϝ āĻāĻ āύ: 250 mg capsule, 200 mg/5 mL suspension, 500 mg IV preparation â ⧍ā§Ģā§Ļ āĻŽāĻŋāĻā§āϰāĻž āĻā§āϝāĻžāĻĒāϏā§āϞ, āϏāĻžāϏāĻĒā§āύāĻļāύ āĻ āĻāύāĻā§āĻāĻļāύāĨ¤
Confidence: 0.99āĨ¤
11. Mechanism â āĻāĻžāϰā§āϝāĻĒā§āϰāĻā§āϰāĻŋā§āĻž
English: Binds to the bacterial 50S ribosomal subunit and inhibits protein synthesis.
āĻŦāĻžāĻāϞāĻž: āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϰ 50S Ribosome-āĻāϰ āϏāĻā§āĻā§ āϝā§āĻā§āϤ āĻšā§ā§ āĻĒā§āϰā§ā§āĻāύā§ā§ āĻĒā§āϰā§āĻāĻŋāύ āϤā§āϰāĻŋ āĻŦāĻžāϧāĻžāĻā§āϰāϏā§āϤ āĻāϰā§āĨ¤
Confidence: 0.99āĨ¤
12. Indications â āĻŦā§āϝāĻŦāĻšāĻžāϰāϝā§āĻā§āϝ āϰā§āĻ
Selected respiratory bacterial infections â āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻļā§āĻŦāĻžāϏāϤāύā§āϤā§āϰā§āϰ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻž āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
Selected skin and soft-tissue infections â āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϤā§āĻŦāĻ āĻ āĻā§āĻŽāϞ āĻāϞāĻžāϰ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻž āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
Selected sexually transmitted bacterial infections â āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϝā§āύāĻŦāĻžāĻšāĻŋāϤ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻž āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
Confidence: 0.98āĨ¤
13. Interactions and Contraindications â āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž āĻ āύāĻŋāώā§āϧāĻžāĻā§āĻāĻž
English: Caution is needed with QT-prolonging medicines, certain antiarrhythmics, warfarin and digoxin.
āĻŦāĻžāĻāϞāĻž: āĻšā§āĻĻā§âāϏā§āĻĒāύā§āĻĻāύā§āϰ āĻāύā§āĻĻā§ āĻĒāϰāĻŋāĻŦāϰā§āϤāύāĻāĻžāϰ⧠āĻāώā§āϧ, āĻāĻŋāĻā§ āĻšā§āĻĻā§âāϰā§āĻā§āϰ āĻāώā§āϧ, Warfarin āĻāĻŦāĻ Digoxin-āĻāϰ āϏāĻā§āĻā§ āϏāϤāϰā§āĻāϤāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
Confidence: 0.95āĨ¤
14. Precautions â āϏāϤāϰā§āĻāϤāĻž
English: Assess bacterial indication, macrolide allergy, liver function and cardiac risk.
āĻŦāĻžāĻāϞāĻž: āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻž āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻāĻžāϰāĻŖ, Macrolide āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ, āϞāĻŋāĻāĻžāϰā§āϰ āĻ āĻŦāϏā§āĻĨāĻž āĻāĻŦāĻ āĻšā§āĻĻā§âāϰā§āĻā§āϰ āĻā§āĻāĻāĻŋ āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.98āĨ¤
15. Dosage and Administration â āĻŽāĻžāϤā§āϰāĻž āĻ āϏā§āĻŦāύāĻŦāĻŋāϧāĻŋ
English: Adult dosing depends on the bacterial infection and clinical indication. A 500 mg once-daily three-day regimen is used for some indications.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻāĻā§āĻĻā§ āĻĄā§āĻ āĻāĻŋāύā§āύ āĻšā§āĨ¤ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāĻŋāĻā§ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāĻāύāĻŋāϤ āϰā§āĻā§ ā§Ģā§Ļā§Ļ āĻŽāĻŋāĻā§āϰāĻž āĻĻāĻŋāύ⧠āĻāĻāĻŦāĻžāϰ āϤāĻŋāύ āĻĻāĻŋāύā§āϰ āĻĄā§āĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻšā§āĨ¤
Important â āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ: This is not a recommended regimen for the current patient because the indication and prescription status are uncertain.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āĻāύā§āϝ āĻāĻāĻŋ āĻā§āύ⧠āύāϤā§āύ āĻĄā§āĻ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āύā§āĨ¤ āĻāĻ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻāώā§āϧāĻāĻŋāϰ āĻĒā§āϰā§ā§āĻāύā§ā§āϤāĻž āĻāĻŦāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āĻĨā§āĻā§ āĻŦāĻžāϤāĻŋāϞ āĻāϰāĻž āĻšā§ā§āĻā§ āĻāĻŋ āύāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āύā§āĨ¤
Confidence: 0.98 for general dosing informationāĨ¤
16. Pregnancy and Lactation â āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύ
English: May be used when appropriately indicated after clinical assessment.
āĻŦāĻžāĻāϞāĻž: āĻāĻĒāϝā§āĻā§āϤ āĻāĻŋāĻāĻŋā§āϏāĻžāĻāϤ āĻāĻžāϰāĻŖ āĻĨāĻžāĻāϞ⧠āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻŽā§āϞā§āϝāĻžā§āύā§āϰ āĻāĻŋāϤā§āϤāĻŋāϤ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.95āĨ¤
17. Other Compositions / Combinations â āĻ āύā§āϝāĻžāύā§āϝ āĻāĻ āύ
English: Capsules, tablets, oral suspension and intravenous formulations are available.
āĻŦāĻžāĻāϞāĻž: āĻā§āϝāĻžāĻĒāϏā§āϞ, āĻā§āϝāĻžāĻŦāϞā§āĻ, āĻāĻžāĻā§āĻžāϰ āϏāĻžāϏāĻĒā§āύāĻļāύ āĻāĻŦāĻ āĻāύāĻā§āĻāĻļāύ āĻĒāĻžāĻā§āĻž āϝāĻžā§āĨ¤
Confidence: 0.99āĨ¤
Clinical Verdict â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ
English: Azithromycin has no direct antifungal activity against dermatophytes. Its use requires a separate bacterial indication.
āĻŦāĻžāĻāϞāĻž: Azithromycin āĻĻāĻžāĻĻā§āϰ āĻāϤā§āϰāĻžāĻā§āϰ āĻŦāĻŋāϰā§āĻĻā§āϧ⧠āĻāĻžāĻ āĻāϰ⧠āύāĻžāĨ¤ āĻāĻāĻŋ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāϤ⧠āĻšāϞ⧠āĻĒā§āĻĨāĻ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϝā§āĻā§āϤāĻŋāϏāĻāĻāϤ āĻāĻžāϰāĻŖ āĻĨāĻžāĻāϤ⧠āĻšāĻŦā§āĨ¤
Overall Confidence: 0.98 for pharmacology; 0.25 for this patient’s indicationāĨ¤
đ MEDICINE 04 â FASTEL 180 MG
1. Generic Name â āĻā§āύā§āϰāĻŋāĻ āύāĻžāĻŽ
Fexofenadine Hydrochloride â āĻĢā§āĻā§āϏā§āĻĢā§āύāĻžāĻĄāĻŋāύ āĻšāĻžāĻāĻĄā§āϰā§āĻā§āϞā§āϰāĻžāĻāĻĄāĨ¤
Confidence: 0.99āĨ¤
2. Brand Name â āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āύāĻžāĻŽ
Fastel 180 mg â Radiant Pharmaceuticals Ltd.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻĄāĻŋā§ā§āύā§āĻ āĻĢāĻžāϰā§āĻŽāĻžāϏāĻŋāĻāĻāĻŋāĻā§āϝāĻžāϞāϏā§āϰ āĻĢāĻžāϏā§āĻā§āϞ ā§§ā§Žā§Ļ āĻŽāĻŋāĻā§āϰāĻž āĻā§āϝāĻžāĻŦāϞā§āĻāĨ¤
Confidence: 0.99āĨ¤
3. MedEx Alternate Brands â āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Fenadin and other fexofenadine brands.
āĻŦāĻžāĻāϞāĻž: Fenadin āĻāĻŦāĻ āĻāĻāĻ āĻā§āύā§āϰāĻŋāĻā§āϰ āĻ āύā§āϝāĻžāύā§āϝ āĻŦā§āϰā§āϝāĻžāύā§āĻĄāĨ¤
Confidence: 0.95āĨ¤
4. MedEx Therapeutic Class â āĻāĻŋāĻāĻŋā§āϏāĻžāĻāϤ āĻļā§āϰā§āĻŖāĻŋ
Anti-histamine â āĻ ā§āϝāĻžāύā§āĻāĻŋāĻšāĻŋāϏā§āĻāĻžāĻŽāĻŋāύāĨ¤
Confidence: 0.99āĨ¤
5. Pharmacological Class â āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Second-Generation H1 Antihistamine â āĻĻā§āĻŦāĻŋāϤā§ā§ āĻĒā§āϰāĻāύā§āĻŽā§āϰ H1 āĻ ā§āϝāĻžāύā§āĻāĻŋāĻšāĻŋāϏā§āĻāĻžāĻŽāĻŋāύāĨ¤
Confidence: 0.99āĨ¤
6. Use/Purpose â āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ
English: Relief of allergic rhinitis symptoms and urticaria.
āĻŦāĻžāĻāϞāĻž: āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻāĻŦāĻ āϤā§āĻŦāĻā§ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻāύāĻŋāϤ āĻāĻžāĻāĻž āĻāĻ āĻžāϰ āĻāĻĒāϏāϰā§āĻ āĻāĻŽāĻžāύā§āĨ¤
Confidence: 0.99āĨ¤
7. Why Prescribed to This Patient â āĻā§āύ āĻĻā§āĻā§āĻž āĻšāϤ⧠āĻĒāĻžāϰā§
English: Possibly for allergic rhinitis or associated itching.
āĻŦāĻžāĻāϞāĻž: āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻ āĻĨāĻŦāĻž āϤā§āĻŦāĻā§āϰ āĻā§āϞāĻāĻžāύāĻŋ āĻāĻŽāĻžāύā§āϰ āĻāύā§āϝ āĻĻā§āĻā§āĻž āĻšā§ā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.80āĨ¤
8. Side Effects â āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
English: Headache, dizziness, nausea and occasional drowsiness.
āĻŦāĻžāĻāϞāĻž: āĻŽāĻžāĻĨāĻžāĻŦā§āϝāĻĨāĻž, āĻŽāĻžāĻĨāĻž āĻā§āϰāĻž, āĻŦāĻŽāĻŋāĻāĻžāĻŦ āĻāĻŦāĻ āĻāĻāύ⧠āĻāĻŋāĻŽā§āύāĻŋāĨ¤
Confidence: 0.98āĨ¤
9. Direct MedEx Link â āĻŽā§āĻĄāĻāĻā§āϏ āϞāĻŋāĻāĻ
10. Unit Price, Strip Price and Composition â āĻŽā§āϞā§āϝ āĻ āĻāĻ āύ
Unit Price â āĻĒā§āϰāϤāĻŋ āĻā§āϝāĻžāĻŦāϞā§āĻ: ā§ŗ13āĨ¤
Strip Price â āĻĻāĻļāĻāĻŋ āĻā§āϝāĻžāĻŦāϞā§āĻ: ā§ŗ130āĨ¤
Other Forms â āĻ āύā§āϝāĻžāύā§āϝ āĻāĻ āύ: 120 mg tablet and oral suspension â ⧧⧍ā§Ļ āĻŽāĻŋāĻā§āϰāĻž āĻā§āϝāĻžāĻŦāϞā§āĻ āĻ āϏāĻžāϏāĻĒā§āύāĻļāύāĨ¤
Confidence: 0.99āĨ¤
11. Mechanism â āĻāĻžāϰā§āϝāĻĒā§āϰāĻā§āϰāĻŋā§āĻž
English: Acts as a selective peripheral H1-receptor inverse agonist, reducing histamine-mediated allergic symptoms.
āĻŦāĻžāĻāϞāĻž: Histamine-āĻāϰ H1 receptor-āĻāϰ āĻāĻžāϰā§āϝāĻā§āϰāĻŽ āĻāĻŽāĻŋā§ā§ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻāĻĒāϏāϰā§āĻ āύāĻŋā§āύā§āϤā§āϰāĻŖ āĻāϰā§āĨ¤
Confidence: 0.99āĨ¤
12. Indications â āĻŦā§āϝāĻŦāĻšāĻžāϰāϝā§āĻā§āϝ āϰā§āĻ
Allergic Rhinitis â āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĨ¤
Chronic Urticaria â āĻĻā§āϰā§āĻāϏā§āĻĨāĻžā§ā§ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻāύāĻŋāϤ āĻāĻžāĻāĻž āĻāĻ āĻžāĨ¤
Allergic Pruritus â āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻāύāĻŋāϤ āĻā§āϞāĻāĻžāύāĻŋāĨ¤
Confidence: 0.98āĨ¤
13. Interactions and Contraindications â āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž āĻ āύāĻŋāώā§āϧāĻžāĻā§āĻāĻž
English: Aluminium/magnesium antacids and certain fruit juices can reduce absorption. Avoid in known hypersensitivity.
āĻŦāĻžāĻāϞāĻž: Aluminium/Magnesium-āϝā§āĻā§āϤ Antacid āĻāĻŦāĻ āĻāĻŋāĻā§ āĻĢāϞā§āϰ āϰāϏ āĻāώā§āϧā§āϰ āĻļā§āώāĻŖ āĻāĻŽāĻžāϤ⧠āĻĒāĻžāϰā§āĨ¤ āĻāώā§āϧāĻāĻŋāϤ⧠āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻĨāĻžāĻāϞ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Confidence: 0.98āĨ¤
14. Precautions â āϏāϤāϰā§āĻāϤāĻž
English: Consider renal impairment, previous allergy and other medicines.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻĄāύāĻŋāϰ āĻāĻžāϰā§āϝāĻā§āώāĻŽāϤāĻž, āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ āĻāώā§āϧā§āϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.95āĨ¤
15. Dosage and Administration â āĻŽāĻžāϤā§āϰāĻž āĻ āϏā§āĻŦāύāĻŦāĻŋāϧāĻŋ
English: For appropriate adult indications, 180 mg once daily is a commonly listed regimen.
āĻŦāĻžāĻāϞāĻž: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϰā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤāĻŦā§āϏā§āĻāĻĻā§āϰ āĻāύā§āϝ ā§§ā§Žā§Ļ āĻŽāĻŋāĻā§āϰāĻž āĻĻāĻŋāύ⧠āĻāĻāĻŦāĻžāϰ āĻāĻāĻāĻŋ āĻĒā§āϰāĻāϞāĻŋāϤ āĻĄā§āĻāĨ¤
Important â āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ: The patient-specific handwritten direction must be confirmed.
āĻŦāĻžāĻāϞāĻž: āĻāĻ āϰā§āĻā§āϰ āĻāύā§āϝ āϞā§āĻāĻž āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.98āĨ¤
16. Pregnancy and Lactation â āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύ
English: Use after individualized assessment of safety and clinical necessity.
āĻŦāĻžāĻāϞāĻž: āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύāĻāĻžāϞ⧠āĻĒā§āϰā§ā§āĻāύā§ā§āϤāĻž āĻ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.95āĨ¤
17. Other Compositions / Combinations â āĻ āύā§āϝāĻžāύā§āϝ āĻāĻ āύ
English: Fexofenadine is available in different tablet strengths and oral suspension formulations.
āĻŦāĻžāĻāϞāĻž: Fexofenadine āĻŦāĻŋāĻāĻŋāύā§āύ āĻŽāĻžāϤā§āϰāĻžāϰ āĻā§āϝāĻžāĻŦāϞā§āĻ āĻāĻŦāĻ āĻāĻžāĻā§āĻžāϰ āϏāĻžāϏāĻĒā§āύāĻļāύ āĻšāĻŋāϏā§āĻŦā§ āĻĒāĻžāĻā§āĻž āϝāĻžā§āĨ¤
Confidence: 0.98āĨ¤
Clinical Verdict â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ
English: Suitable for selected allergic symptoms but does not eradicate fungal infections.
āĻŦāĻžāĻāϞāĻž: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻāĻĒāϏāϰā§āĻ āĻāĻŽāĻžāϤ⧠āĻāĻžāϰā§āϝāĻāϰ, āĻāĻŋāύā§āϤ⧠āĻĻāĻžāĻĻā§āϰ āĻāϤā§āϰāĻžāĻ āϧā§āĻŦāĻāϏ āĻāϰ⧠āύāĻžāĨ¤
Overall Confidence: 0.95āĨ¤
đ MEDICINE 05 â ABC ANTI-FUNGAL BAR
1. Generic Name â āĻā§āύā§āϰāĻŋāĻ āύāĻžāĻŽ
Reported Ingredients â āĻĒā§āϰāĻāĻžāĻļāĻŋāϤ āĻāĻĒāĻžāĻĻāĻžāύ: Ketoconazole + Zinc Pyrithione + Glycerine.
āĻŦāĻžāĻāϞāĻž: āĻā§āĻā§āĻā§āύāĻžāĻāϞ, āĻāĻŋāĻā§āĻ āĻĒāĻžāĻāϰāĻŋāĻĨāĻŋāĻāύ āĻ āĻā§āϞāĻŋāϏāĻžāϰāĻŋāύāĨ¤
Important â āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ: Exact formulation and concentrations must be checked against the product label.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰāĻā§āϤ āĻāĻĒāĻžāĻĻāĻžāύ āĻāĻŦāĻ āĻĒā§āϰāϤāĻŋāĻāĻŋ āĻāĻĒāĻžāĻĻāĻžāύā§āϰ āĻŽāĻžāϤā§āϰāĻž āĻĒāĻŖā§āϝā§āϰ āĻŽā§ā§āĻ āĻĨā§āĻā§ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.75āĨ¤
2. Brand Name â āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āύāĻžāĻŽ
ABC Anti-Fungal Bar â S-PA Trading International.
āĻŦāĻžāĻāϞāĻž: āĻāϏ-āĻĒāĻŋāĻ āĻā§āϰā§āĻĄāĻŋāĻ āĻāύā§āĻāĻžāϰāύā§āϝāĻžāĻļāύāĻžāϞā§āϰ āĻāĻŦāĻŋāϏāĻŋ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ āĻŦāĻžāϰāĨ¤
Confidence: 0.90āĨ¤
3. Alternate Brands â āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Fungikill Soap and other antifungal cleansing bars.
āĻŦāĻžāĻāϞāĻž: Fungikill Soap āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ āϏāĻžāĻŦāĻžāύāĨ¤
Confidence: 0.85āĨ¤
4. MedEx Therapeutic Class â āĻŽā§āĻĄāĻāĻā§āϏā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžāĻāϤ āĻļā§āϰā§āĻŖāĻŋ
Not independently verified on MedEx â āĻŽā§āĻĄāĻāĻā§āϏ⧠āĻāĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻĒāĻŖā§āϝā§āϰ āĻļā§āϰā§āĻŖāĻŋ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžā§āύāĻŋāĨ¤
āĻŦāĻžāĻāϞāĻž: āĻĒāĻŖā§āϝāĻāĻŋāϰ āĻāύā§āϝ āĻ āύā§āĻŽāĻžāύ āĻāϰ⧠āĻā§āύ⧠MedEx Therapeutic Class āĻĻā§āĻā§āĻž āĻšāĻā§āĻā§ āύāĻžāĨ¤
Confidence: 0.99 for verification limitationāĨ¤
5. Pharmacological Class â āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Topical Antifungal Cleansing Product â āϤā§āĻŦāĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ āĻĒāϰāĻŋāώā§āĻāĻžāϰāĻāĨ¤
Confidence: 0.90āĨ¤
6. Use/Purpose â āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ
English: Supportive cleansing in selected fungal skin conditions.
āĻŦāĻžāĻāϞāĻž: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϤā§āĻŦāĻā§āϰ āϏāĻŽāϏā§āϝāĻžā§ āĻĒāϰāĻŋāώā§āĻāĻžāϰ-āĻĒāϰāĻŋāĻā§āĻāύā§āύāϤāĻžāϰ āϏāĻšāĻžā§āĻ āĻāĻĒāĻžā§āĨ¤
Confidence: 0.90āĨ¤
7. Why Prescribed to This Patient â āĻā§āύ āĻĻā§āĻā§āĻž āĻšāϤ⧠āĻĒāĻžāϰā§
English: Likely intended as supportive skin care during antifungal treatment.
āĻŦāĻžāĻāϞāĻž: āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ āϤā§āĻŦāĻ āĻĒāϰāĻŋāώā§āĻāĻžāϰ āϰāĻžāĻāĻžāϰ āϏāĻšāĻžā§āĻ āĻĒāĻŖā§āϝ āĻšāĻŋāϏā§āĻŦā§ āĻĻā§āĻā§āĻž āĻšā§ā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.75āĨ¤
8. Side Effects â āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
English: Dryness, burning, irritation and contact dermatitis.
āĻŦāĻžāĻāϞāĻž: āϤā§āĻŦāĻ āĻļā§āώā§āĻ āĻšā§ā§ āϝāĻžāĻā§āĻž, āĻā§āĻŦāĻžāϞāĻž, āĻ āϏā§āĻŦāϏā§āϤāĻŋ āĻ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻāύāĻŋāϤ āĻĒā§āϰāĻĻāĻžāĻšāĨ¤
Confidence: 0.90āĨ¤
9. Direct MedEx Link â āĻŽā§āĻĄāĻāĻā§āϏ āϞāĻŋāĻāĻ
Verified MedEx Product Page â āϝāĻžāĻāĻžāĻāĻā§āϤ āĻŽā§āĻĄāĻāĻā§āϏ āĻĒā§āώā§āĻ āĻž: Not found â āĻĒāĻžāĻā§āĻž āϝāĻžā§āύāĻŋāĨ¤
Verified Retail Reference â āϝāĻžāĻāĻžāĻāĻā§āϤ āĻŦāĻŋāĻā§āϰā§āϤāĻĨā§āϝ:
ABC Anti-Fungal Bar 75 g â Arogga
āĻŦāĻžāĻāϞāĻž: āĻāĻ āĻĒāĻŖā§āϝā§āϰ āϏāϰāĻžāϏāϰāĻŋ MedEx āĻĒā§āώā§āĻ āĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžā§āύāĻŋāĨ¤ āĻŦāĻŋāĻāϞā§āĻĒāĻāĻžāĻŦā§ āĻŦāĻžāĻāϞāĻžāĻĻā§āĻļāĻŋ āĻ āύāϞāĻžāĻāύ āĻĢāĻžāϰā§āĻŽā§āϏāĻŋāϰ āĻĒāĻŖā§āϝā§āϰ āϤāĻĨā§āϝ āĻĻā§āĻā§āĻž āĻšā§ā§āĻā§āĨ¤
10. Unit Price, Strip Price and Composition â āĻŽā§āϞā§āϝ āĻ āĻāĻ āύ
75 g Bar â ā§ā§Ģ āĻā§āϰāĻžāĻŽ āϏāĻžāĻŦāĻžāύ: Approximately ā§ŗ585 â āĻāύā§āĻŽāĻžāύāĻŋāĻ ā§Ģā§Žā§Ģ āĻāĻžāĻāĻžāĨ¤
Strip Price â āϏā§āĻā§āϰāĻŋāĻĒ āĻŽā§āϞā§āϝ: Not applicable â āĻĒā§āϰāϝā§āĻā§āϝ āύā§āĨ¤
Confidence: 0.95 for checked retail listingāĨ¤
11. Mechanism â āĻāĻžāϰā§āϝāĻĒā§āϰāĻā§āϰāĻŋā§āĻž
English: Ketoconazole inhibits fungal ergosterol synthesis; zinc pyrithione has antimicrobial activity, while glycerine helps retain moisture.
āĻŦāĻžāĻāϞāĻž: Ketoconazole āĻāϤā§āϰāĻžāĻā§āϰ āĻā§āώāĻāĻŋāϞā§āϞāĻŋ āϤā§āϰāĻŋāϤ⧠āĻŦāĻžāϧāĻž āĻĻā§ā§, Zinc Pyrithione-āĻāϰ āĻā§āĻŦāĻžāĻŖā§āĻŦāĻŋāϰā§āϧ⧠āĻāĻžāϰā§āϝāĻā§āϰāĻŽ āϰā§ā§āĻā§ āĻāĻŦāĻ Glycerine āϤā§āĻŦāĻā§āϰ āĻāϰā§āĻĻā§āϰāϤāĻž āϧāϰ⧠āϰāĻžāĻāϤ⧠āϏāĻžāĻšāĻžāϝā§āϝ āĻāϰā§āĨ¤
Confidence: 0.95 for ingredient pharmacologyāĨ¤
12. Indications â āĻŦā§āϝāĻŦāĻšāĻžāϰāϝā§āĻā§āϝ āĻ āĻŦāϏā§āĻĨāĻž
English: Adjunctive cleansing for selected superficial fungal skin disorders.
āĻŦāĻžāĻāϞāĻž: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϤā§āĻŦāĻā§āϰ āϏāĻŽāϏā§āϝāĻžā§ āϏāĻšāĻžā§āĻ āĻĒāϰāĻŋāώā§āĻāĻžāϰāĻ āĻšāĻŋāϏā§āĻŦā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.85āĨ¤
13. Interactions and Contraindications â āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž āĻ āύāĻŋāώā§āϧāĻžāĻā§āĻāĻž
English: Avoid use in individuals with known hypersensitivity to the ingredients.
āĻŦāĻžāĻāϞāĻž: āĻā§āύ⧠āĻāĻĒāĻžāĻĻāĻžāύ⧠āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻĨāĻžāĻāϞ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻāĻāĻŋāϤ āύā§āĨ¤
Confidence: 0.95āĨ¤
14. Precautions â āϏāϤāϰā§āĻāϤāĻž
English: Avoid eyes, mucosal surfaces and irritated or damaged skin unless the product instructions permit use.
āĻŦāĻžāĻāϞāĻž: āĻĒāĻŖā§āϝā§āϰ āύāĻŋāϰā§āĻĻā§āĻļāύāĻžā§ āĻ āύā§āĻŽāϤāĻŋ āύāĻž āĻĨāĻžāĻāϞ⧠āĻā§āĻ, āĻļā§āϞā§āώā§āĻŽāĻŋāĻ āĻāĻŋāϞā§āϞāĻŋ āĻāĻŦāĻ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻā§āώāϤāĻŋāĻā§āϰāϏā§āϤ āϤā§āĻŦāĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻā§āĻžāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.95āĨ¤
15. Dosage and Administration â āĻŦā§āϝāĻŦāĻšāĻžāϰāĻŦāĻŋāϧāĻŋ
English: Follow the manufacturer’s verified instructions and the treating physician’s advice.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰāϏā§āϤā§āϤāĻāĻžāϰāĻā§āϰ āϝāĻžāĻāĻžāĻāĻā§āϤ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āĻāĻŦāĻ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻĒāϰāĻžāĻŽāϰā§āĻļ āĻ āύā§āϝāĻžā§ā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.95āĨ¤
16. Pregnancy and Lactation â āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύ
English: Product-specific safety information is limited; seek clinical guidance.
āĻŦāĻžāĻāϞāĻž: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻĒāĻŖā§āϝāĻāĻŋāϰ āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύāϏāĻāĻā§āϰāĻžāύā§āϤ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āϤāĻĨā§āϝ āϏā§āĻŽāĻŋāϤāĨ¤ āĻĒā§āϰā§ā§āĻāύ āĻ āύā§āϝāĻžā§ā§ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻĒāϰāĻžāĻŽāϰā§āĻļ āύāĻŋāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.80āĨ¤
17. Other Compositions / Combinations â āĻ āύā§āϝāĻžāύā§āϝ āĻāĻ āύ
English: Other marketed antifungal soaps may contain ketoconazole with zinc pyrithione or other cleansing ingredients.
āĻŦāĻžāĻāϞāĻž: āĻŦāĻžāĻāĻžāϰā§āϰ āĻ āύā§āϝāĻžāύā§āϝ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ āϏāĻžāĻŦāĻžāύ⧠Ketoconazole-āĻāϰ āϏāĻā§āĻā§ Zinc Pyrithione āĻŦāĻž āĻ āύā§āϝ āĻĒāϰāĻŋāώā§āĻāĻžāϰāĻ āĻāĻĒāĻžāĻĻāĻžāύ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.85āĨ¤
Clinical Verdict â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ
English: This product may support hygiene but should not replace established antifungal therapy.
āĻŦāĻžāĻāϞāĻž: āϏāĻžāĻŦāĻžāύāĻāĻŋ āϤā§āĻŦāĻ āĻĒāϰāĻŋāώā§āĻāĻžāϰ āϰāĻžāĻāϤ⧠āϏāĻšāĻžā§āĻ āĻšāϤ⧠āĻĒāĻžāϰā§, āĻāĻŋāύā§āϤ⧠āĻĒā§āϰāĻŽāĻžāĻŖāĻāĻŋāϤā§āϤāĻŋāĻ āĻŽā§āϞ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻŦāĻŋāĻāϞā§āĻĒ āύā§āĨ¤
Overall Confidence: 0.85āĨ¤
đ MEDICINE 06 â SNOFAS NASAL SPRAY
1. Generic Name â āĻā§āύā§āϰāĻŋāĻ āύāĻžāĻŽ
Fluticasone Furoate â āĻĢā§āϞā§āĻāĻŋāĻāĻžāϏāύ āĻĢāĻŋāĻāϰā§ā§ā§āĻāĨ¤
Confidence: 0.99āĨ¤
2. Brand Name â āĻŦā§āϰā§āϝāĻžāύā§āĻĄ āύāĻžāĻŽ
Snofas Nasal Spray â Opsonin Pharma Ltd.
āĻŦāĻžāĻāϞāĻž: āĻ āĻĒāϏā§āύāĻŋāύ āĻĢāĻžāϰā§āĻŽāĻžāϰ āϏā§āύā§āĻĢāĻžāϏ āύā§āϝāĻžāĻāĻžāϞ āϏā§āĻĒā§āϰā§āĨ¤
Confidence: 0.99āĨ¤
3. MedEx Alternate Brands â āĻŦāĻŋāĻāϞā§āĻĒ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ
Avamist, Avaspray, Rhinomist, Fixonase.
āĻŦāĻžāĻāϞāĻž: āĻāĻāĻ āĻā§āύā§āϰāĻŋāĻā§āϰ āĻ āύā§āϝāĻžāύā§āϝ āύā§āϝāĻžāĻāĻžāϞ āϏā§āĻĒā§āϰ⧠āĻŦā§āϰā§āϝāĻžāύā§āĻĄāĨ¤
Confidence: 0.98āĨ¤
4. MedEx Therapeutic Class â āĻāĻŋāĻāĻŋā§āϏāĻžāĻāϤ āĻļā§āϰā§āĻŖāĻŋ
Nasal Steroid Preparations â āύāĻžāĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āϏā§āĻā§āϰā§ā§āĻĄāĻāĻžāϤā§ā§ āĻāώā§āϧāĨ¤
Confidence: 0.99āĨ¤
5. Pharmacological Class â āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ
Intranasal Corticosteroid â āύāĻžāĻā§āϰ āĻā§āϤāϰ⧠āĻŦā§āϝāĻŦāĻšā§āϤ āĻāϰā§āĻāĻŋāĻā§āϏā§āĻā§āϰā§ā§āĻĄāĨ¤
Confidence: 0.99āĨ¤
6. Use/Purpose â āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ
English: Control of inflammation associated with allergic rhinitis.
āĻŦāĻžāĻāϞāĻž: āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻāύāĻŋāϤ āĻĒā§āϰāĻĻāĻžāĻš āύāĻŋā§āύā§āϤā§āϰāĻŖ āĻāϰāĻžāĨ¤
Confidence: 0.99āĨ¤
7. Why Prescribed to This Patient â āĻā§āύ āĻĻā§āĻā§āĻž āĻšāϤ⧠āĻĒāĻžāϰā§
English: Probably intended for allergic rhinitis symptoms.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻāĻĒāϏāϰā§āĻ āĻāĻŽāĻžāύā§āϰ āĻāύā§āϝ āĻĻā§āĻā§āĻž āĻšā§ā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.85āĨ¤
8. Side Effects â āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž
English: Nasal irritation, dryness, epistaxis, headache and rarely clinically important corticosteroid-related effects.
āĻŦāĻžāĻāϞāĻž: āύāĻžāĻā§āϰ āĻā§āϤāϰ⧠āĻā§āĻŦāĻžāϞāĻž, āĻļā§āώā§āĻāϤāĻž, āύāĻžāĻ āĻĻāĻŋā§ā§ āϰāĻā§āϤ āĻĒā§āĻž, āĻŽāĻžāĻĨāĻžāĻŦā§āϝāĻĨāĻž āĻāĻŦāĻ āĻŦāĻŋāϰāϞ āĻā§āώā§āϤā§āϰ⧠āĻāϰā§āĻāĻŋāĻā§āϏā§āĻā§āϰā§ā§āĻĄāĻāύāĻŋāϤ āĻ āύā§āϝāĻžāύā§āϝ āϏāĻŽāϏā§āϝāĻžāĨ¤
Confidence: 0.98āĨ¤
9. Direct MedEx Link â āĻŽā§āĻĄāĻāĻā§āϏ āϞāĻŋāĻāĻ
10. Unit Price, Strip Price and Composition â āĻŽā§āϞā§āϝ āĻ āĻāĻ āύ
Strength â āĻŽāĻžāϤā§āϰāĻž: 27.5 mcg/spray â āĻĒā§āϰāϤāĻŋ āϏā§āĻĒā§āϰ⧠⧍ā§.ā§Ģ āĻŽāĻžāĻāĻā§āϰā§āĻā§āϰāĻžāĻŽāĨ¤
Pack â āĻĒā§āϝāĻžāĻ: 120 metered sprays â ⧧⧍ā§ĻāĻāĻŋ āύāĻŋāϰā§āϧāĻžāϰāĻŋāϤ āϏā§āĻĒā§āϰā§āĨ¤
Pack Price â āĻĒā§āϝāĻžāĻā§āϰ āĻŽā§āϞā§āϝ: ā§ŗ275āĨ¤
Strip Price â āϏā§āĻā§āϰāĻŋāĻĒ āĻŽā§āϞā§āϝ: Not applicable â āĻĒā§āϰāϝā§āĻā§āϝ āύā§āĨ¤
Confidence: 0.99āĨ¤
11. Mechanism â āĻāĻžāϰā§āϝāĻĒā§āϰāĻā§āϰāĻŋā§āĻž
English: Activates glucocorticoid receptors and suppresses inflammatory mediator activity in the nasal mucosa.
āĻŦāĻžāĻāϞāĻž: āύāĻžāĻā§āϰ āĻā§āϤāϰā§āϰ Glucocorticoid Receptor-āĻāϰ āĻŽāĻžāϧā§āϝāĻŽā§ āĻĒā§āϰāĻĻāĻžāĻšāϏā§āώā§āĻāĻŋāĻāĻžāϰ⧠āĻĒāĻĻāĻžāϰā§āĻĨā§āϰ āĻāĻžāϰā§āϝāĻā§āϰāĻŽ āĻāĻŽāĻŋā§ā§ āĻĻā§ā§āĨ¤
Confidence: 0.99āĨ¤
12. Indications â āĻŦā§āϝāĻŦāĻšāĻžāϰāϝā§āĻā§āϝ āϰā§āĻ
Seasonal Allergic Rhinitis â āĻŽā§āϏā§āĻŽāĻŋ āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĨ¤
Perennial Allergic Rhinitis â āϏāĻžāϰāĻž āĻŦāĻāϰāĻŦā§āϝāĻžāĻĒā§ āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĨ¤
Confidence: 0.99āĨ¤
13. Interactions and Contraindications â āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž āĻ āύāĻŋāώā§āϧāĻžāĻā§āĻāĻž
English: Strong CYP3A4 inhibitors may increase systemic exposure to fluticasone. Itraconazole is a relevant potential interacting medicine.
āĻŦāĻžāĻāϞāĻž: āĻļāĻā§āϤāĻŋāĻļāĻžāϞ⧠CYP3A4 inhibitor āĻāώā§āϧā§āϰ āĻāĻžāϰāĻŖā§ Fluticasone-āĻāϰ āĻļāϰā§āϰ⧠āĻļā§āώāĻŖ āĻŦā§ā§ā§ āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤ Itraconazole-āĻāϰ āϏāĻā§āĻā§ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž āĻŽā§āϞā§āϝāĻžā§āύ āĻĒā§āϰā§ā§āĻāύāĨ¤
Confidence: 0.95āĨ¤
14. Precautions â āϏāϤāϰā§āĻāϤāĻž
English: Use cautiously in recurrent nosebleeds, untreated nasal infection, glaucoma or previous nasal surgery.
āĻŦāĻžāĻāϞāĻž: āĻŦāĻžāϰāĻŦāĻžāϰ āύāĻžāĻ āĻĻāĻŋā§ā§ āϰāĻā§āϤ āĻĒā§āĻž, āύāĻžāĻā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžāĻšā§āύ āϏāĻāĻā§āϰāĻŽāĻŖ, Glaucoma āĻŦāĻž āύāĻžāĻā§āϰ āĻ āϏā§āϤā§āϰā§āĻĒāĻāĻžāϰā§āϰ āĻāϤāĻŋāĻšāĻžāϏ āĻĨāĻžāĻāϞ⧠āϏāϤāϰā§āĻāϤāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
Confidence: 0.95āĨ¤
15. Dosage and Administration â āĻŽāĻžāϤā§āϰāĻž āĻ āĻŦā§āϝāĻŦāĻšāĻžāϰāĻŦāĻŋāϧāĻŋ
English: A commonly listed adult starting regimen is two sprays in each nostril once daily, with adjustment according to response and product instructions.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰāĻžāĻĒā§āϤāĻŦā§āϏā§āĻāĻĻā§āϰ āĻāύā§āϝ āĻ āύā§āĻ āĻā§āώā§āϤā§āϰ⧠āĻĒā§āϰāϤāĻŋāĻāĻŋ āύāĻžāĻā§ āĻĻā§āĻ āϏā§āĻĒā§āϰ⧠āĻĻāĻŋāύ⧠āĻāĻāĻŦāĻžāϰ āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ āĻĄā§āĻ āĻšāĻŋāϏā§āĻŦā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻšā§āĨ¤ āĻĒāϰāĻŦāϰā§āϤ⧠āĻĄā§āĻ āϰā§āĻā§āϰ āĻāύā§āύāϤāĻŋ āĻāĻŦāĻ āĻĒāĻŖā§āϝā§āϰ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āĻ āύā§āϝāĻžā§ā§ āύāĻŋāϰā§āϧāĻžāϰāĻŋāϤ āĻšā§āĨ¤
Important â āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ: The original handwritten dose is not sufficiently clear to confirm this regimen for the patient.
āĻŦāĻžāĻāϞāĻž: āĻŽā§āϞ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻšāĻžāϤā§āϰ āϞā§āĻāĻž āϝāĻĨā§āώā§āĻ āϏā§āĻĒāώā§āĻ āύā§āĨ¤ āϤāĻžāĻ āϰā§āĻā§āϰ āĻāύā§āϝ āĻāĻ āĻĄā§āĻāĻ āĻĻā§āĻā§āĻž āĻšā§ā§āĻā§ āĻŦāϞ⧠āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Confidence: 0.98 for general drug informationāĨ¤
16. Pregnancy and Lactation â āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύ
English: Use after individualized assessment of clinical benefit and potential risk.
āĻŦāĻžāĻāϞāĻž: āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻ āϏā§āϤāύā§āϝāĻĻāĻžāύāĻāĻžāϞ⧠āĻĒā§āϰā§ā§āĻāύā§ā§āϤāĻž āĻāĻŦāĻ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻā§āĻāĻāĻŋ āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.95āĨ¤
17. Other Compositions / Combinations â āĻ āύā§āϝāĻžāύā§āϝ āĻāĻ āύ
English: Other fluticasone furoate nasal preparations and inhaled products exist, but different formulations are not automatically interchangeable.
āĻŦāĻžāĻāϞāĻž: Fluticasone Furoate-āĻāϰ āĻ āύā§āϝāĻžāύā§āϝ āύā§āϝāĻžāĻāĻžāϞ āϏā§āĻĒā§āϰ⧠āĻ āĻļā§āĻŦāĻžāϏā§āϰ āĻŽāĻžāϧā§āϝāĻŽā§ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻ āύ āϰā§ā§āĻā§āĨ¤ āϤāĻŦā§ āϏāĻŦ formulation āϏāϰāĻžāϏāϰāĻŋ āĻĒāϰāĻŋāĻŦāϰā§āϤāύāϝā§āĻā§āϝ āύā§āĨ¤
Confidence: 0.98āĨ¤
Clinical Verdict â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ
English: Evidence-based treatment for allergic rhinitis when clinically indicated, but potential interaction with itraconazole warrants review.
āĻŦāĻžāĻāϞāĻž: āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āύāĻŋāĻļā§āĻāĻŋāϤ āĻšāϞ⧠āĻāĻāĻŋ āĻĒā§āϰāĻŽāĻžāĻŖāĻāĻŋāϤā§āϤāĻŋāĻ āĻāĻŋāĻāĻŋā§āϏāĻžāĨ¤ āϤāĻŦā§ Itraconazole-āĻāϰ āϏāĻā§āĻā§ āϏāĻŽā§āĻāĻžāĻŦā§āϝ interaction āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
Overall Confidence: 0.95āĨ¤
đ§ 12. BANGLADESH MEDICINE COMPARISON â TABLE 1
āĻŦāĻžāĻāϞāĻžāĻĻā§āĻļā§ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āĻāϰā§āĻŽāϰā§āĻā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻāώā§āϧ
| No. | Generic Medicine â āĻā§āύā§āϰāĻŋāĻ | Therapeutic Class â āĻāĻŋāĻāĻŋā§āϏāĻžāĻāϤ āĻļā§āϰā§āĻŖāĻŋ | Purpose â āĻāĻĻā§āĻĻā§āĻļā§āϝ |
|---|---|---|---|
| 1 | Luliconazole â āϞā§āϞāĻŋāĻā§āύāĻžāĻāϞ | Miscellaneous Topical Agents â āϤā§āĻŦāĻā§āϰ āĻ āύā§āϝāĻžāύā§āϝ āĻāώā§āϧ | Localized Dermatophytosis â āϏā§āĻŽāĻŋāϤ āĻĻāĻžāĻĻ |
| 2 | Clotrimazole â āĻā§āϞā§āĻā§āϰāĻŋāĻŽāĻžāĻāϞ | Topical Antifungal â āĻŦāĻžāĻšā§āϝāĻŋāĻ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ | Superficial Fungal Infection â āϤā§āĻŦāĻā§āϰ āĻāĻĒāϰāĻŋāĻāĻžāĻā§āϰ āĻāϤā§āϰāĻžāĻ āϏāĻāĻā§āϰāĻŽāĻŖ |
| 3 | Terbinafine Topical â āĻāĻžāϰāĻŦāĻŋāύāĻžāĻĢāĻŋāύ āĻā§āϰāĻŋāĻŽ | Topical Antifungal Preparations â āĻŦāĻžāĻšā§āϝāĻŋāĻ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ | Dermatophyte Infection â āĻĻāĻžāĻĻ |
| 4 | Ketoconazole Topical â āĻā§āĻā§āĻā§āύāĻžāĻāϞ āĻā§āϰāĻŋāĻŽ | Drugs for Subcutaneous and Mycoses â āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϰā§āĻā§āϰ āĻāώā§āϧ | Selected Fungal Skin Conditions â āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāϤā§āϰāĻžāĻ āϏāĻāĻā§āϰāĻŽāĻŖ |
| 5 | Itraconazole Oral â āĻāĻā§āϰāĻžāĻā§āύāĻžāĻāϞ | Systemic Triazole Antifungal â āĻŽā§āĻā§ āĻāĻžāĻā§āĻžāϰ āĻā§āϰāĻžā§āĻžāĻā§āϞ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ | Selected Extensive or Refractory Fungal Infections â āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻŦā§āϝāĻžāĻĒāĻ āĻŦāĻž āĻāĻŋāĻāĻŋā§āϏāĻžāĻĒā§āϰāϤāĻŋāϰā§āϧ⧠āĻāϤā§āϰāĻžāĻ āϏāĻāĻā§āϰāĻŽāĻŖ |
| 6 | Terbinafine Oral â āĻāĻžāϰāĻŦāĻŋāύāĻžāĻĢāĻŋāύ | Systemic Allylamine Antifungal â āĻŽā§āĻā§ āĻāĻžāĻā§āĻžāϰ āĻ ā§āϝāĻžāϞāĻžāĻāϞāĻ ā§āϝāĻžāĻŽāĻŋāύ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ | Selected Dermatophyte and Nail Infections â āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻĻāĻžāĻĻ āĻ āύāĻā§āϰ āĻāϤā§āϰāĻžāĻ āϏāĻāĻā§āϰāĻŽāĻŖ |
Clinical Confidence â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻŦāĻŋāĻļā§āĻŦāĻžāϏāϝā§āĻā§āϝāϤāĻž: 0.95āĨ¤
Important â āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ: This table lists possible therapeutic options; these medicines are not intended to be prescribed together automatically.
āĻŦāĻžāĻāϞāĻž: āĻā§āĻŦāĻŋāϞāĻāĻŋāϤ⧠āĻŦāĻŋāĻāĻŋāύā§āύ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻŦāĻŋāĻāϞā§āĻĒ āĻĻā§āĻāĻžāύ⧠āĻšā§ā§āĻā§āĨ¤ āϏāĻŦ āĻāώā§āϧ āĻāĻāϏāĻā§āĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻžāϰ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āύā§āĨ¤
đŠ 13. BANGLADESH MEDICINE COMPARISON â TABLE 2
āĻŦāĻžāĻāϞāĻžāĻĻā§āĻļā§ āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻ āĻā§āϞāĻāĻžāύāĻŋāϤ⧠āĻŦā§āϝāĻŦāĻšā§āϤ āĻāώā§āϧ
| No. | Generic â āĻā§āύā§āϰāĻŋāĻ | Pharmacological Class â āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĻā§āϝāĻžāϞ āĻļā§āϰā§āĻŖāĻŋ | Purpose â āĻāĻĻā§āĻĻā§āĻļā§āϝ |
|---|---|---|---|
| 1 | Fexofenadine â āĻĢā§āĻā§āϏā§āĻĢā§āύāĻžāĻĄāĻŋāύ | Second-Generation Antihistamine â āĻĻā§āĻŦāĻŋāϤā§ā§ āĻĒā§āϰāĻāύā§āĻŽā§āϰ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻšāĻŋāϏā§āĻāĻžāĻŽāĻŋāύ | Allergic Rhinitis/Urticaria â āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ/āĻāĻžāĻāĻž āĻāĻ āĻž |
| 2 | Cetirizine â āϏā§āĻāĻŋāϰāĻŋāĻāĻŋāύ | Second-Generation Antihistamine â āĻĻā§āĻŦāĻŋāϤā§ā§ āĻĒā§āϰāĻāύā§āĻŽā§āϰ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻšāĻŋāϏā§āĻāĻžāĻŽāĻŋāύ | Allergic Symptoms â āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻāĻĒāϏāϰā§āĻ |
| 3 | Levocetirizine â āϞā§āĻā§āϏā§āĻāĻŋāϰāĻŋāĻāĻŋāύ | Second-Generation Antihistamine â āĻĻā§āĻŦāĻŋāϤā§ā§ āĻĒā§āϰāĻāύā§āĻŽā§āϰ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻšāĻŋāϏā§āĻāĻžāĻŽāĻŋāύ | Allergy Relief â āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻāĻĒāϏāϰā§āĻ āύāĻŋā§āύā§āϤā§āϰāĻŖ |
| 4 | Fluticasone Furoate Nasal â āĻĢā§āϞā§āĻāĻŋāĻāĻžāϏāύ āĻĢāĻŋāĻāϰā§ā§ā§āĻ | Intranasal Corticosteroid â āύāĻžāĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāϰā§āĻāĻŋāĻā§āϏā§āĻā§āϰā§ā§āĻĄ | Allergic Rhinitis â āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ |
| 5 | Mometasone Furoate Nasal â āĻŽā§āĻŽā§āĻāĻžāϏāύ āĻĢāĻŋāĻāϰā§ā§ā§āĻ | Intranasal Corticosteroid â āύāĻžāĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāϰā§āĻāĻŋāĻā§āϏā§āĻā§āϰā§ā§āĻĄ | Allergic Rhinitis â āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ |
| 6 | Azelastine Nasal â āĻ ā§āϝāĻžāĻā§āϞāĻžāϏā§āĻāĻŋāύ | Intranasal Antihistamine â āύāĻžāĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻšāĻŋāϏā§āĻāĻžāĻŽāĻŋāύ | Nasal Allergy Symptoms â āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻāĻĒāϏāϰā§āĻ |
Confidence: 0.95āĨ¤
Important â āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ: Choice of medicine depends on symptoms, comorbidities, contraindications and treatment response.
āĻŦāĻžāĻāϞāĻž: āĻā§āύ āĻāώā§āϧ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻšāĻŦā§ āϤāĻž āϰā§āĻā§āϰ āĻāĻĒāϏāϰā§āĻ, āĻ āύā§āϝāĻžāύā§āϝ āϰā§āĻ, āĻāώā§āϧā§āϰ āύāĻŋāώā§āϧāĻžāĻā§āĻāĻž āĻāĻŦāĻ āĻāĻŋāĻāĻŋā§āϏāĻžā§ āϏāĻžā§āĻžāϰ āĻāĻĒāϰ āύāĻŋāϰā§āĻāϰ āĻāϰā§āĨ¤
đ§ 14. DOCTOR’S DIAGNOSIS VS INDEPENDENT DIAGNOSIS
āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϰā§āĻāύāĻŋāϰā§āĻŖā§ āĻŦāύāĻžāĻŽ āϏā§āĻŦāĻžāϧā§āύ āϰā§āĻāύāĻŋāϰā§āĻŖā§
Doctor’s Documented Dx â āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϞā§āĻāĻž āϰā§āĻāύāĻŋāϰā§āĻŖā§
Not documented â āϞā§āĻāĻž āύā§āĻāĨ¤
Independent Provisional Dx â āϏā§āĻŦāĻžāϧā§āύ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϰā§āĻāύāĻŋāϰā§āĻŖā§
Dx 1: Suspected Superficial Dermatophytosis (Tinea Infection; Site Unspecified).
āĻŦāĻžāĻāϞāĻž: āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϤā§āĻŦāĻā§āϰ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ āĻŦāĻž āĻĻāĻžāĻĻ; āĻāĻā§āϰāĻžāύā§āϤ āϏā§āĻĨāĻžāύ āĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻāĨ¤
Confidence: 0.70āĨ¤
Dx 2: Possible Coexisting Allergic Rhinitis.
āĻŦāĻžāĻāϞāĻž: āϏāĻšāĻžāĻŦāϏā§āĻĨāĻžāύāĻāĻžāϰ⧠āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻāύāĻŋāϤ āĻĒā§āϰāĻĻāĻžāĻšā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻžāĨ¤
Confidence: 0.75āĨ¤
đŠ Similarities â āĻŽāĻŋāϞ
- English: Itraconazole and luliconazole are consistent with treatment of certain fungal skin infections. āĻŦāĻžāĻāϞāĻž: Itraconazole āĻ Luliconazole āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϤā§āĻŦāĻā§āϰ āϰā§āĻā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āϏāĻā§āĻā§ āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖāĨ¤
- English: The printed advice about transmission and clothing hygiene is consistent with concern about a contagious skin condition. āĻŦāĻžāĻāϞāĻž: āϰā§āĻ āĻā§āĻā§āĻžāĻā§ āĻšāĻā§āĻž āĻ āĻāĻžāĻĒā§ āĻĒāϰāĻŋāώā§āĻāĻžāϰ āϰāĻžāĻāĻžāϰ āύāĻŋāϰā§āĻĻā§āĻļ āϏāĻāĻā§āϰāĻžāĻŽāĻ āĻāϰā§āĻŽāϰā§āĻā§āϰ āϏāύā§āĻĻā§āĻšāĻā§ āϏāĻŽāϰā§āĻĨāύ āĻāϰā§āĨ¤
- English: Fexofenadine and fluticasone nasal spray are consistent with management of possible allergic rhinitis. āĻŦāĻžāĻāϞāĻž: Fexofenadine āĻ Fluticasone Nasal Spray āύāĻžāĻā§āϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āϏāĻā§āĻā§ āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖāĨ¤
Similarity Assessment Confidence â āĻŽāĻŋāϞā§āϰ āĻŽā§āϞā§āϝāĻžā§āύ: 0.85āĨ¤
đ§ Differences â āĻ āĻŽāĻŋāϞ
- English: The physician did not document a diagnosis. āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻāĻŋā§āϏāĻ āĻā§āύ⧠āϰā§āĻāύāĻŋāϰā§āĻŖā§ āϞā§āĻā§āύāύāĻŋāĨ¤
- English: The independent diagnosis is based mainly on medication selection. āĻŦāĻžāĻāϞāĻž: āϏā§āĻŦāĻžāϧā§āύ āϰā§āĻāύāĻŋāϰā§āĻŖā§ āĻĒā§āϰāϧāĻžāύāϤ āĻāώā§āϧā§āϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻĻā§āĻā§ āĻāϰāĻž āĻšā§ā§āĻā§āĨ¤
- English: The anatomical site and appearance of the skin lesion are unknown. āĻŦāĻžāĻāϞāĻž: āϤā§āĻŦāĻā§āϰ āĻā§āώāϤā§āϰ āĻ āĻŦāϏā§āĻĨāĻžāύ āĻ āĻĒā§āϰāĻā§āϤ āĻā§āĻšāĻžāϰāĻž āĻāĻžāύāĻž āύā§āĻāĨ¤
- English: A bacterial infection cannot be established from the uncertain azithromycin entry. āĻŦāĻžāĻāϞāĻž: Azithromycin-āĻāϰ āĻ āϏā§āĻĒāώā§āĻ āύāĻŋāϰā§āĻĻā§āĻļ āĻĨā§āĻā§ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžā§ āύāĻžāĨ¤
Final Comparison â āĻā§ā§āĻžāύā§āϤ āϤā§āϞāύāĻž
English: Direct diagnostic agreement cannot be measured because the physician did not record a diagnosis. The independent assessment is broadly consistent with the apparent treatment pattern.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻāĻŋā§āϏāĻ āϰā§āĻā§āϰ āύāĻžāĻŽ āύāĻž āϞā§āĻāĻžā§ āĻĻā§āĻāĻŋ āϰā§āĻāύāĻŋāϰā§āĻŖā§ā§āϰ āϏāϰāĻžāϏāϰāĻŋ āĻŽāĻŋāϞ āύāĻŋāϰā§āϧāĻžāϰāĻŖ āϏāĻŽā§āĻāĻŦ āύā§āĨ¤ āϤāĻŦā§ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻāώā§āϧā§āϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻĻā§āĻĻā§āĻļā§āϝā§āϰ āϏāĻā§āĻā§ āϏā§āĻŦāĻžāϧā§āύ āĻŽā§āϞā§āϝāĻžā§āύā§āϰ āĻŽā§āĻāĻžāĻŽā§āĻāĻŋ āϏāĻžāĻŽāĻā§āĻāϏā§āϝ āϰā§ā§āĻā§āĨ¤
Confidence: 0.90 for comparison methodologyāĨ¤
đŠ 15. DOCTOR’S ORIGINAL ADVICE
āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻŽā§āϞ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻŽā§āĻĻā§āϰāĻŋāϤ āĻŦāĻžāĻāϞāĻžā§ āĻāĻžāϰāĻāĻŋ āύāĻŋāϰā§āĻĻā§āĻļ āϰā§ā§āĻā§āĨ¤
1. āĻāĻĒāύāĻžāϰ āϰā§āĻāĻāĻŋ āĻā§āĻā§āĻžāĻā§āĨ¤
English Meaning: Your condition is contagious.
āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž: āĻāĻŋāĻāĻŋā§āϏāĻ āϏāĻāĻā§āϰāĻžāĻŽāĻ āϤā§āĻŦāĻā§āϰ āϰā§āĻā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰ⧠āĻāĻ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āĻĻāĻŋā§ā§āĻā§āύ āĻŦāϞ⧠āĻŦā§āĻāĻž āϝāĻžā§āĨ¤
2. āĻĒā§āϰāϤāĻŋāĻĻāĻŋāύ āĻĒāϰāύā§āϰ āĻāĻžāĻĒā§, āĻāĻžāĻŽāĻāĻž āϧā§āĻŦā§āύāĨ¤
English Meaning: Wash your clothes and towels regularly.
āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž: āĻāĻžāĻĒā§ āĻ āĻāĻžāĻŽāĻāĻžāϰ āĻŽāĻžāϧā§āϝāĻŽā§ āϏāĻāĻā§āϰāĻŽāĻŖ āĻā§āĻžāύā§āϰ āĻā§āĻāĻāĻŋ āĻāĻŽāĻžāϤ⧠āĻĒāϰāĻŋāώā§āĻāĻžāϰ-āĻĒāϰāĻŋāĻā§āĻāύā§āύāϤāĻž āĻŦāĻāĻžā§ āϰāĻžāĻāϤ⧠āĻŦāϞāĻž āĻšā§ā§āĻā§āĨ¤
3. āĻāĻāĻāύ āĻāϰā§āĻāĻāύā§āϰ āĻāĻžāĻĒā§ āĻĒāϰāĻŦā§āύ āύāĻžāĨ¤
English Meaning: Do not share clothing with other people.
āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž: āĻĒāϰāĻŋāĻŦāĻžāϰā§āϰ āϏāĻĻāϏā§āϝāĻĻā§āϰ āĻŽāϧā§āϝ⧠āĻŦā§āϝāĻā§āϤāĻŋāĻāϤ āĻāĻžāĻĒā§ āĻŦāĻŋāύāĻŋāĻŽā§ āĻā§āĻžāϤ⧠āĻŦāϞāĻž āĻšā§ā§āĻā§āĨ¤
4. āĻĒāϰāĻŋāĻŦāĻžāϰā§āϰ āĻ āύā§āϝāĻžāύā§āϝ āϏāĻŦāĻžāĻ āĻāĻŋāĻāĻŋā§āϏāĻž āύāĻŋāĻŦā§āύāĨ¤
English Meaning: Other family members should receive medical attention.
āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž: āĻĒāϰāĻŋāĻŦāĻžāϰā§āϰ āĻ āύā§āϝ āϏāĻĻāϏā§āϝāĻĻā§āϰ āĻāĻāĻ āϧāϰāύā§āϰ āϰā§āĻ āĻāĻā§ āĻāĻŋ āύāĻž āϤāĻž āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤ āϤāĻŦā§ āĻāĻĒāϏāϰā§āĻāĻšā§āύ āϏāĻŦāĻžāĻāĻā§ āϏā§āĻŦā§āĻāĻā§āϰāĻŋā§āĻāĻžāĻŦā§ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ āĻĻā§āĻā§āĻžāϰ āĻĒā§āϰā§ā§āĻāύ āύā§āĻāĨ¤
Confidence for printed advice transcription â āĻŽā§āĻĻā§āϰāĻŋāϤ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āĻļāύāĻžāĻā§āϤāĻāϰāĻŖ: 0.95āĨ¤
đ§ 16. GUIDELINE-BASED MANAGEMENT
āĻāĻžāĻāĻĄāϞāĻžāĻāύ āĻ āύā§āϝāĻžā§ā§ āĻāĻŋāĻāĻŋā§āϏāĻž āĻĒāϰāĻŋāĻāϞā§āĻĒāύāĻž
Step 1 â Confirm the Diagnosis
āĻĒā§āϰāĻĨāĻŽ āϧāĻžāĻĒ â āϰā§āĻāύāĻŋāϰā§āĻŖā§ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž
English: Examine the skin and perform KOH microscopy when clinically indicated.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āϤā§āĻŦāĻ āĻĒāϰā§āĻā§āώāĻž āĻāϰāϤ⧠āĻšāĻŦā§ āĻāĻŦāĻ āĻĒā§āϰā§ā§āĻāύ āĻšāϞ⧠KOH āĻĒāϰā§āĻā§āώāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.95āĨ¤
Step 2 â Evaluate Disease Extent
āĻĻā§āĻŦāĻŋāϤā§ā§ āϧāĻžāĻĒ â āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻŦāĻŋāϏā§āϤāĻžāϰ āĻŽā§āϞā§āϝāĻžā§āύ
English: Determine whether the infection is localized, extensive, recurrent or treatment resistant.
āĻŦāĻžāĻāϞāĻž: āϏāĻāĻā§āϰāĻŽāĻŖ āϏā§āĻŽāĻŋāϤ, āĻŦā§āϝāĻžāĻĒāĻ, āĻŦāĻžāϰāĻŦāĻžāϰ āĻšāĻā§āĻž āĻ āĻĨāĻŦāĻž āĻāĻŋāĻāĻŋā§āϏāĻžāĻĒā§āϰāϤāĻŋāϰā§āϧ⧠āĻāĻŋ āύāĻž āϤāĻž āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.95āĨ¤
Step 3 â Select Antifungal Therapy
āϤā§āϤā§ā§ āϧāĻžāĻĒ â āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ āύāĻŋāϰā§āĻŦāĻžāĻāύ
English: Localized uncomplicated dermatophytosis often responds to topical antifungal treatment.
āĻŦāĻžāĻāϞāĻž: āϏā§āĻŽāĻŋāϤ āĻ āϏāĻžāϧāĻžāϰāĻŖ āĻĻāĻžāĻĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻ āύā§āĻ āϏāĻŽā§ āĻļā§āϧ⧠āϤā§āĻŦāĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ āϝāĻĨā§āώā§āĻāĨ¤
English: Systemic treatment may be appropriate for selected extensive, refractory or complicated infections.
āĻŦāĻžāĻāϞāĻž: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻŦā§āϝāĻžāĻĒāĻ, āĻāĻŋāĻāĻŋā§āϏāĻžā§ āύāĻž āϏāĻžāϰāĻž āĻ āĻĨāĻŦāĻž āĻāĻāĻŋāϞ āϏāĻāĻā§āϰāĻŽāĻŖā§ āĻŽā§āĻā§ āĻāĻžāĻā§āĻžāϰ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ āĻĒā§āϰā§ā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.95āĨ¤
Step 4 â Review Systemic Antifungal Safety
āĻāϤā§āϰā§āĻĨ āϧāĻžāĻĒ â āĻŽā§āĻā§ āĻāĻžāĻā§āĻžāϰ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞā§āϰ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž
English: Review liver disease, heart failure, pregnancy and relevant drug interactions before systemic itraconazole treatment.
āĻŦāĻžāĻāϞāĻž: āĻŽā§āĻā§ āĻāĻžāĻā§āĻžāϰ Itraconazole āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻā§ āϞāĻŋāĻāĻžāϰā§āϰ āϰā§āĻ, āĻšā§āĻĻā§âāϰā§āĻ, āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ āĻāώā§āϧā§āϰ āϏāĻā§āĻā§ āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.98āĨ¤
Step 5 â Assess Possible Allergic Rhinitis
āĻĒāĻā§āĻāĻŽ āϧāĻžāĻĒ â āϏāĻŽā§āĻāĻžāĻŦā§āϝ āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻŽā§āϞā§āϝāĻžā§āύ
English: Confirm nasal symptoms and select appropriate treatment according to severity and clinical findings.
āĻŦāĻžāĻāϞāĻž: āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻāĻĒāϏāϰā§āĻ āϝāĻžāĻāĻžāĻ āĻāϰ⧠āϰā§āĻā§āϰ āϤā§āĻŦā§āϰāϤāĻž āĻ āύā§āϝāĻžā§ā§ āĻāĻŋāĻāĻŋā§āϏāĻž āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.95āĨ¤
Step 6 â Review Antibiotic Requirement
āώāώā§āĻ āϧāĻžāĻĒ â āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžā§ā§āĻāĻŋāĻā§āϰ āĻĒā§āϰā§ā§āĻāύā§ā§āϤāĻž āϝāĻžāĻāĻžāĻ
English: Avoid azithromycin unless there is a supported bacterial indication.
āĻŦāĻžāĻāϞāĻž: āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻāĻĒāϝā§āĻā§āϤ āĻāĻžāϰāĻŖ āύāĻž āĻĨāĻžāĻāϞ⧠Azithromycin āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻāĻāĻŋāϤ āύā§āĨ¤
Confidence: 0.98āĨ¤
đŠ 17. PRESCRIPTION SAFETY ASSESSMENT
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āĻŽā§āϞā§āϝāĻžā§āύ
| Medicine â āĻāώā§āϧ | Main Concern â āĻĒā§āϰāϧāĻžāύ āϏāĻŽāϏā§āϝāĻž | Required Review â āĻĒā§āϰā§ā§āĻāύā§ā§ āĻŽā§āϞā§āϝāĻžā§āύ | Confidence |
|---|---|---|---|
| Itracon SUBA | Unclear dose, hepatic and cardiac risks â āĻ āϏā§āĻĒāώā§āĻ āĻĄā§āĻ, āϞāĻŋāĻāĻžāϰ āĻ āĻšā§āĻĻā§âāϰā§āĻā§āϰ āĻā§āĻāĻāĻŋ | Verify dose and safety â āĻĄā§āĻ āĻ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āϝāĻžāĻāĻžāĻ | 0.98 |
| Tinacure | Diagnosis unconfirmed â āϰā§āĻ āύāĻŋāĻļā§āĻāĻŋāϤ āύ⧠| Examine skin lesion â āϤā§āĻŦāĻā§āϰ āĻā§āώāϤ āĻĒāϰā§āĻā§āώāĻž | 0.95 |
| Zimax | Possible cancellation; no documented bacterial indication â āĻŦāĻžāϤāĻŋāϞ āĻšā§ā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§; āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻž āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻĒā§āϰāĻŽāĻžāĻŖ āύā§āĻ | Confirm actual prescription status â āĻāώā§āϧāĻāĻŋ āĻĻā§āĻā§āĻž āĻšā§ā§āĻā§ āĻāĻŋ āύāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž | 0.98 |
| Fastel | Indication not documented â āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻžāϰāĻŖ āϞā§āĻāĻž āύā§āĻ | Review allergy symptoms â āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻāĻĒāϏāϰā§āĻ āϝāĻžāĻāĻžāĻ | 0.90 |
| ABC Bar | Exact composition uncertain â āĻĒā§āϰāĻā§āϤ āĻāĻ āύ āĻ āύāĻŋāĻļā§āĻāĻŋāϤ | Check product label â āĻĒāĻŖā§āϝā§āϰ āĻŽā§ā§āĻ āϝāĻžāĻāĻžāĻ | 0.95 |
| Snofas | Potential interaction with itraconazole â āĻāĻā§āϰāĻžāĻā§āύāĻžāĻāϞā§āϰ āϏāĻā§āĻā§ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž | Review interaction risk â āĻĒāĻžāϰāϏā§āĻĒāϰāĻŋāĻ āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻžāϰ āĻā§āĻāĻāĻŋ āĻŽā§āϞā§āϝāĻžā§āύ | 0.95 |
đ§ 18. TEN CLINICAL DECISION-MAKING MODULES
ā§§ā§ĻāĻāĻŋ āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ āĻā§āϰāĻšāĻŖā§āϰ āĻŽāĻĄāĻŋāĻāϞ
đ§ MODULE 01 â CLINICAL DECISION-MAKING ALGORITHM
āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ āĻā§āϰāĻšāĻŖā§āϰ āϧāĻžāĻĒāĻāĻŋāϤā§āϤāĻŋāĻ āĻĒāĻĻā§āϧāϤāĻŋ
English Meaning â āĻāĻāϰā§āĻāĻŋ āĻŦā§āϝāĻžāĻā§āϝāĻž: A structured approach to diagnosis, investigation and treatment.
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ: āϰā§āĻāύāĻŋāϰā§āĻŖā§, āĻĒāϰā§āĻā§āώāĻž āĻ āĻāĻŋāĻāĻŋā§āϏāĻž āύāĻŋāϰā§āϧāĻžāϰāĻŖā§āϰ āĻāĻāĻāĻŋ āϧāĻžāĻĒāĻāĻŋāϤā§āϤāĻŋāĻ āĻĒāĻĻā§āϧāϤāĻŋāĨ¤
Clinical Application â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻĒā§āϰā§ā§āĻ
Assess symptoms â Examine lesions â Consider differential diagnoses â Perform relevant tests â Select treatment â Review response.
āĻŦāĻžāĻāϞāĻž: āĻāĻĒāϏāϰā§āĻ āĻŽā§āϞā§āϝāĻžā§āύ â āϤā§āĻŦāĻ āĻĒāϰā§āĻā§āώāĻž â āĻŦāĻŋāĻāϞā§āĻĒ āϰā§āĻ āĻŦāĻŋāĻŦā§āĻāύāĻž â āĻĒā§āϰā§ā§āĻāύā§ā§ āĻĒāϰā§āĻā§āώāĻž â āĻāĻŋāĻāĻŋā§āϏāĻž āύāĻŋāϰā§āĻŦāĻžāĻāύ â āĻāĻŋāĻāĻŋā§āϏāĻžā§ āϏāĻžā§āĻž āĻŽā§āϞā§āϝāĻžā§āύāĨ¤
āϏāĻšāĻ āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž
āĻĒā§āϰāĻĨāĻŽā§ āϰā§āĻāĻāĻŋ āĻā§ āϤāĻž āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤ āĻāϰāĻĒāϰ āϏā§āĻ āϰā§āĻā§āϰ āĻāύā§āϝ āĻāĻĒāϝā§āĻā§āϤ āĻāĻŋāĻāĻŋā§āϏāĻž āĻĻāĻŋāϤ⧠āĻšāĻŦā§āĨ¤ āĻļā§āϧ⧠āĻāώā§āϧ āĻĻā§āĻā§ āύāĻŋāĻļā§āĻāĻŋāϤ āϰā§āĻāύāĻŋāϰā§āĻŖā§ āĻāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Patient-Specific Assessment â āϰā§āĻā§āĻāĻŋāϤā§āϤāĻŋāĻ āĻŽā§āϞā§āϝāĻžā§āύ
English: Suspected dermatophytosis requires clinical verification before treatment adequacy can be determined.
āĻŦāĻžāĻāϞāĻž: āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĻāĻžāĻĻ āϏāϰāĻžāϏāϰāĻŋ āĻĒāϰā§āĻā§āώāĻž āĻāϰ⧠āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤ āϤāĻžāϰāĻĒāϰ āĻāĻŋāĻāĻŋā§āϏāĻž āϝāĻĨāĻžāϝāĻĨ āĻāĻŋ āύāĻž āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāĻž āϝāĻžāĻŦā§āĨ¤
Evidence â āĻĒā§āϰāĻŽāĻžāĻŖ
English: Clinical examination and KOH testing improve diagnostic assessment when tinea is uncertain.
āĻŦāĻžāĻāϞāĻž: āĻĻāĻžāĻĻ āϏāĻŽā§āĻĒāϰā§āĻā§ āϏāύā§āĻĻā§āĻš āĻĨāĻžāĻāϞ⧠āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻž āĻ KOH āĻĒāϰā§āĻā§āώāĻž āϰā§āĻāύāĻŋāϰā§āĻŖā§ā§ āϏāĻžāĻšāĻžāϝā§āϝ āĻāϰā§āĨ¤
Confidence: 0.96āĨ¤
đŠ MODULE 02 â DIAGNOSTIC EVIDENCE AND UNCERTAINTY
āϰā§āĻāύāĻŋāϰā§āĻŖā§ā§āϰ āĻĒā§āϰāĻŽāĻžāĻŖ āĻ āĻ āύāĻŋāĻļā§āĻā§āϤāĻž
English Meaning: Evaluation of supporting evidence and the limits of diagnostic certainty.
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ: āϰā§āĻāύāĻŋāϰā§āĻŖā§ā§āϰ āĻĒāĻā§āώ⧠āĻĨāĻžāĻāĻž āĻĒā§āϰāĻŽāĻžāĻŖ āĻ āĻ āύāĻŋāĻļā§āĻā§āϤāĻžāϰ āϏā§āĻŽāĻž āĻŽā§āϞā§āϝāĻžā§āύāĨ¤
Clinical Application â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻĒā§āϰā§ā§āĻ
English: Separate documented findings from inferred possibilities.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϞāĻŋāĻāĻŋāϤ āϤāĻĨā§āϝ āĻāĻŦāĻ āĻ āύā§āĻŽāĻžāύāĻāĻŋāϤā§āϤāĻŋāĻ āϏāĻŽā§āĻāĻžāĻŦāύāĻžāĻā§ āĻāϞāĻžāĻĻāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
āϏāĻšāĻ āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž
Itraconazole āĻĻā§āĻā§āĻž āĻšā§ā§āĻā§ āĻŽāĻžāύā§āĻ āϰā§āĻā§āϰ āĻĻāĻžāĻĻ āύāĻŋāĻļā§āĻāĻŋāϤ āύā§āĨ¤ āĻāĻāĻ āĻāώā§āϧ āĻŦāĻŋāĻāĻŋāύā§āύ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϰā§āĻā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Patient-Specific Assessment â āϰā§āĻā§āĻāĻŋāϤā§āϤāĻŋāĻ āĻŽā§āϞā§āϝāĻžā§āύ
English: No lesion examination or fungal test result is available.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āϤā§āĻŦāĻā§āϰ āĻā§āώāϤ āĻĒāϰā§āĻā§āώāĻžāϰ āϤāĻĨā§āϝ āĻŦāĻž āĻāϤā§āϰāĻžāĻ āĻļāύāĻžāĻā§āϤāĻāϰāĻŖā§āϰ āϰāĻŋāĻĒā§āϰā§āĻ āύā§āĻāĨ¤
Evidence â āĻĒā§āϰāĻŽāĻžāĻŖ
English: Dermatophytosis may clinically resemble eczema and other inflammatory skin disorders.
āĻŦāĻžāĻāϞāĻž: āĻĻāĻžāĻĻ āĻ āύā§āĻ āϏāĻŽā§ āĻāĻāĻāĻŋāĻŽāĻž āĻŦāĻž āĻ āύā§āϝāĻžāύā§āϝ āϤā§āĻŦāĻā§āϰ āĻĒā§āϰāĻĻāĻžāĻšāĻāύāĻŋāϤ āϰā§āĻā§āϰ āĻŽāϤ⧠āĻĻā§āĻāϤ⧠āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.98 for uncertainty assessmentāĨ¤
đ§ MODULE 03 â PRESCRIPTION SAFETY AUDIT
āĻāώā§āϧā§āϰ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āύāĻŋāϰā§āĻā§āώāĻž
English Meaning: Assessment of indications, doses, interactions, contraindications and possible prescribing errors.
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ: āĻāώā§āϧā§āϰ āĻāĻžāϰāĻŖ, āĻĄā§āĻ, āĻĒāĻžāϰāϏā§āĻĒāϰāĻŋāĻ āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž, āύāĻŋāώā§āϧāĻžāĻā§āĻāĻž āĻ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ-āĻā§āϞ āϝāĻžāĻāĻžāĻāĨ¤
Clinical Application â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻĒā§āϰā§ā§āĻ
English: Review systemic itraconazole dosing, possible azithromycin cancellation and itraconazoleâfluticasone interaction.
āĻŦāĻžāĻāϞāĻž: Itraconazole-āĻāϰ āĻĄā§āĻ, Azithromycin āĻŦāĻžāϤāĻŋāϞ āĻšā§ā§āĻā§ āĻāĻŋ āύāĻž āĻāĻŦāĻ ItraconazoleâFluticasone interaction āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
āϏāĻšāĻ āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āϏāĻŦ āĻāώā§āϧ āϏāϰāĻžāϏāϰāĻŋ āĻāĻžāϞāĻŋā§ā§ āϝāĻžāĻā§āĻžāϰ āĻāĻā§ āĻ āϏā§āĻĒāώā§āĻ āύāĻŋāϰā§āĻĻā§āĻļāύāĻžāĻā§āϞ⧠āĻĒāϰāĻŋāώā§āĻāĻžāϰ āĻāϰāĻž āĻāϰā§āϰāĻŋāĨ¤
Patient-Specific Assessment â āϰā§āĻā§āĻāĻŋāϤā§āϤāĻŋāĻ āĻŽā§āϞā§āϝāĻžā§āύ
English: The handwritten dose and antibiotic status are not sufficiently clear for safe dispensing decisions.
āĻŦāĻžāĻāϞāĻž: āĻšāĻžāϤā§āϰ āϞā§āĻāĻž āĻĄā§āĻ āĻ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžā§ā§āĻāĻŋāĻ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āύāĻŋāϰā§āĻĻā§āĻļ āύāĻŋāϰāĻžāĻĒāĻĻā§ āĻāώā§āϧ āĻĻā§āĻā§āĻžāϰ āĻŽāϤ⧠āϝāĻĨā§āώā§āĻ āϏā§āĻĒāώā§āĻ āύā§āĨ¤
Evidence â āĻĒā§āϰāĻŽāĻžāĻŖ
English: Itraconazole has clinically important CYP3A4 interactions and hepatic/cardiac warnings.
āĻŦāĻžāĻāϞāĻž: Itraconazole-āĻāϰ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ CYP3A4 interaction āĻāĻŦāĻ āϞāĻŋāĻāĻžāϰ āĻ āĻšā§āĻĻā§âāϝāύā§āϤā§āϰāϏāĻāĻā§āϰāĻžāύā§āϤ āϏāϤāϰā§āĻāϤāĻž āϰā§ā§āĻā§āĨ¤
Confidence: 0.98āĨ¤
đŠ MODULE 04 â RED FLAGS AND EMERGENCY REFERRAL
āĻŦāĻŋāĻĒāĻĻāϏāĻāĻā§āϤ āĻ āĻāϰā§āϰāĻŋ āϰā§āĻĢāĻžāϰā§āϞ
English Meaning: Identification of symptoms requiring urgent medical evaluation.
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ: āϝā§āϏāĻŦ āĻāĻĒāϏāϰā§āĻ āĻĻā§āĻāĻž āĻĻāĻŋāϞ⧠āĻāϰā§āϰāĻŋ āĻāĻŋāĻāĻŋā§āϏāĻž āĻĒā§āϰā§ā§āĻāύ, āϏā§āĻā§āϞ⧠āĻļāύāĻžāĻā§āϤ āĻāϰāĻžāĨ¤
Clinical Application â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻĒā§āϰā§ā§āĻ
English: Assess breathing difficulty, severe allergic reactions, jaundice, rapidly spreading painful lesions and new signs of heart failure.
āĻŦāĻžāĻāϞāĻž: āĻļā§āĻŦāĻžāϏāĻāώā§āĻ, āĻā§āϰā§āϤāϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ, āĻāύā§āĻĄāĻŋāϏ, āĻĻā§āϰā§āϤ āĻā§āĻŋā§ā§ āĻĒā§āĻž āĻŦā§āϝāĻĨāĻžāϝā§āĻā§āϤ āĻā§āώāϤ āĻāĻŦāĻ āύāϤā§āύ āĻšā§āĻĻā§âāϝāύā§āϤā§āϰā§āϰ āϏāĻŽāϏā§āϝāĻžāϰ āϞāĻā§āώāĻŖ āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
āϏāĻšāĻ āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž
āϏāĻžāϧāĻžāϰāĻŖ āĻĻāĻžāĻĻ āĻāϰā§āϰāĻŋ āϰā§āĻ āύā§āĨ¤ āĻāĻŋāύā§āϤ⧠āĻļā§āĻŦāĻžāϏāĻāώā§āĻ, āĻā§āĻ āĻšāϞā§āĻĻ āĻšā§ā§ āϝāĻžāĻā§āĻž, āĻĒāĻž āĻĢā§āϞ⧠āϝāĻžāĻā§āĻž āĻ āĻĨāĻŦāĻž āĻā§āϰā§āϤāϰ āĻāώā§āϧ-āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž āĻšāϞ⧠āĻĻā§āϰā§āϤ āĻšāĻžāϏāĻĒāĻžāϤāĻžāϞ⧠āϝā§āϤ⧠āĻšāĻŦā§āĨ¤
Patient-Specific Assessment â āϰā§āĻā§āĻāĻŋāϤā§āϤāĻŋāĻ āĻŽā§āϞā§āϝāĻžā§āύ
English: No red flags were recorded, but their absence cannot be assumed.
āĻŦāĻžāĻāϞāĻž: āĻā§āύ⧠āĻŦāĻŋāĻĒāĻĻāϏāĻāĻā§āϤ āϞā§āĻāĻž āύā§āĻāĨ¤ āϤāĻŦā§ āĻāϰ āĻ āϰā§āĻĨ āϰā§āĻā§āϰ āĻŦāĻŋāĻĒāĻĻāϏāĻāĻā§āϤ āύā§āĻâāĻāĻŽāύ āύā§āĨ¤
Evidence â āĻĒā§āϰāĻŽāĻžāĻŖ
English: Itraconazole product labeling includes warnings about serious liver injury and heart failure.
āĻŦāĻžāĻāϞāĻž: Itraconazole-āĻāϰ āĻāώā§āϧ-āύāĻŋāϰā§āĻĻā§āĻļāύāĻžā§ āĻā§āϰā§āϤāϰ āϞāĻŋāĻāĻžāϰ-āĻā§āώāϤāĻŋ āĻāĻŦāĻ āĻšā§āĻĻā§âāϝāύā§āϤā§āϰā§āϰ āĻāĻžāϰā§āϝāĻā§āώāĻŽāϤāĻž āĻāĻŽā§ āϝāĻžāĻā§āĻžāϰ āĻā§āĻāĻāĻŋ āĻāϞā§āϞā§āĻ āϰā§ā§āĻā§āĨ¤
Confidence: 0.98āĨ¤
đ§ MODULE 05 â EVIDENCE-BASED TREATMENT COMPARISON
āĻĒā§āϰāĻŽāĻžāĻŖāĻāĻŋāϤā§āϤāĻŋāĻ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āϤā§āϞāύāĻž
English Meaning: Comparison of prescribed therapy with established guidelines and clinical evidence.
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ: āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻĻā§āĻā§āĻž āĻāώā§āϧā§āϰ āϏāĻā§āĻā§ āϏā§āĻŦā§āĻā§āϤ āĻāĻžāĻāĻĄāϞāĻžāĻāύ āĻ āĻŦā§āĻā§āĻāĻžāύāĻŋāĻ āĻĒā§āϰāĻŽāĻžāĻŖā§āϰ āϤā§āϞāύāĻžāĨ¤
Clinical Application â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻĒā§āϰā§ā§āĻ
English: Compare topical antifungal therapy, systemic antifungal treatment, allergy treatment and the need for antibiotics.
āĻŦāĻžāĻāϞāĻž: āĻŦāĻžāĻšā§āϝāĻŋāĻ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ, āĻŽā§āĻā§ āĻāĻžāĻā§āĻžāϰ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ, āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻāĻŋāĻāĻŋā§āϏāĻž āĻāĻŦāĻ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžā§ā§āĻāĻŋāĻā§āϰ āĻĒā§āϰā§ā§āĻāύā§ā§āϤāĻž āϤā§āϞāύāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
āϏāĻšāĻ āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž
āϏā§āĻŽāĻŋāϤ āĻĻāĻžāĻĻā§ āĻ āύā§āĻ āϏāĻŽā§ āĻā§āϰāĻŋāĻŽ āϝāĻĨā§āώā§āĻ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ āĻŦā§āϝāĻžāĻĒāĻ āĻŦāĻž āĻāĻāĻŋāϞ āϏāĻāĻā§āϰāĻŽāĻŖā§ āĻŽā§āĻā§ āĻāĻžāĻā§āĻžāϰ āĻāώā§āϧ āĻĒā§āϰā§ā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ āĻāĻžā§āĻž āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžā§ā§āĻāĻŋāĻ āĻĒā§āϰā§ā§āĻāύ āĻšā§ āύāĻžāĨ¤
Patient-Specific Assessment â āϰā§āĻā§āĻāĻŋāϤā§āϤāĻŋāĻ āĻŽā§āϞā§āϝāĻžā§āύ
English: The extent of disease is unknown, so the need for systemic antifungal treatment cannot be confirmed.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻāĻāĻŋ āĻāϤāĻāĻž āĻā§āĻŋā§ā§āĻā§ āϤāĻž āĻāĻžāύāĻž āύā§āĻāĨ¤ āϤāĻžāĻ āĻŽā§āĻā§ āĻāĻžāĻā§āĻžāϰ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ āĻ āĻĒāϰāĻŋāĻšāĻžāϰā§āϝ āĻāĻŋāϞ āĻāĻŋ āύāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžāĻā§āĻā§ āύāĻžāĨ¤
Evidence â āĻĒā§āϰāĻŽāĻžāĻŖ
English: Current evidence supports topical treatment for many localized infections and systemic therapy for selected extensive or refractory cases.
āĻŦāĻžāĻāϞāĻž: āĻŦāϰā§āϤāĻŽāĻžāύ āĻĒā§āϰāĻŽāĻžāĻŖ āĻ āύā§āϝāĻžā§ā§ āĻ āύā§āĻ āϏā§āĻŽāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖā§ āĻŦāĻžāĻšā§āϝāĻŋāĻ āĻāĻŋāĻāĻŋā§āϏāĻž āϝāĻĨā§āώā§āĻ āĻāĻŦāĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻŦā§āϝāĻžāĻĒāĻ āĻŦāĻž āĻāĻŋāĻāĻŋā§āϏāĻžāĻĒā§āϰāϤāĻŋāϰā§āϧ⧠āϏāĻāĻā§āϰāĻŽāĻŖā§ āĻŽā§āĻā§ āĻāĻžāĻā§āĻžāϰ āĻāώā§āϧ āĻĒā§āϰā§ā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.95āĨ¤
đŠ MODULE 06 â FOLLOW-UP AND CLINICAL OUTCOMES
āĻĢāϞā§āĻāĻĒ āĻ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻĢāϞāĻžāĻĢāϞ
English Meaning: Evaluation of treatment response, adverse effects, recurrence and clinical recovery.
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ: āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻāĻžāϰā§āϝāĻāĻžāϰāĻŋāϤāĻž, āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž, āϰā§āĻ āĻĢāĻŋāϰ⧠āĻāϏāĻž āĻāĻŦāĻ āϏā§āϏā§āĻĨāϤāĻž āĻŽā§āϞā§āϝāĻžā§āύāĨ¤
Clinical Application â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻĒā§āϰā§ā§āĻ
English: Assess improvement in itching, scaling, lesion size and nasal symptoms.
āĻŦāĻžāĻāϞāĻž: āĻā§āϞāĻāĻžāύāĻŋ, āĻā§āϏāĻž āĻāĻ āĻž, āĻā§āώāϤā§āϰ āĻāĻāĻžāϰ āĻāĻŦāĻ āύāĻžāĻā§āϰ āĻāĻĒāϏāϰā§āĻ āĻāĻŽāĻā§ āĻāĻŋ āύāĻž āĻĻā§āĻāϤ⧠āĻšāĻŦā§āĨ¤
āϏāĻšāĻ āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž
āĻāώā§āϧ āĻĻā§āĻā§āĻžāϰ āĻĒāϰ⧠āϰā§āĻā§ āĻāĻžāϞ⧠āĻšāĻā§āĻā§āύ āĻāĻŋ āύāĻž āϤāĻž āĻĻā§āĻāĻž āĻāϰā§āϰāĻŋāĨ¤ āĻĒā§āϰā§ā§āĻāύ⧠āϰā§āĻāύāĻŋāϰā§āĻŖā§ āĻ āĻāĻŋāĻāĻŋā§āϏāĻž āĻĒā§āύāϰā§āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Patient-Specific Assessment â āϰā§āĻā§āĻāĻŋāϤā§āϤāĻŋāĻ āĻŽā§āϞā§āϝāĻžā§āύ
English: No follow-up findings or treatment outcomes are available.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āĻĢāϞā§āĻāĻĒā§āϰ āĻĢāϞāĻžāĻĢāϞ āĻŦāĻž āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻĒāϰ⧠āĻāύā§āύāϤāĻŋāϰ āϤāĻĨā§āϝ āĻĒāĻžāĻā§āĻž āϝāĻžā§āύāĻŋāĨ¤
Evidence â āĻĒā§āϰāĻŽāĻžāĻŖ
English: Lack of response should prompt reassessment of diagnosis, adherence and possible antifungal resistance.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻāĻŋā§āϏāĻžā§ āĻāύā§āύāϤāĻŋ āύāĻž āĻšāϞ⧠āϰā§āĻāύāĻŋāϰā§āĻŖā§, āϏāĻ āĻŋāĻāĻāĻžāĻŦā§ āĻāώā§āϧ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāĻŦāĻ āĻāϤā§āϰāĻžāĻā§āϰ āĻāώā§āϧāĻĒā§āϰāϤāĻŋāϰā§āϧā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āĻĒā§āύāϰā§āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.95āĨ¤
đ§ MODULE 07 â INVESTIGATION INTERPRETATION
āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ āĻŦāĻŋāĻļā§āϞā§āώāĻŖ
English Meaning: Interpretation of laboratory results in relation to clinical findings.
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ: āϰā§āĻā§āϰ āĻļāĻžāϰā§āϰāĻŋāĻ āĻ āĻŦāϏā§āĻĨāĻž āĻ āĻāĻĒāϏāϰā§āĻā§āϰ āϏāĻā§āĻā§ āϞā§āϝāĻžāĻŦāϰā§āĻāϰāĻŋ āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ āĻŽāĻŋāϞāĻŋā§ā§ āĻĻā§āĻāĻžāĨ¤
Clinical Application â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻĒā§āϰā§ā§āĻ
English: Interpret KOH results, fungal culture and relevant safety investigations according to clinical findings.
āĻŦāĻžāĻāϞāĻž: KOH āĻĒāϰā§āĻā§āώāĻž, āĻĢāĻžāĻā§āĻāĻžāϞ āĻāĻžāϞāĻāĻžāϰ āĻāĻŦāĻ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻžāϏāĻāĻā§āϰāĻžāύā§āϤ āĻĒāϰā§āĻā§āώāĻžāĻā§āϞ⧠āϰā§āĻā§āϰ āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻ āĻŦāϏā§āĻĨāĻžāϰ āϏāĻā§āĻā§ āĻŽāĻŋāϞāĻŋā§ā§ āĻŦā§āϝāĻžāĻā§āϝāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
āϏāĻšāĻ āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž
KOH āĻĒāϰā§āĻā§āώāĻžā§ āĻāϤā§āϰāĻžāĻā§āϰ āĻšāĻžāĻāĻĢāĻž āĻĒāĻžāĻā§āĻž āĻā§āϞ⧠āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϰā§āĻā§āϰ āĻĒāĻā§āώ⧠āĻĒā§āϰāĻŽāĻžāĻŖ āĻĒāĻžāĻā§āĻž āϝāĻžā§āĨ¤ āϤāĻŦā§ āύā§āϤāĻŋāĻŦāĻžāĻāĻ āĻĢāϞāĻžāĻĢāϞ āϏāĻŦ āĻā§āώā§āϤā§āϰ⧠āĻāϤā§āϰāĻžāĻ āϏāĻāĻā§āϰāĻŽāĻŖ āĻĒā§āϰā§āĻĒā§āϰāĻŋ āĻŦāĻžāϤāĻŋāϞ āĻāϰ⧠āύāĻžāĨ¤
Patient-Specific Assessment â āϰā§āĻā§āĻāĻŋāϤā§āϤāĻŋāĻ āĻŽā§āϞā§āϝāĻžā§āύ
English: No investigation result is available for interpretation.
āĻŦāĻžāĻāϞāĻž: āĻŦāĻŋāĻļā§āϞā§āώāĻŖ āĻāϰāĻžāϰ āĻŽāϤ⧠āĻā§āύ⧠āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ āύā§āĻāĨ¤
Evidence â āĻĒā§āϰāĻŽāĻžāĻŖ
English: KOH microscopy is commonly used in the diagnostic assessment of suspected tinea.
āĻŦāĻžāĻāϞāĻž: āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĻāĻžāĻĻā§āϰ āϰā§āĻāύāĻŋāϰā§āĻŖā§ā§ KOH āĻĒāϰā§āĻā§āώāĻž āĻāĻāĻāĻŋ āĻĒā§āϰāĻāϞāĻŋāϤ āĻĒāĻĻā§āϧāϤāĻŋāĨ¤
Confidence: 0.95āĨ¤
đŠ MODULE 08 â PATIENT EDUCATION
āϰā§āĻā§āĻā§ āϏā§āĻŦāĻžāϏā§āĻĨā§āϝāĻļāĻŋāĻā§āώāĻž
English Meaning: Providing understandable guidance about disease, treatment, hygiene and prevention.
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ: āϰā§āĻ, āĻāĻŋāĻāĻŋā§āϏāĻž, āĻĒāϰāĻŋāώā§āĻāĻžāϰ-āĻĒāϰāĻŋāĻā§āĻāύā§āύāϤāĻž āĻāĻŦāĻ āĻĒā§āϰāϤāĻŋāϰā§āϧ āϏāĻŽā§āĻĒāϰā§āĻā§ āϰā§āĻā§āĻā§ āϏāĻšāĻ āĻāĻžāώāĻžā§ āĻŦā§āĻāĻžāύā§āĨ¤
Clinical Application â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻĒā§āϰā§ā§āĻ
English: Encourage correct medication use, clean clothing, personal hygiene and avoidance of unnecessary steroid creams.
āĻŦāĻžāĻāϞāĻž: āϏāĻ āĻŋāĻāĻāĻžāĻŦā§ āĻāώā§āϧ āĻŦā§āϝāĻŦāĻšāĻžāϰ, āĻāĻžāĻĒā§ āĻĒāϰāĻŋāώā§āĻāĻžāϰ āϰāĻžāĻāĻž, āĻŦā§āϝāĻā§āϤāĻŋāĻāϤ āĻĒāϰāĻŋāĻā§āĻāύā§āύāϤāĻž āĻāĻŦāĻ āĻ āĻĒā§āϰā§ā§āĻāύā§ā§ āϏā§āĻā§āϰā§ā§āĻĄ āĻā§āϰāĻŋāĻŽ āĻĒāϰāĻŋāĻšāĻžāϰā§āϰ āĻĒāϰāĻžāĻŽāϰā§āĻļ āĻĻāĻŋāϤ⧠āĻšāĻŦā§āĨ¤
āϏāĻšāĻ āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž
āĻĻāĻžāĻĻ āϏāύā§āĻĻā§āĻš āĻšāϞ⧠āĻāĻā§āϰāĻžāύā§āϤ āϏā§āĻĨāĻžāύ āĻĒāϰāĻŋāώā§āĻāĻžāϰ āĻ āĻļā§āĻāύāĻž āϰāĻžāĻāĻŦā§āύāĨ¤ āĻ āύā§āϝā§āϰ āĻāĻžāĻĒā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻŦā§āύ āύāĻžāĨ¤ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āĻāĻžā§āĻž āύāϤā§āύ āĻā§āϰāĻŋāĻŽ āϝā§āĻ āĻāϰāĻŦā§āύ āύāĻžāĨ¤
Patient-Specific Assessment â āϰā§āĻā§āĻāĻŋāϤā§āϤāĻŋāĻ āĻŽā§āϞā§āϝāĻžā§āύ
English: The patient should receive clear instructions about itraconazole dosing and whether azithromycin was cancelled.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āĻā§ Itraconazole-āĻāϰ āϏāĻ āĻŋāĻ āĻĄā§āĻ āĻāĻŦāĻ Azithromycin āĻŦāĻžāϤāĻŋāϞ āĻšā§ā§āĻā§ āĻāĻŋ āύāĻž āϤāĻž āĻĒāϰāĻŋāώā§āĻāĻžāϰāĻāĻžāĻŦā§ āĻāĻžāύāĻžāύ⧠āĻĒā§āϰā§ā§āĻāύāĨ¤
Evidence â āĻĒā§āϰāĻŽāĻžāĻŖ
English: CDC advises avoiding steroid-containing creams for suspected ringworm unless appropriately directed.
āĻŦāĻžāĻāϞāĻž: CDC āĻĻāĻžāĻĻ āϏāύā§āĻĻā§āĻš āĻšāϞ⧠āĻ āĻĒā§āϰā§ā§āĻāύā§ā§ āϏā§āĻā§āϰā§ā§āĻĄāϝā§āĻā§āϤ āĻā§āϰāĻŋāĻŽ āĻŦā§āϝāĻŦāĻšāĻžāϰ āύāĻž āĻāϰāĻžāϰ āĻĒāϰāĻžāĻŽāϰā§āĻļ āĻĻā§ā§āĨ¤
Confidence: 0.98āĨ¤
đ§ MODULE 09 â GUIDELINE UPDATE AND EVIDENCE QUALITY
āĻāĻžāĻāĻĄāϞāĻžāĻāύ āĻāĻĒāĻĄā§āĻ āĻ āĻŦā§āĻā§āĻāĻžāύāĻŋāĻ āĻĒā§āϰāĻŽāĻžāĻŖā§āϰ āĻŽāĻžāύ
English Meaning: Reviewing recent guidelines and evaluating the reliability of supporting evidence.
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ: āϏāĻžāĻŽā§āĻĒā§āϰāϤāĻŋāĻ āĻāĻŋāĻāĻŋā§āϏāĻž āĻāĻžāĻāĻĄāϞāĻžāĻāύ āĻ āϏāĻāĻļā§āϞāĻŋāώā§āĻ āĻāĻŦā§āώāĻŖāĻžāϰ āύāĻŋāϰā§āĻāϰāϝā§āĻā§āϝāϤāĻž āĻŽā§āϞā§āϝāĻžā§āύāĨ¤
Clinical Application â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻĒā§āϰā§ā§āĻ
English: Use dermatophytosis guidance, CDC recommendations on resistant ringworm and ARIAâEAACI allergic rhinitis guidelines.
āĻŦāĻžāĻāϞāĻž: āĻĻāĻžāĻĻā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻž āύāĻŋāϰā§āĻĻā§āĻļāύāĻž, CDC-āĻāϰ āĻĒā§āϰāϤāĻŋāϰā§āϧ⧠āĻĻāĻžāĻĻāϏāĻāĻā§āϰāĻžāύā§āϤ āϤāĻĨā§āϝ āĻāĻŦāĻ ARIAâEAACI-āĻāϰ āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻāĻžāĻāĻĄāϞāĻžāĻāύ āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
āϏāĻšāĻ āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž
āĻāĻžāĻāĻĄāϞāĻžāĻāύ āĻĨā§āĻā§ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āύāĻŋā§āĻŽ āĻāĻžāύāĻž āϝāĻžā§āĨ¤ āĻāĻŋāύā§āϤ⧠āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻāĻžāĻāĻĄāϞāĻžāĻāύ āĻĒā§āϰā§ā§āĻā§āϰ āĻāĻā§ āϰā§āĻā§āϰ āϧāϰāύ āĻ āϤā§āĻŦā§āϰāϤāĻž āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰāϤ⧠āĻšā§āĨ¤
Patient-Specific Assessment â āϰā§āĻā§āĻāĻŋāϤā§āϤāĻŋāĻ āĻŽā§āϞā§āϝāĻžā§āύ
English: Evidence supports the general therapeutic roles of the prescribed medicines but does not establish that every medicine was necessary in this patient.
āĻŦāĻžāĻāϞāĻž: āĻŦā§āĻā§āĻāĻžāύāĻŋāĻ āĻĒā§āϰāĻŽāĻžāĻŖ āĻ āύā§āϝāĻžā§ā§ āĻāώā§āϧāĻā§āϞā§āϰ āϏāĻžāϧāĻžāϰāĻŖ āĻāĻŋāĻāĻŋā§āϏāĻžāĻāϤ āĻā§āĻŽāĻŋāĻāĻž āϰā§ā§āĻā§āĨ¤ āĻāĻŋāύā§āϤ⧠āĻāĻ āϰā§āĻā§āϰ āĻāύā§āϝ āĻĒā§āϰāϤāĻŋāĻāĻŋ āĻāώā§āϧ āĻĒā§āϰā§ā§āĻāύā§ā§ āĻāĻŋāϞâāĻāĻŽāύ āύāĻŋāĻļā§āĻā§āϤāĻž āύā§āĻāĨ¤
Evidence â āĻĒā§āϰāĻŽāĻžāĻŖ
English: AAFP 2025, CDC 2026 and ARIAâEAACI recommendations provide relevant guidance.
āĻŦāĻžāĻāϞāĻž: AAFP ⧍ā§Ļ⧍ā§Ģ, CDC ⧍ā§Ļ⧍ā§Ŧ āĻāĻŦāĻ ARIAâEAACI-āĻāϰ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āĻāĻ āϰā§āĻāĻā§āϞā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžā§ āĻĒā§āϰāĻžāϏāĻā§āĻāĻŋāĻāĨ¤
Confidence: 0.98 for source relevanceāĨ¤
đŠ MODULE 10 â MEDICAL SEO AND ARTICLE TRANSPARENCY
āĻŽā§āĻĄāĻŋāĻā§āϝāĻžāϞ SEO āĻ āϤāĻĨā§āϝ āĻĒā§āϰāĻāĻžāĻļā§āϰ āϏā§āĻŦāĻā§āĻāϤāĻž
English Meaning: Optimizing evidence-based medical content for discoverability while clearly communicating uncertainty and limitations.
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ: āϏāĻ āĻŋāĻ āĻāĻŋāĻāĻŋā§āϏāĻžāĻŦāĻŋāώā§āĻ āϤāĻĨā§āϝ āϏāĻžāϰā§āĻ āĻāĻā§āĻāĻŋāύā§āϰ āĻāύā§āϝ āĻāĻĒāϝā§āĻā§āĻāĻžāĻŦā§ āϏāĻžāĻāĻžāύ⧠āĻāĻŦāĻ āϰā§āĻāύāĻŋāϰā§āĻŖā§ā§āϰ āĻ āύāĻŋāĻļā§āĻā§āϤāĻž āĻ āϏā§āĻŽāĻžāĻŦāĻĻā§āϧāϤāĻž āϏā§āĻĒāώā§āĻāĻāĻžāĻŦā§ āĻĒā§āϰāĻāĻžāĻļ āĻāϰāĻžāĨ¤
Clinical Application â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻĒā§āϰā§ā§āĻ
SEO Title â āϏāĻžāϰā§āĻ āĻļāĻŋāϰā§āύāĻžāĻŽ:
Suspected Dermatophytosis with Allergic Rhinitis â Clinical Case Review.
āĻŦāĻžāĻāϞāĻž: āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĻāĻžāĻĻ āĻ āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻā§āϏ āϰāĻŋāĻāĻŋāĻāĨ¤
Focus Keyword â āĻĒā§āϰāϧāĻžāύ āĻā§āĻā§āĻžāϰā§āĻĄ:
Superficial Dermatophytosis â āϤā§āĻŦāĻā§āϰ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
Secondary Keywords â āϏāĻšāĻžā§āĻ āĻā§āĻā§āĻžāϰā§āĻĄ:
Tinea, Itraconazole, Luliconazole, Allergic Rhinitis, Prescription Review.
āĻŦāĻžāĻāϞāĻž: āĻĻāĻžāĻĻ, āĻāĻā§āϰāĻžāĻā§āύāĻžāĻāϞ, āϞā§āϞāĻŋāĻā§āύāĻžāĻāϞ, āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻāĻŦāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āĻŦāĻŋāĻļā§āϞā§āώāĻŖāĨ¤
āϏāĻšāĻ āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž
āϝā§āĻšā§āϤ⧠āϰā§āĻāĻāĻŋ āύāĻŋāĻļā§āĻāĻŋāϤ āύā§, āϤāĻžāĻ āĻāϰā§āĻāĻŋāĻā§āϞā§āϰ āĻļāĻŋāϰā§āύāĻžāĻŽā§ Suspected â āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻļāĻŦā§āĻĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
Patient-Specific Assessment â āϰā§āĻā§āĻāĻŋāϤā§āϤāĻŋāĻ āĻŽā§āϞā§āϝāĻžā§āύ
English: The patient’s identity is retained in this private review as supplied, but public publication requires appropriate consent and privacy review.
āĻŦāĻžāĻāϞāĻž: āĻŦā§āϝāĻā§āϤāĻŋāĻāϤ āĻŦāĻŋāĻļā§āϞā§āώāĻŖā§ āĻĻā§āĻā§āĻž āϰā§āĻā§āϰ āĻĒāϰāĻŋāĻā§ āϰāĻžāĻāĻž āĻšā§ā§āĻā§āĨ¤ āϤāĻŦā§ āĻĒā§āϰāĻāĻžāĻļā§āϝ āĻā§ā§āĻŦāϏāĻžāĻāĻā§ āĻĒā§āϰāĻāĻžāĻļā§āϰ āĻāĻā§ āϰā§āĻā§āϰ āĻāĻĒāϝā§āĻā§āϤ āϏāĻŽā§āĻŽāϤāĻŋ āĻāĻŦāĻ āĻŦā§āϝāĻā§āϤāĻŋāĻāϤ āϤāĻĨā§āϝā§āϰ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Evidence â āĻĒā§āϰāĻŽāĻžāĻŖ
English: Transparent reporting distinguishes documented medical findings from clinical inference.
āĻŦāĻžāĻāϞāĻž: āϏā§āĻŦāĻā§āĻāĻāĻžāĻŦā§ āϤāĻĨā§āϝ āĻĒā§āϰāĻāĻžāĻļ āĻāϰāϞ⧠āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϞāĻŋāĻāĻŋāϤ āϤāĻĨā§āϝ āĻāĻŦāĻ āϏā§āĻŦāĻžāϧā§āύāĻāĻžāĻŦā§ āĻāϰāĻž āϧāĻžāϰāĻŖāĻžāϰ āĻĒāĻžāϰā§āĻĨāĻā§āϝ āĻĒāĻžāĻ āĻ āĻŦā§āĻāϤ⧠āĻĒāĻžāϰā§āύāĨ¤
Confidence: 0.98āĨ¤
đ§ 19. REFERRAL RECOMMENDATION
āĻā§āύ āĻŦāĻŋāĻļā§āώāĻā§āĻā§āϰ āĻāĻžāĻā§ āϰā§āĻā§āĻā§ āĻĒāĻžāĻ āĻžāĻŦā§āύ?
Primary Referral â āĻĒā§āϰāϧāĻžāύ āϰā§āĻĢāĻžāϰā§āϞ
Dermatologist â āĻāϰā§āĻŽāϰā§āĻ āĻŦāĻŋāĻļā§āώāĻā§āĻāĨ¤
Reason â āĻāĻžāϰāĻŖ: Evaluation of suspected dermatophytosis, particularly if extensive, recurrent or treatment resistant.
āĻŦāĻžāĻāϞāĻž: āĻĻāĻžāĻĻ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āĻāĻŦāĻ āϏāĻāĻā§āϰāĻŽāĻŖ āĻŦā§āϝāĻžāĻĒāĻ, āĻĒā§āύāϰāĻžāĻŦā§āϤā§āϤ āĻ āĻĨāĻŦāĻž āĻāĻŋāĻāĻŋā§āϏāĻžāĻĒā§āϰāϤāĻŋāϰā§āϧ⧠āĻšāϞ⧠āĻāĻĒāϝā§āĻā§āϤ āĻāĻŋāĻāĻŋā§āϏāĻž āύāĻŋāϰā§āϧāĻžāϰāĻŖā§āϰ āĻāύā§āϝāĨ¤
Confidence: 0.95āĨ¤
Secondary Referral â āĻĻā§āĻŦāĻŋāϤā§ā§ āϰā§āĻĢāĻžāϰā§āϞ
ENT Specialist / Allergist â āύāĻžāĻ-āĻāĻžāύ-āĻāϞāĻž āĻŦāĻž āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻŦāĻŋāĻļā§āώāĻā§āĻāĨ¤
Reason â āĻāĻžāϰāĻŖ: Persistent or inadequately controlled nasal allergy symptoms.
āĻŦāĻžāĻāϞāĻž: āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻĻā§āϰā§āĻāϏā§āĻĨāĻžā§ā§ āĻšāϞ⧠āĻ āĻĨāĻŦāĻž āĻāĻŋāĻāĻŋā§āϏāĻžā§ āύāĻŋā§āύā§āϤā§āϰāĻŖ āύāĻž āĻšāϞā§āĨ¤
Confidence: 0.90āĨ¤
đŠ 20. EDUCATIONAL CLINICAL PRESCRIPTION DEMO
āĻļāĻŋāĻā§āώāĻž āĻ āĻĄāĻā§āĻŽā§āύā§āĻā§āĻļāύā§āϰ āĻāύā§āϝ āύāĻŽā§āύāĻž āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ
Patient â āϰā§āĻā§: Nasima Begum â āύāĻžāϏāĻŋāĻŽāĻž āĻŦā§āĻāĻŽāĨ¤
Age â āĻŦā§āϏ: 35 years â ā§Šā§Ģ āĻŦāĻāϰāĨ¤
Original Consultation Date â āĻŽā§āϞ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āϤāĻžāϰāĻŋāĻ: 20 October 2026 â ⧍ā§Ļ āĻ āĻā§āĻā§āĻŦāϰ ⧍ā§Ļ⧍ā§ŦāĨ¤
C/C â Chief Complaints â āĻĒā§āϰāϧāĻžāύ āĻ āĻāĻŋāϝā§āĻ
Not documented in original prescription â āĻŽā§āϞ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āϞā§āĻāĻž āύā§āĻāĨ¤
HPI â History of Present Illness â āĻŦāϰā§āϤāĻŽāĻžāύ āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ
Not documented â āϞā§āĻāĻž āύā§āĻāĨ¤
O/E â On Examination â āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ
Not documented â āϞā§āĻāĻž āύā§āĻāĨ¤
Investigation â āϰā§āĻāύāĻŋāϰā§āĻŖā§ā§āϰ āĻĒāϰā§āĻā§āώāĻž
No physician-documented investigation â āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϞā§āĻāĻž āĻā§āύ⧠āĻĒāϰā§āĻā§āώāĻž āύā§āĻāĨ¤
Provisional Diagnosis â āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϰā§āĻāύāĻŋāϰā§āĻŖā§
Dx 1: Suspected Superficial Dermatophytosis (Site Unspecified).
āĻŦāĻžāĻāϞāĻž: āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĻāĻžāĻĻ āĻŦāĻž āϤā§āĻŦāĻā§āϰ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ; āĻāĻā§āϰāĻžāύā§āϤ āϏā§āĻĨāĻžāύ āĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻāĨ¤
Dx 2: Possible Allergic Rhinitis.
āĻŦāĻžāĻāϞāĻž: āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻāύāĻŋāϤ āĻĒā§āϰāĻĻāĻžāĻšā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻžāĨ¤
D/D â Differential Diagnosis â āĻŦāĻŋāĻāϞā§āĻĒ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϰā§āĻ
Eczema â āĻāĻāĻāĻŋāĻŽāĻžāĨ¤
Pityriasis Versicolor â āĻā§āϞāĻŋāĨ¤
Cutaneous Candidiasis â āϤā§āĻŦāĻā§āϰ āĻā§āϝāĻžāύāĻĄāĻŋāĻĄāĻž āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
Other inflammatory skin disorders â āĻ āύā§āϝāĻžāύā§āϝ āĻĒā§āϰāĻĻāĻžāĻšāĻāύāĻŋāϤ āĻāϰā§āĻŽāϰā§āĻāĨ¤
Medication Reconciliation â āĻāώā§āϧ āϝāĻžāĻāĻžāĻ
Original medicines requiring review â āĻŽā§āϞ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āϝā§āϏāĻŦ āĻāώā§āϧ āϝāĻžāĻāĻžāĻ āĻĒā§āϰā§ā§āĻāύ:
- Itracon SUBA 65 mg â āĻĄā§āĻ āĻ āϏāĻŽā§āĻāĻžāϞ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
- Tinacure Cream â āĻāĻā§āϰāĻžāύā§āϤ āϏā§āĻĨāĻžāύ āĻ āĻŦā§āϝāĻŦāĻšāĻžāϰāĻŦāĻŋāϧāĻŋ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
- Zimax 500 mg â āĻāώā§āϧāĻāĻŋ āĻŦāĻžāϤāĻŋāϞ āĻāϰāĻž āĻšā§ā§āĻā§ āĻāĻŋ āύāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
- Fastel 180 mg â āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻžāϰāĻŖ āĻ āĻĄā§āĻ āϝāĻžāĻāĻžāĻ āĻĒā§āϰā§ā§āĻāύāĨ¤
- ABC Antifungal Bar â āĻĒāĻŖā§āϝā§āϰ āĻĒā§āϰāĻā§āϤ āĻāĻĒāĻžāĻĻāĻžāύ āĻ āĻŦā§āϝāĻŦāĻšāĻžāϰāĻŦāĻŋāϧāĻŋ āϝāĻžāĻāĻžāĻ āĻĒā§āϰā§ā§āĻāύāĨ¤
- Snofas Nasal Spray â āϏā§āĻĒā§āϰā§āϰ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āĻ āϏāĻŽā§āĻāĻžāĻŦā§āϝ interaction āϝāĻžāĻāĻžāĻ āĻĒā§āϰā§ā§āĻāύāĨ¤
Clinical Plan â āĻāĻŋāĻāĻŋā§āϏāĻž āĻĒāϰāĻŋāĻāϞā§āĻĒāύāĻž
English: Confirm the diagnosis, reconcile medication instructions, assess safety and select treatment based on clinical findings.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻāύāĻŋāϰā§āĻŖā§ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāϤ⧠āĻšāĻŦā§, āĻāώā§āϧā§āϰ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠āĻšāĻŦā§, āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰāϤ⧠āĻšāĻŦā§ āĻāĻŦāĻ āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞā§āϰ āĻāĻŋāϤā§āϤāĻŋāϤ⧠āĻāĻŋāĻāĻŋā§āϏāĻž āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Follow-up â āĻĒā§āύāϰāĻžā§ āĻŽā§āϞā§āϝāĻžā§āύ
English: Review according to symptoms, treatment response and medication safety.
āĻŦāĻžāĻāϞāĻž: āĻāĻĒāϏāϰā§āĻ, āĻāĻŋāĻāĻŋā§āϏāĻžā§ āĻāύā§āύāϤāĻŋ āĻāĻŦāĻ āĻāώā§āϧā§āϰ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āĻ āύā§āϝāĻžā§ā§ āĻĒā§āύāϰāĻžā§ āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Referral â āϰā§āĻĢāĻžāϰā§āϞ
Dermatology â āĻāϰā§āĻŽāϰā§āĻ āĻŦāĻŋāĻāĻžāĻāĨ¤
ENT/Allergy if indicated â āĻĒā§āϰā§ā§āĻāύ āĻšāϞ⧠āύāĻžāĻ-āĻāĻžāύ-āĻāϞāĻž āĻŦāĻž āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āĻŦāĻŋāĻāĻžāĻāĨ¤
Important â āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ: This is an educational clinical documentation example, not a new prescription authorizing medication dispensing.
āĻŦāĻžāĻāϞāĻž: āĻāĻāĻŋ āĻļāĻŋāĻā§āώāĻžāĻŽā§āϞāĻ āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻĄāĻā§āĻŽā§āύā§āĻā§āĻļāύā§āϰ āύāĻŽā§āύāĻžāĨ¤ āĻāĻāĻŋ āύāϤā§āύ āĻāώā§āϧ āĻĻā§āĻā§āĻžāϰ āĻ āύā§āĻŽā§āĻĻāĻŋāϤ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ āύā§āĨ¤
Confidence: 0.95 for documentation accuracy; diagnosis remains provisionalāĨ¤
đ§ 21. FINAL CLINICAL ASSESSMENT
āĻā§ā§āĻžāύā§āϤ āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻŽā§āϞā§āϝāĻžā§āύ
Doctor’s Documented Diagnosis â āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϞāĻŋāĻāĻŋāϤ āϰā§āĻāύāĻŋāϰā§āĻŖā§
Not documented â āϞā§āĻāĻž āύā§āĻāĨ¤
Independent Provisional Diagnosis â āϏā§āĻŦāĻžāϧā§āύ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϰā§āĻāύāĻŋāϰā§āĻŖā§
Dx: Suspected Superficial Dermatophytosis (Tinea Infection; Site Unspecified) with Possible Coexisting Allergic Rhinitis.
āĻŦāĻžāĻāϞāĻž: āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϤā§āĻŦāĻā§āϰ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ āĻŦāĻž āĻĻāĻžāĻĻ (āĻāĻā§āϰāĻžāύā§āϤ āϏā§āĻĨāĻžāύ āĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ), āϏāĻā§āĻā§ āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻāύāĻŋāϤ āĻĒā§āϰāĻĻāĻžāĻšā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻžāĨ¤
Diagnostic Confidence â āϰā§āĻāύāĻŋāϰā§āĻŖā§ā§āϰ āĻŦāĻŋāĻļā§āĻŦāĻžāϏāϝā§āĻā§āϝāϤāĻž: 0.65/1.00āĨ¤
Clinical Justification â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āϝā§āĻā§āϤāĻŋ
English: The combination of itraconazole, luliconazole and antifungal cleansing advice supports suspicion of a fungal skin disorder.
āĻŦāĻžāĻāϞāĻž: Itraconazole, Luliconazole āĻāĻŦāĻ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ āĻĒāϰāĻŋāώā§āĻāĻžāϰ-āĻĒāϰāĻŋāĻā§āĻāύā§āύāϤāĻžāϰ āύāĻŋāϰā§āĻĻā§āĻļāύāĻž āϤā§āĻŦāĻā§āϰ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϰā§āĻā§āϰ āϏāύā§āĻĻā§āĻšāĻā§ āϏāĻŽāϰā§āĻĨāύ āĻāϰā§āĨ¤
English: The presence of fexofenadine and intranasal fluticasone suggests possible treatment for allergic rhinitis.
āĻŦāĻžāĻāϞāĻž: Fexofenadine āĻāĻŦāĻ āύāĻžāĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ Fluticasone āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āύāĻŋāϰā§āĻĻā§āĻļ āĻāϰā§āĨ¤
English: Neither diagnosis is confirmed by documented examination findings or laboratory testing.
āĻŦāĻžāĻāϞāĻž: āĻā§āύ⧠āϰā§āĻāĻ āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻžāϰ āϞāĻŋāĻāĻŋāϤ āĻĢāϞāĻžāĻĢāϞ āĻŦāĻž āϞā§āϝāĻžāĻŦāϰā§āĻāϰāĻŋ āĻĒāϰā§āĻā§āώāĻžāϰ āĻŽāĻžāϧā§āϝāĻŽā§ āύāĻŋāĻļā§āĻāĻŋāϤ āĻšā§āύāĻŋāĨ¤
đŠ 22. OVERVIEW / SUMMARY
āϏāĻžāϰāϏāĻāĻā§āώā§āĻĒ
This case involves a 35-year-old patient whose prescription contains oral and topical antifungal medicines, an antihistamine, an intranasal corticosteroid, an antifungal cleansing product and a possibly cancelled antibiotic.
āĻŦāĻžāĻāϞāĻž: āĻāĻ āĻā§āĻ¸ā§ ā§Šā§Ģ āĻŦāĻāϰ āĻŦā§āϏ⧠āϰā§āĻā§āϰ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻŽā§āĻā§ āĻāĻžāĻā§āĻžāϰ āĻ āϤā§āĻŦāĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ, āĻ ā§āϝāĻžāύā§āĻāĻŋāĻšāĻŋāϏā§āĻāĻžāĻŽāĻŋāύ, āύā§āϝāĻžāĻāĻžāϞ āϏā§āĻā§āϰā§ā§āĻĄ, āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ āϏāĻžāĻŦāĻžāύ āĻāĻŦāĻ āϏāĻŽā§āĻāĻŦāϤ āĻŦāĻžāϤāĻŋāϞ āĻāϰāĻž āĻāĻāĻāĻŋ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžā§ā§āĻāĻŋāĻ āϰā§ā§āĻā§āĨ¤
The leading working diagnosis is suspected superficial dermatophytosis with possible allergic rhinitis.
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰāϧāĻžāύ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϰā§āĻāύāĻŋāϰā§āĻŖā§ āĻšāϞ⧠āϤā§āĻŦāĻā§āϰ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ āĻŦāĻž āĻĻāĻžāĻĻ, āϏāĻā§āĻā§ āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻžāĨ¤
The absence of documented symptoms, examination findings and investigation results is the most important limitation.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āĻāĻĒāϏāϰā§āĻ, āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ āĻāĻŦāĻ āϞā§āϝāĻžāĻŦāϰā§āĻāϰāĻŋ āϰāĻŋāĻĒā§āϰā§āĻ āύāĻž āĻĨāĻžāĻāĻžāĻ āĻāĻ āĻŽā§āϞā§āϝāĻžā§āύā§āϰ āϏāĻŦāĻā§ā§ā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āϏā§āĻŽāĻžāĻŦāĻĻā§āϧāϤāĻžāĨ¤
Overall Confidence: 0.65āĨ¤
đ§ 23. ACTIONABLE CLINICAL PLAN
āĻāϰāĻŖā§ā§ āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻĒāϰāĻŋāĻāϞā§āĻĒāύāĻž
1. Confirm Dermatological Diagnosis â āĻāϰā§āĻŽāϰā§āĻ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻžāĨ¤
Examine the lesion and consider KOH testing when indicated.
āĻŦāĻžāĻāϞāĻž: āϤā§āĻŦāĻā§āϰ āĻā§āώāϤ āĻĒāϰā§āĻā§āώāĻž āĻāϰ⧠āĻĒā§āϰā§ā§āĻāύ āĻ āύā§āϝāĻžā§ā§ KOH āĻĒāϰā§āĻā§āώāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
2. Verify Itraconazole Dose â āĻāĻā§āϰāĻžāĻā§āύāĻžāĻāϞā§āϰ āĻĄā§āĻ āϝāĻžāĻāĻžāĻāĨ¤
Confirm the handwritten regimen with the prescriber.
āĻŦāĻžāĻāϞāĻž: āĻšāĻžāϤā§āϰ āϞā§āĻāĻž āĻĄā§āĻ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻāĻžāĻ āĻĨā§āĻā§ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
3. Clarify Zimax Status â āĻāĻŋāĻŽā§āϝāĻžāĻā§āϏ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻ āĻŦāϏā§āĻĨāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻžāĨ¤
Determine whether azithromycin was prescribed or cancelled.
āĻŦāĻžāĻāϞāĻž: Azithromycin āĻĻā§āĻā§āĻž āĻšā§ā§āĻā§, āύāĻžāĻāĻŋ āĻā§āĻā§ āĻĻā§āĻā§āĻž āĻšā§ā§āĻā§ āϤāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
4. Assess Medication Safety â āĻāώā§āϧā§āϰ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āĻŽā§āϞā§āϝāĻžā§āύāĨ¤
Review liver disease, heart failure, pregnancy and drug interactions.
āĻŦāĻžāĻāϞāĻž: āϞāĻŋāĻāĻžāϰ, āĻšā§āĻĻā§âāϝāύā§āϤā§āϰ, āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻž āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ āĻāώā§āϧā§āϰ āϏāĻā§āĻā§ āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
5. Evaluate Nasal Symptoms â āύāĻžāĻā§āϰ āĻāĻĒāϏāϰā§āĻ āĻŽā§āϞā§āϝāĻžā§āύāĨ¤
Confirm whether the patient has allergic rhinitis.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āϏāϤā§āϝāĻŋāĻ āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋ āϰā§ā§āĻā§ āĻāĻŋ āύāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
6. Plan Clinical Follow-up â āĻĢāϞā§āĻāĻĒ āύāĻŋāϰā§āϧāĻžāϰāĻŖāĨ¤
Review treatment response and any adverse effects.
āĻŦāĻžāĻāϞāĻž: āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻāύā§āύāϤāĻŋ āĻ āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.95āĨ¤
đŠ 24. REFERENCE LIST
āĻāĻŋāĻāĻŋā§āϏāĻžāĻŦāĻŋāĻā§āĻāĻžāύā§āϰ āϤāĻĨā§āϝāϏā§āϤā§āϰ
A. Standard Medical Textbooks â āĻŽāĻžāύāϏāĻŽā§āĻŽāϤ āĻāĻŋāĻāĻŋā§āϏāĻžāĻŦāĻŋāĻā§āĻāĻžāύā§āϰ āĻĒāĻžāĻ ā§āϝāĻĒā§āϏā§āϤāĻ
1. Harrison’s Principles of Internal Medicine. 22nd Edition.
Relevant topics: Fungal Infections, Infectious Diseases and Allergic Disorders.
āĻŦāĻžāĻāϞāĻž: āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ, āϏāĻāĻā§āϰāĻžāĻŽāĻ āϰā§āĻ āĻāĻŦāĻ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻāύāĻŋāϤ āϰā§āĻā§āϰ āĻĒā§āϰāĻžāϏāĻā§āĻāĻŋāĻ āĻ āϧā§āϝāĻžā§āĨ¤
2. Andrews’ Diseases of the Skin: Clinical Dermatology. 14th Edition.
Relevant topics: Superficial Fungal Infections and Dermatophytosis.
āĻŦāĻžāĻāϞāĻž: āϤā§āĻŦāĻā§āϰ āĻāĻĒāϰāĻŋāĻāĻžāĻā§āϰ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ āĻ āĻĻāĻžāĻĻ āϏāĻŽā§āĻĒāϰā§āĻāĻŋāϤ āĻ āϧā§āϝāĻžā§āĨ¤
3. Katzung’s Basic & Clinical Pharmacology.
Relevant topics: Antifungal Drugs, Macrolide Antibiotics, Antihistamines and Corticosteroids.
āĻŦāĻžāĻāϞāĻž: āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ, āĻŽā§āϝāĻžāĻā§āϰā§āϞāĻžāĻāĻĄ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻŦāĻžā§ā§āĻāĻŋāĻ, āĻ ā§āϝāĻžāύā§āĻāĻŋāĻšāĻŋāϏā§āĻāĻžāĻŽāĻŋāύ āĻ āĻāϰā§āĻāĻŋāĻā§āϏā§āĻā§āϰā§ā§āĻĄā§āϰ āĻĢāĻžāϰā§āĻŽāĻžāĻā§āϞāĻāĻŋāĨ¤
4. Goodman & Gilman’s The Pharmacological Basis of Therapeutics.
Relevant topics: Antimicrobial Pharmacology, Drug Interactions and Corticosteroids.
āĻŦāĻžāĻāϞāĻž: āĻā§āĻŦāĻžāĻŖā§āĻŦāĻŋāϰā§āϧ⧠āĻāώā§āϧ, āĻāώā§āϧā§āϰ āĻĒāĻžāϰāϏā§āĻĒāϰāĻŋāĻ āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻž āĻāĻŦāĻ āĻāϰā§āĻāĻŋāĻā§āϏā§āĻā§āϰā§ā§āĻĄā§āϰ āĻāĻžāϰā§āϝāĻĒā§āϰāĻā§āϰāĻŋā§āĻžāĨ¤
B. Clinical Guidelines â āĻāĻŋāĻāĻŋā§āϏāĻž āĻāĻžāĻāĻĄāϞāĻžāĻāύ
5. American Family Physician. Diagnosis and Management of Tinea Infections. 2025.
āĻŦāĻžāĻāϞāĻž: āĻĻāĻžāĻĻ āĻ āĻ āύā§āϝāĻžāύā§āϝ Tinea āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϰā§āĻāύāĻŋāϰā§āĻŖā§ āĻāĻŦāĻ āĻāĻŋāĻāĻŋā§āϏāĻž āϏāĻŽā§āĻĒāϰā§āĻāĻŋāϤ āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻžāĨ¤
6. CDC. Clinician Brief: Emerging Ringworm. Updated 13 October 2026.
āĻŦāĻžāĻāϞāĻž: āύāϤā§āύ āĻāĻŦāĻ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ-āĻĒā§āϰāϤāĻŋāϰā§āϧ⧠āĻĻāĻžāĻĻ āϏāĻŽā§āĻĒāϰā§āĻā§ āĻāĻŋāĻāĻŋā§āϏāĻāĻĻā§āϰ āύāĻŋāϰā§āĻĻā§āĻļāύāĻžāĨ¤
7. CDC. Treatment of Ringworm. Updated 21 October 2026.
āĻŦāĻžāĻāϞāĻž: āĻĻāĻžāĻĻā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻž, āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāĻŦāĻ āϏā§āĻā§āϰā§ā§āĻĄ āĻā§āϰāĻŋāĻŽ āĻā§āĻŋā§ā§ āĻāϞāĻžāϰ āύāĻŋāϰā§āĻĻā§āĻļāύāĻžāĨ¤
8. ARIAâEAACI Guidelines, 2024â2025 Revision, Part I.
āĻŦāĻžāĻāϞāĻž: āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϤ⧠āύāĻžāĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāώā§āϧ āϏāĻŽā§āĻĒāϰā§āĻāĻŋāϤ āĻāĻžāĻāĻĄāϞāĻžāĻāύāĨ¤
DOI: 10.1111/all.70131.
9. ARIAâEAACI Guidelines, 2024â2025 Revision, Part II.
āĻŦāĻžāĻāϞāĻž: āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϤ⧠āĻŽā§āĻā§ āĻāĻžāĻā§āĻžāϰ āĻ āĻā§āĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāώā§āϧ āϏāĻŽā§āĻĒāϰā§āĻāĻŋāϤ āĻāĻžāĻāĻĄāϞāĻžāĻāύāĨ¤
DOI: 10.1111/all.70305.
C. Peer-Reviewed Journals with Verified DOI â DOI-āϝāĻžāĻāĻžāĻāĻā§āϤ āĻāĻŦā§āώāĻŖāĻž
10. Caplan AS, et al. Clinical Course, Antifungal Susceptibility, and Genomic Sequencing of Trichophyton indotineae. JAMA Dermatology. 2024;160(7):701â709.
DOI: 10.1001/jamadermatol.2024.1126.
āĻŦāĻžāĻāϞāĻž: Trichophyton indotineae āĻāϤā§āϰāĻžāĻā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖ, āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ āϏāĻāĻŦā§āĻĻāύāĻļā§āϞāϤāĻž āĻāĻŦāĻ āĻāĻŋāύāĻāϤ āĻŦāĻŋāĻļā§āϞā§āώāĻŖ āύāĻŋā§ā§ āĻāĻŦā§āώāĻŖāĻžāĨ¤
11. Gupta AK, et al. Trichophyton indotineae: Epidemiology, Antifungal Resistance and Antifungal Stewardship Strategies. Journal of the European Academy of Dermatology and Venereology. 2026;40(1):29â45.
DOI: 10.1111/jdv.20810.
āĻŦāĻžāĻāϞāĻž: Trichophyton indotineae-āĻāϰ āĻŦāĻŋāϏā§āϤāĻžāϰ, āĻāώā§āϧāĻĒā§āϰāϤāĻŋāϰā§āϧ āĻāĻŦāĻ āĻ ā§āϝāĻžāύā§āĻāĻŋāĻĢāĻžāĻā§āĻāĻžāϞ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āϝāĻĨāĻžāϰā§āĻĨāϤāĻž āύāĻŋā§ā§ āĻŦā§āĻā§āĻāĻžāύāĻŋāĻ āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻžāĨ¤
12. ARIAâEAACI GuidelinesâPart I: Intranasal Treatments. Allergy. 2026;81(4):954â976.
DOI: 10.1111/all.70131.
āĻŦāĻžāĻāϞāĻž: āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻ āϰāĻžāĻāύāĻžāĻāĻāĻŋāϏ⧠āύāĻžāĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāώā§āϧ āύāĻŋā§ā§ āĻĒā§āϰāĻŽāĻžāĻŖāĻāĻŋāϤā§āϤāĻŋāĻ āϏā§āĻĒāĻžāϰāĻŋāĻļāĨ¤
D. Bangladesh Drug Information â āĻŦāĻžāĻāϞāĻžāĻĻā§āĻļā§āϰ āĻāώā§āϧāϏāĻāĻā§āϰāĻžāύā§āϤ āϤāĻĨā§āϝāϏā§āϤā§āϰ
13. MedEx Bangladesh â Itracon SUBA 65 mg.
āĻŦāĻžāĻāϞāĻž: Itraconazole-āĻāϰ āĻŦā§āϰā§āϝāĻžāύā§āĻĄ, āĻĄā§āĻ, āĻŽā§āϞā§āϝ, āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋā§āĻžāĨ¤
14. MedEx Bangladesh â Tinacure 1% Cream.
āĻŦāĻžāĻāϞāĻž: Luliconazole āĻā§āϰāĻŋāĻŽā§āϰ āϤāĻĨā§āϝāĨ¤
15. MedEx Bangladesh â Zimax 500 mg.
āĻŦāĻžāĻāϞāĻž: Azithromycin-āĻāϰ āϤāĻĨā§āϝāĨ¤
16. MedEx Bangladesh â Fastel 180 mg.
āĻŦāĻžāĻāϞāĻž: Fexofenadine-āĻāϰ āϤāĻĨā§āϝāĨ¤
17. MedEx Bangladesh â Snofas Nasal Spray.
āĻŦāĻžāĻāϞāĻž: Fluticasone Furoate-āĻāϰ āϤāĻĨā§āϝāĨ¤
18. Arogga Bangladesh â ABC Anti-Fungal Bar.
āĻŦāĻžāĻāϞāĻž: ABC Anti-Fungal Bar-āĻāϰ āĻāĻĒāĻžāĻĻāĻžāύ āĻ āĻŦāĻžāĻāĻžāϰāĻŽā§āϞā§āϝā§āϰ āϤāĻĨā§āϝāĨ¤
đ§ 25. ARTICLE TRANSPARENCY AND PUBLICATION INFORMATION
āĻāϰā§āĻāĻŋāĻā§āϞā§āϰ āϏā§āĻŦāĻā§āĻāϤāĻž āĻ āĻĒā§āϰāĻāĻžāĻļāύāĻžāϏāĻāĻā§āϰāĻžāύā§āϤ āϤāĻĨā§āϝ
Article Type â āĻāϰā§āĻāĻŋāĻā§āϞā§āϰ āϧāϰāύ: Educational Clinical Case Review â āĻļāĻŋāĻā§āώāĻžāĻŽā§āϞāĻ āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻā§āϏ āĻŦāĻŋāĻļā§āϞā§āώāĻŖāĨ¤
Original Prescription â āĻŽā§āϞ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ: 1 â āĻāĻāĻāĻŋāĨ¤
Investigation Reports â āĻĒāϰā§āĻā§āώāĻžāϰ āϰāĻŋāĻĒā§āϰā§āĻ: 0 â āĻļā§āύā§āϝāĨ¤
Additional Clinical Images â āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻāĻŦāĻŋ: 0 â āĻļā§āύā§āϝāĨ¤
Diagnostic Status â āϰā§āĻāύāĻŋāϰā§āĻŖā§ā§āϰ āĻ āĻŦāϏā§āĻĨāĻž: Provisional â āϏāĻŽā§āĻāĻžāĻŦā§āϝāĨ¤
Evidence Limitation â āĻĒā§āϰāĻŽāĻžāĻŖā§āϰ āϏā§āĻŽāĻžāĻŦāĻĻā§āϧāϤāĻž: No documented symptoms, examination or confirmatory investigation â āϞāĻŋāĻāĻŋāϤ āĻāĻĒāϏāϰā§āĻ, āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻž āĻŦāĻž āϰā§āĻ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻžāϰ āĻĒāϰā§āĻā§āώāĻžāϰ āϤāĻĨā§āϝ āύā§āĻāĨ¤
Confidence Interpretation â āϏā§āĻā§āϰā§āϰ āĻ āϰā§āĻĨ: Scores represent qualitative confidence in the available evidence, not validated probabilities that the patient has a particular disease.
āĻŦāĻžāĻāϞāĻž: āĻāĻāĻžāύ⧠āĻŦā§āϝāĻŦāĻšā§āϤ āϏā§āĻā§āϰāĻā§āϞ⧠āĻāĻĒāϞāĻŦā§āϧ āϤāĻĨā§āϝā§āϰ āĻāĻŋāϤā§āϤāĻŋāϤ⧠āĻŦāĻŋāĻļā§āĻŦāĻžāϏāϝā§āĻā§āϝāϤāĻžāϰ āĻā§āĻŖāĻāϤ āĻŽā§āϞā§āϝāĻžā§āύāĨ¤ āĻāĻā§āϞ⧠āϰā§āĻ āĻšāĻā§āĻžāϰ āĻŦā§āĻā§āĻāĻžāύāĻŋāĻāĻāĻžāĻŦā§ āϝāĻžāĻāĻžāĻāĻā§āϤ āĻļāϤāĻāϰāĻž āϏāĻŽā§āĻāĻžāĻŦāύāĻž āύā§āĨ¤
Publication Privacy â āĻĒā§āϰāĻāĻžāĻļāύāĻžāϰ āĻā§āĻĒāύā§ā§āϤāĻž: Appropriate patient consent is required before publicly disclosing identifying medical information.
āĻŦāĻžāĻāϞāĻž: āϰā§āĻā§āϰ āĻĒāϰāĻŋāĻā§ āĻļāύāĻžāĻā§āϤ āĻāϰāĻž āϝāĻžā§ āĻāĻŽāύ āĻāĻŋāĻāĻŋā§āϏāĻžāϤāĻĨā§āϝ āĻĒā§āϰāĻāĻžāĻļā§āϰ āĻāĻā§ āĻāĻĒāϝā§āĻā§āϤ āϏāĻŽā§āĻŽāϤāĻŋ āĻĒā§āϰā§ā§āĻāύāĨ¤
đŠ FINAL ARTICLE AUTHORSHIP
āϞā§āĻāĻā§āϰ āϤāĻĨā§āϝ
Author Name â āϞā§āĻāĻā§āϰ āύāĻžāĻŽ: Md. Rafiqul Islam Lipu.
Md.Rafiqul Islam Lipu
Website â āĻā§ā§āĻŦāϏāĻžāĻāĻ: LIPU MED â raiyyantahsan.comāĨ¤
Date â āϤāĻžāϰāĻŋāĻ: Monday, 2 November 2026 â āϏā§āĻŽāĻŦāĻžāϰ, ⧍ āύāĻā§āĻŽā§āĻŦāϰ ⧍ā§Ļ⧍ā§ŦāĨ¤
Preparation Time â āĻĒā§āϰāϏā§āϤā§āϤāĻŋāϰ āϏāĻŽā§: Bangladesh Standard Time â āĻŦāĻžāĻāϞāĻžāĻĻā§āĻļ āϏāĻŽā§āĨ¤
Case Number â āĻā§āϏ āύāĻŽā§āĻŦāϰ: TC(1486).
Department Code â āĻŦāĻŋāĻāĻžāĻā§ā§ āĻā§āĻĄ: 02.
Dermatology Case Number â āĻāϰā§āĻŽāϰā§āĻ āĻŦāĻŋāĻāĻžāĻā§āϰ āĻā§āϏ āύāĻŽā§āĻŦāϰ: 107.
Clinical Assessment Status â āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻŽā§āϞā§āϝāĻžā§āύā§āϰ āĻ āĻŦāϏā§āĻĨāĻž: Provisional, Evidence-Based and Pending Clinical Confirmation â āϏāĻŽā§āĻāĻžāĻŦā§āϝ, āĻĒā§āϰāĻŽāĻžāĻŖāĻāĻŋāϤā§āϤāĻŋāĻ āĻāĻŦāĻ āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āύāĻŋāĻļā§āĻāĻŋāϤāĻāϰāĻŖā§āϰ āĻ āĻĒā§āĻā§āώāĻžā§āĨ¤
FINAL Dx: Suspected Superficial Dermatophytosis (Tinea Infection; Site Unspecified) with Possible Coexisting Allergic Rhinitis.
āĻā§ā§āĻžāύā§āϤ āϏāĻŽā§āĻāĻžāĻŦā§āϝ Dx: āϤā§āĻŦāĻā§āϰ āĻāϤā§āϰāĻžāĻāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖ āĻŦāĻž āĻĻāĻžāĻĻ (āĻāĻā§āϰāĻžāύā§āϤ āϏā§āĻĨāĻžāύ āĻ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ), āϏāĻā§āĻā§ āύāĻžāĻā§āϰ āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāĻāύāĻŋāϤ āĻĒā§āϰāĻĻāĻžāĻšā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻžāĨ¤
Final Diagnostic Confidence: 0.65/1.00āĨ¤